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Abstract
The ability to synthesize custom de novo DNA constructs rapidly, accurately, and
inexpensively is highly desired by researchers, as synthetic genes and longer DNA
constructs are enabling to numerous powerful applications in both traditional molecular
biology and the emerging field of synthetic biology, from the synthesis of large sets of
novel proteins to the complete re-writing of bacterial genomes. However, the current
cost of de novo synthesis--driven largely by reagent and handling costs-is a significant
barrier to the widespread availability of such technology. The use of microfluidic
technology greatly reduces reaction volumes and corresponding reagent and handling
costs. Additionally, microfluidic technology enables large numbers of complex reactions
to be performed in parallel, while facilitating the automation and integration of multiple
processes in a single device. While microfluidic devices have been used to miniaturize a
variety of chemical and biological processes, the benefits of such devices have yet to be
realized in the area of de novo DNA synthesis.
This thesis reports the first demonstration of gene synthesis in a microfluidic
environment. A variety of DNA constructs with sizes as large as 1 kb were fabricated in
parallel in a multi-chamber microfluidic device at volumes one to two orders of
magnitude lower than those utilized in conventional bench top techniques. This thesis
also reports on progress toward the direct synthesis of genes from hybrid microfluidic-
DNA microarray devices, the integration of microfluidic gene synthesis with on-chip
protein synthesis, and the microfluidic hierarchical synthesis of long DNA molecules.
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2 Gene Synthesis: applications and methods
Figure 2.1: Double-stranded B-DNA. From TheDNAStore.com
This chapter of the thesis overviews two major topics: (1) current and envisioned applications for
synthetic DNA over orders of magnitude of construct size, and (2) an evaluation of the various
technologies that have been used for the assembly of such constructs to date. Put simply, what
are the uses of synthetic DNA, and how do you build it?
Additionally, I will briefly discuss several complementary technologies in sections 2.2.3 and 2.4,
namely gene parsing (i.e. the software-based design of short, chemically synthesized
oligonucleotides used in gene synthesis), and DNA error correction. I will also introduce the role
of high-density DNA microarrays in section 2.1.1. These foundational technologies have played,
and will continue to play, significant roles in increasing the availability of cheap, accurate, and
long synthetic DNA.
2.1 100 to 102 bases: short oligonucleotides by chemical synthesis
Short, chemically synthesized oligonucleotides are indispensable tools in the tool kit of modem
biology. As related to the work of this thesis, short oligos serve primarily as a set of building
materials for the construction of larger synthetic DNA constructs, gene-length and longer. They
are the bricks of DNA manufacturing.
Modem synthesis of DNA is based on phosphoramidite chemistry originating from the work of
Caruthers in the 1980s', and is now a widespread, commercially available service. Short
1 Beaucage, S.L. & Caruthers, M.H. in Bioorganic Chemistry: Nucleic Acids. (ed. S.M. Hecht) 36-74
(Oxford University Press, Oxford; 1996).
oligonucleotides of approximately 100 bases in length can be designed and ordered on a
computer, and physical molecules can arrive by mail overnight. Achieving the ease and relative
low cost of this process is, in the short term, a modest and, by some metrics, an already realized
goal for both academic and commercial entities working on the synthesis of constructs gene-
length and longer. At the writing of this thesis, synthetic genes ordered from Codon Devices, a
commercial synthetic DNA vendor, costs
Synthesizing short oligonucleotides is accomplished via traditional DNA phosphoramidite
chemistry', whereby chemically protected nucleotides are added one at a time in a linear
polymerization reaction to a solid support (e.g. controlled-pore glass (CPG)). After each
nucleotide base addition, acid is utilized to cleave the protecting group, leaving a reactive
hydroxyl group to which subsequent protected bases can couple. This process is shown
schematically in Figure 2.2.
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Figure 2.2: Phosphoramidite synthesis cycle.
The phosphoramidites themselves are derived from sugar cane2 and are commercially available.
Four bottles containing phosphoramidites, as sold by Glen Research, are shown in Figure 2.3a. It
is remarkable to consider that this purified chemistry provides the set of synthetic small
molecules from which entire synthetic bacterial genomes can be constructed. The entire process
2 Y. Sanghvi (2007). A Roadmap to the Assembly of Synthetic DNA from Raw Materials,
http://hdl.handle.net/1721.1/39657
of chemical synthesis is automated utilizing commercially available DNA synthesis machines,
such as the one shown in Figure 2.3b.
(A) (B)
I
Figure 2.3: (a) Phosphoramidites from Glen Research. (b) An ABI 394 synthesizer from Applied
Biosystems.
As building materials that, when properly assembled, yield constructs that encode biological
programs, minimizing errors in the synthesis of short oligonucleotides is of the utmost
importance. As shall be seen throughout this thesis, the error rate of each individual DNA
fabrication process contributes overall to the level of effort and difficulty of assembling perfect
constructs of the desired size; thus, reduction of error in any of the synthesis steps described,
particularly high-error-rate processes, is always welcome (although, as we shall see later in
section 2.2, high error rates in chemical synthesis or subsequent steps may prove acceptable if
error correction is sufficiently robust).
Currently, errors in final synthetic DNA products arise largely from phosphoramidite synthesis,
rendering it the most fallible step in the manufacturing process. The most common source of
error from chemical synthesis arises when the protecting group of a growing DNA strand is not
removed, resulting in either a truncated product (when no further addition occurs) or an internal
deletion (when in subsequent rounds addition occurs)3 . Other types of errors include depurination
and various types of DNA damage resulting from chemical treatment. The efficiency of the
protecting group removal step is -99%; thus, the final crude yield is -0. 9 9N * 100%, where N is
the number of bases in the final strand. Figure 2.4, from Stewart et al.4, nicely summarizes the
impact of even small alterations in step-wise yield upon the final population of full-length desired
3 For example, see Table 5.1 for a comparison of the frequency of various error types for gene
synthesis in microfluidic and macroscopic environments. Deletions account for 83% and 70% of the total
types of errors observed, respectively.
4 Stewart, L. and Burgin, A.B. (2005) Whole Gene Synthesis: A Gene-O-Matic Future. Frontiers in
Drug Design & Discovery, 1, 297-341.
species relative to species with deletions (i.e. N-minus 1 mer). As we can see, even slight
variations in the efficiency of chemical reactions (here comparing 99.0% to 99.5% removal
efficiency of the protecting group) can have a significant impact upon both the quality and
quantity of the synthesized oligonucleotides. The cumulative effect of these minor inefficiencies
renders the process of constructing a high percentage of full-length oligonucleotides larger than
even 100 bases extremely difficult. These deficiencies in the synthesis process ultimately limit
the size of the oligonucleotides that can be utilized for gene synthesis, as even modest quantities
of low-quality oligos (present in larger proportion for longer oligos) can have considerable impact
upon the probability of fabricating a perfect DNA construct. As this probability decreases, the
subsequent resources (e.g. cloning, sequencing) that must be devoted to producing this error free
gene similarly increases. As we shall see in section 2.2.2, the enzymatic methods utilized to
assemble these short oligos into gene-length constructs necessitates minimum oligo sizes as well,
thus high-lighting the importance of stringency and accuracy in the oligo synthesis process itself.
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Figure 2.4: Effects of DNA strand length and chemical reaction efficiency in oligonucleotide synthesis.
From Stewart et al.4
Finally, when built massively in parallel on a solid support (e.g. microscope slide) via DNA
microarray technology, short, chemically synthesized oligonucleotides provide a wealth of cheap
construction material for gene synthesis. Just as the advent of microarray technology made
possible the dramatic leap from low to high throughput for gene expression assays, thus revealing
new vistas of research and analysis, it is hoped that the use of microarrays for gene synthesis will
have a similar groundbreaking effect, enabling levels of synthesis throughput heretofore
-
-- -- 
------ -------- 
--
unattainable. Efforts in employing DNA microarrays in concert with microfluidic devices will be
touched upon in Chapter 5 and explored more deeply in Chapter 6.
2.2 102 to 103 bases: single genes by in vitro enzymatic synthesis
Given the capacity to easily obtain single genes (which covers a vast range of construct size;
constructs from hundreds to even tens of thousands of base pairs can be considered "single
genes." The focus of this work is on single genes approximately one thousand base pairs long or
shorter), myriad applications are possible, from the synthesis of libraries of genes for large-scale
combinatorial studies of synthetic protein designs5, the reengineering of proteins for improved
crystallization 6, to enabling novel projects such as the complete synthesis of a library of canine
olfactory receptors (OR) genes7. Currently, these projects are considerably difficult to pursue
given the extensive requirements in time and resources devoted simply to manipulating and
manufacturing large sets of desired DNA constructs. Readily available cheap, on-demand,
synthetic DNA would significantly enable such research efforts.
Synthesis of genes on the order of hundreds of base pairs is readily accomplished utilizing
enzyme-mediated methods, which can broadly be divided into those directed by DNA ligase or
DNA polymerase for construct assembly from oligos. In both cases, a heterogeneous mixture of
products is generated, so polymerase is typically used to subsequently amplify synthesized genes
to desired quantities via polymerase chain reaction (PCR). Prominent examples of gene synthesis
using both construction methods have been reported with steady advances in technique since the
work of Khorana et al.8, who famously synthesized the yeast alanine tRNA gene by ligating short
6 to 8 base oligos.
Gene synthesis by ligase or polymerase mediated assembly is based fundamentally on the same
paradigm, whereby the ability of oligonucleotides to form hydrogen-bonded Watson-Crick
double-stranded DNA is exploited to initially hybridize overlapping short oligos. The process of
designing the oligonucleotides given a starting DNA sequence-taking into account, for example,
s Hecht;
6 Dyda et al.; Crystal structure of the catalytic domain of HIV-1 integrase; similarity to other
polynucleotidyl transferases. Science 266 1981-1986.
Shuguang Zhang, DARPA RealNose project
8 Khorana, H.G. (1968) Nucleic acid synthesis in the study of the genetic code, in Nobel Lectures:
Physiology or Medicine (1963-1970). Elsevier Science Ltd, Amsterdam, pp. 341-369.
oligo length and positioning relative to other oligos-is referred to as "parsing," and will be
discussed in greater depth in sections 2.2.2 and 2.2.3. Once annealed, ligase can be employed to
covalently link the ends of each oligo, or alternatively, polymerase can be utilized to extend
overlapping pairs of oligos, yielding the desired full-length construct after multiple rounds of
extension via thermocycling (as in PCR). Two examples of gene synthesis mediated by ligase
and polymerase, respectively, are shown schematically in Figures 2.5 (a) and (b). The method of
assembly shown in 2.5(a), from Bang and Church 9, relies initially upon a stringent, high-
temperature annealing condition (700 C) and thermostable ligase to covalently join a pool of 5'-
phosphorylated oligos. The use of thermostable ligase builds upon the work of Au et al.'0 , who
similarly employed high temperature annealing to avoid the formation of secondary structure and
mismatches that occurs at lower temperatures (e.g. 370 C for T4 DNA ligase), and were prominent
during early gene synthesis work prior to the advent of PCR (e.g. Khorana et al. 8). Two selection
steps utilizing exonucleases and endonucleases are employed to purify the desired species before
PCR is used to amplify the final product.
The method from Stemmer et al."1 , shown in figure 2.5 (b), utilizes polymerase for the assembly
of gene-length constructs from short oligos. This protocol similarly readily yields full-length
genes, beginning again with the initial annealing of oligos based upon designed Watson-Crick
base-pairing, followed by multiple rounds of thermocycling with polymerase. There are,
however, two important distinctions between the ligase and polymerase mediated methods:
firstly, the oligos used with polymerase do not require 5'-phosphorylation; thus, the additional
resources and effort to phosphorylate the 5'-terminus of each oligo, either during chemical
synthesis or prior to assembly via polynucleotide kinase, is not required. Eliminating this
additional step removes the associated resources required for phosphorylation, which can be
expensive when performed during chemical synthesis, and also removes another unnecessary
source of error or inefficiency during biochemical addition prior to assembly. Secondly,
polymerase is able to fill in gaps between oligos, meaning they are not required to be designed
such that they meet end to end as required by ligase. This design flexibility provides additional
degrees of freedom for any software tool utilized in parsing the synthetic gene and designing
9 Bang, D. and Church, G. (2007) Gene synthesis by circular assembly amplification. Nature
Methods, 5, 37-39.10 Au, L.C., Yang, F.Y., Yang, W.J., Lo, S.H., and Kao, C.F. (1998) Gene Synthesis by a LCR-
Based Approach: High-level Production of Leptin-L54 Using Synthetic Gene in Escherichia coli.
Biomedical and Biophysical Research Communications 248 200-203.
11 Stemmer, W.P., Crameri, A., Ha,K.D., Brennan, T.M. and Heyneker, H.L. (1995) Single-step
assembly of a gene and entire plasmid from large numbers of oligonucleotides. Gene, 164, 49-53.
oligos. Thus, these two factors have led our research group to favor the use of polymerase over
ligase as the primary engine to drive gene synthesis.
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Figure 2.5: Schematics for gene synthesis mediated by (a) ligase, from Bang and Church9 and by (b)
polymerase, from Stemmer et al. 1.
As we shall see, these techniques for construct assembly on the order of hundreds of base pairs
will prove to be foundational for the fabrication of longer constructs, up to complete bacterial
genomes. The techniques employed to assemble any long construct is ultimately built from
intermediate pieces on this size-scale, and as I will discuss in sections 2.3 and 2.4, a hierarchical
approach is generally employed for synthesis of long DNA. The miniaturization into microfluidic
format of this hierarchical synthesis approach for long DNA molecules is the subject of Chapter
8.
As a final point regarding nomenclature, multiple terms have been coined to describe polymerase-
mediated synthesis of genes. Our research group has settled on the term "Polymerase
Construction and Amplification" (PCA), as first named by Mullis et a112, and I will use this
throughout this thesis when describing polymerase-mediated synthesis of genes, which is the
primary technique utilized in this work.
2.2.1 Factors and tradeoffs for synthesis of short genes
In designing the oligos that will utilized for gene synthesis, a number of factors must be carefully
considered in order to best optimize the assembly reaction. As mentioned in section 2.1,
oligonucleotide length is a crucial factor: if oligos are too long, errors from chemical synthesis
can reach unacceptable levels, (see figure 2.4), leading to poor synthesis yield, or in some cases
incomplete assembly. If oligos are too short, the overlapping regions may not be sufficiently long
to ensure stable priming. Typical overlap length is approximately the length used for PCR
primers, e.g. 15 to 20 bases, depending upon the composition of the oligo and thus annealing
temperature. Longer overlaps generally promote hybridization specificity, and are thus desirable.
As already discussed in reference to the described ligase-based assembly techniques, the overall
annealing temperature of each oligo pair should be kept as high as possible to again maximize
hybridization specificity and reduce undesired oligo interactions. Annealing temperatures in the
range of 60 to 700C are preferred. Similarly, annealing temperatures should be kept
homogeneous throughout the designed pairs of oligo interactions; non-homogeneous annealing
will ultimately decrease the synthesis efficiency.
Another crucial factor is the number of oligos per assembly reaction. As the complexity of the
oligo pool increases, the likelihood of mispriming and other undesirable interactions increases,
thus inhibiting assembly or ultimately preventing assembly entirely. Additionally, for ligase-
based synthesis, large numbers of oligos lead to greater numbers of ligations per assembly
reaction. As the number of oligos is reduced, however, of course only smaller final constructs
can be manufactured (depending upon the length of the oligos). As we shall see in sections 2.3
and 2.4, constructs of approximately 500 bp or smaller are widely reported to be of an appropriate
size for subsequent manipulations when building large structures, while in the work reported in
this thesis, constructs of approximately 1 kb in size can be readily assembled in a single reaction.
Increasing the size of constructs that can be built per reaction can potentially reduce the total
12 Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., and Erlich, H. (1986) Specific enzymatic
amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol, 51, 263-
273.
number of reactions necessary when building large constructs. The factors discussed are
summarized in Table 2.1 below.
TABLE 2.1: Summary of several factors that impact gene synthesis
Factor Commentary
Too short, overlaps not long enough for stable priming;
too long, will have errors from chemical synthesis
High as possible to maximize hybridization specificity,Annealing (melting) temperature (Tm) homogeneous as possible to maximize PCR efficiency
Number of oligos per assembly Too many, likelihood of mispriming increases,
reaction preventing assembly; smaller pools lead to smaller finalproducts
Numerous other factors ultimately affect the quality of gene synthesis. The impact of additional
factors, such as oligo vendor and polymerase choice, are characterized and reported in Carr et
al. 13
2.2.2 Parsing Software
Given the variety of factors that ultimately impact the quality of gene synthesis, a diverse set of
useful software tools have been developed to optimize these parameters in assisting researchers in
oligonucleotide design. Parsing genes, or, taking the DNA sequence of a desired gene and
partitioning the sequence into overlapping oligos (for both strands), can be readily accomplished
using a number of these tools. The genes synthesized in this thesis were parsed utilizing DNA
Works, developed by Hoover et al. 14 The parsing software available for gene synthesis is
summarized and mapped according to publication date and citation in Wu et al.' 5 . The relevant
figure is reproduced in figure 2.6, and the reader should investigate Wu et al. for the complete list
of references. Genes can also be parsed without the aid of such tools (i.e. "naively"), by simply
setting an oligo length (e.g. 40 bases) and overlap length (e.g. 20 bases), thus yielding the desired
oligos "by hand," without optimizing any of the discussed parameters. This method has been
13 Carr et al. (2008) Practical Gene Synthesis. Manuscript in preparation.
14 Hoover, D.M. and Lubkowski, J. (2002) DNAWorks: an automated method for designing
oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res., 30, e43.
15 Wu, G., Dress, L., and Freeland, S.J. (2007) Optimal encoding rules for synthetic genes: the need
for a community effort. Mol Sys Bio 3:134
2.3.1 Multiple genes
Easy accessibility to DNA constructs on the order of thousands of base pairs will ultimately
enable some of the most exciting applications of synthetic biology. Effective microbial
engineering for drug 7" 18 energy 19' 20, and material21 production ultimately requires a more
complete understanding of the complex processes of cells, and given constructs on this size scale
systematic experimentation and analysis of gene and multiple gene constructs could be
conducted, allowing researchers to unravel and optimize their behavior. A fine example of this
type of experimentation is the work done by Elowitz et al., 22 where they constructed a synthetic
oscillating network which they termed a "repressilator" via 'rational network design.' The
motivation of this type of work is again two-fold: firstly, in the process of building synthetic
systems, can we learn something about natural occurring systems? And secondly, can we get
good enough at building synthetic systems so we can engineer new cellular behaviors? The DNA
machinery driving repressilator function is shown in figure 2.7, and as in the common refrain,
required significant resources and effort simply to manufacture, highlighting yet again the
potential enabling power of DNA synthesis on the size-scale of thousands of bases.
a Repressilator Reporter
PLjac0l
amrn tetR-lite
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Figure 2.7: (a) A schematic of a repressilator. From Elowitz and Leibler.22
17 R, Keasling JD. 2006. Production of the Antimalarial Drug Precursor Artemisinic Acid in
Engineered Yeast. Nature 440: 940-943.
18 Martin, V.J., Pietera, D.J., Withers, S.T., Newman, J.D. and Keasling, J.D. (2003) Engineering a
mevalonate pathway in Escherichia coli for production of terpenoids. Nat. Biotechnol., 21, 796-802.
19 Lynd LR, van Zyl WH, McBride JE, Laser M. 2005. Consolidated Bioprocessing of Cellulosic
Biomass: An Update. Current Opinion in Biotechnology 16: 577-58320 United States Department of Energy, Biological and Environmental Research Advisory
Committee. 2004. Synthetic Genomes: Technologies and Impact.
http://www.sc.doe.gov/ober/berac/SynBio.pdf
21 Aldor IS, Keasling JD. 2003. Process Design for Microbial Plastic Factories: Metabolic
Engineering of Polyhydroxyalkanoates. Current Opinion in Biotechnology 14: 475-483.
22 Elowitz, M.B. and Leibler, S. (2000) A synthetic oscillatory network of transcriptional regulators.
Nature, 403, 335-338.
This process of design (rational or naive), synthesis, and characterization is a concept that will be
applied for the motivation of the work in Chapter 7 regarding the microfluidic synthesis of DNA
constructs followed by protein synthesis.
2.3.2 Viral Genomes and vaccines
As a special class of constructs on the size-scale of thousands of base pairs, viral genomes have
also recently been synthesized, with some fanfare23' 24. Significantly, these demonstrations, while
illustrative of some of the dangerous applications of gene synthesis, also point toward the great
promise that synthesis on this size-scale has for vaccine development20 . Given the outbreak of a
new virus, once sequenced, any laboratory in the world with gene synthesis capabilities could
produce vaccines even without the original infectious organism. Again, large variant libraries
could also be produced to create vaccines with broad immune responses against similarly diverse
viruses like human immunodeficiency virus (HIV) and hepatitis C.
F 2 (IM5 bp)
C
Figure 2.7: Schematics for gene synthesis mediated by (a) ligase, from Bang and Church[refl
and by (b) polymerase, from Stemmer et al.[REFl .
23 Cello, J., Paul, A.V., and Wimmer, E. (2002) Chemical synthesis of poliovirus cDNA: generation
of infectious virus in the absence of natural template. Science, 297, 1016-1018.24 Smith, H.O., Hutchison, C.A., 3rd, Pfannkoch, C., and Venter, J.C. (2003) Generating a synthetic
genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl
Acad Sci USA, 100, 15440-15445.
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5 Parallel gene synthesis in a microfluidic device
Figure 5.1: Optical image of a multi-layer PDMS device
esu d for microfluidic gene synthesis
The work in this chapter was published in "D.S. Kong, P.A. Carr, L. Chen, S. Zhang, J.M.
Jacobson, 'Parallel gene synthesis in a microfluidic device,' Nucleic Acids Research, vol. 35, no.
8, e61, Apr, 2007."
5.1 Introduction
It has long been recognized that the capacity to design and synthesize genes and longer DNA
constructs can be enabling to a broad cross section of applications within molecular biology'
including the study of large sets of single genes 2, the design of genetic circuitry3, the engineering
of entire metabolic pathways for target molecule manufacture4, and even the construction and re-
engineering of viral and bacterial genomes5' 6 7.
S Khorana, H.G. (1968) Nucleic acid synthesis in the study of the genetic code, in Nobel Lectures:
Physiology or Medicine (1963-1970). Elsevier Science Ltd, Amsterdam, pp. 341-369.
2 The MGC Project Team (2004) The status, quality, and expansion of the NIH full-length cDNA
project: the mammalian gene collection (MGC). Genome Res., 14, 2121-2127.
Elowitz, M.B. and Leibler, S. (2000) A synthetic oscillatory network of transcriptional regulators.
Nature, 403, 335-338.
4 Martin, V.J., Pietera, D.J., Withers, S.T., Newman, J.D. and Keasling, J.D. (2003) Engineering a
mevalonate pathway in Escherichia coli for production of terpenoids. Nat. Biotechnol., 21, 796-802.
Cello, J., Paul, A.V., and Wimmer, E. (2002) Chemical synthesis of poliovirus cDNA: generation
of infectious virus in the absence of natural template. Science, 297, 1016-1018.
6 Smith, H.O., Hutchison, C.A., 3rd, Pfannkoch, C., and Venter, J.C. (2003) Generating a synthetic
genome by whole genome assembly: phiX 174 bacteriophage from synthetic oligonucleotides. Proc Natl
Acad Sci USA, 100, 15440-15445.
Hutchison, C. A., III, Peterson, S. N., Gill, S. R., Cline, R. T., White, O., Fraser, C. M., Smith, H.
0. and Venter, J. C. (1999) Global Transposon Mutagenesis and a Minimal Mycoplasma Genome. Science
286, 2165-2169.
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The core technology for custom DNA synthesis centers on the assembly of pools of
oligonucleotides (oligos), typically less than 50 nucleotides in length, into increasingly larger
DNA molecules. These oligos, hereafter referred to as "construction oligos," are synthesized by
variations of phosphoramidite chemistry8, and are the building blocks for the different gene
synthesis techniques developed thus far. The most widely reported methods for building long
DNA molecules involve variations of the polymerase-mediated assembly technique shown in
Figure 5.2, collectively termed Polymerase Construction and Amplification (PCA)9'10 . Here,
much like in the more conventional Polymerase Chain Reaction (PCR), three temperature steps
are employed to denature, anneal, and elongate the various overlapping construction oligos until,
after multiple rounds of thermocycling, the desired full length DNA construct is obtained.
Furthermore, assembly and amplification can be performed in a single reaction with the
introduction of amplifying primers"1 . Thus, once a minute quantity of full length product is
assembled, this product is amplified as per PCR. Using such polymerase-mediated techniques,
researchers have successfully synthesized DNA constructs as large as 12 kb'2 and 15 kb. A PCA
process was also employed as the first step in generating a 32 kb DNA construct by Santi and co-
workers"3. In addition, significant progress has been made in correcting synthesis errors, which
originate primarily from the phosphoramidite synthesis of initial oligonucleotide building blocks.
The use of protein-mediated error correction has been effective in increasing the accuracy of
synthetic DNA14,15,'16, with error rates as low as 1 per 10,000 base pairs reported.
8 Caruthers, M.H. (1985) Gene synthesis machines: DNA chemistry and its uses. Science, 230,
281-285.
9 Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., and Erlich, H. (1986) Specific enzymatic
amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol, 51, 263-
273.
to0 Stemmer, W.P., Crameri, A., Ha,K.D., Brennan, T.M. and Heyneker, H.L. (1995) Single-step
assembly of a gene and entire plasmid from large numbers of oligonucleotides. Gene, 164, 49-53.
11 Tian, J., Gong, H., Sheng, N., Zhou, X., Gulari, E., Gao, X., and Church, G. (2004) Accurate
multiplex gene synthesis from programmable DNA microchips. Nature, 432, 1050-1054.
12 Xiong, A.S., Yao, Q.H., Peng, R.H., Duan, H., Li, X., Fan, H.Q., Cheng, Z.M., and Li, Y. (2006)
PCR-based accurate synthesis of long DNA sequences. Nature Protocols, 1, 791-797.
13 Kodumal, S.J., Patel, K.G., Reid, R., Menzella, H.G., Welch, M., and Santi, D.V. (2004) Total
synthesis of long DNA sequences: synthesis of a contiguous 32-kb polyketide synthase gene cluster. Proc
Natl Acad Sci USA, 101, 15573-15578.
14 Carr, P.A., Park, J.S., Lee, Y.J., Yu, T., Zhang, S. and Jacobson, J.M. (2004) Protein-mediated
error correction for de novo DNA synthesis. Nucleic Acids Res., 32, e162.
15 Binkowski, B.F., Richmond, K.E., Kaysen, J., Sussman, M.R., and Belshaw, P.J. (2005)
Correcting errors in synthetic DNA through consensus shuffling. Nucleic Acids Res., 33, e55.
16 Fuhrmann, M., Oertel, W., Berthold, P., and Hegemann, P. (2005) Removal of
mismatched bases from synthetic genes by enzymatic mismatch cleavage. Nucleic Acids Res.,
33, e58.
Figure 5.2: Schematic for gene synthesis by Polymerase Construction and Amplification (PCA). Multiple
rounds of oligo annealing and extension by DNA polymerase generate successively longer DNA
assemblies from a starting pool of construction oligos, typically < 50 nt, until the full-length gene isproduced. The pool of heterogeneous DNA products is enriched for the full-length species by
amplification in a separate subsequent reaction, or in the same reaction by including amplifying primers in
the reaction mixture.
Despite these promising results significant challenges remain, most significantly the cost and time
of synthesizing long constructs. Currently, while conventionally synthesized oligos are available
at a cost on the order of $0.1 dollars per nucleotide, the cost for custom gene synthesis services is
significantly higher, on the order of $1.00-$1.60 dollars per base pair, with the major expenditure
components for such long syntheses being attributable to reagent and sample handling.
Microfluidic technology provides an elegant means to overcome these limitations. By scaling
reactions down to volumes of less than a microliter, reagent costs can be substantially reduced17 .
Furthermore, microfluidic technology enables highly parallelized synthesis along with the
potential for automated sample handling and process integration.
17 Liu, J., Hansen, C., and Quake, S.R. (2003) Solving the "world-to-chip" interface problem with a
microfluidic matrix. Anal. Chem., 75,4718-4723.
In this paper we report what is to our knowledge the first gene synthesis conducted in a
microfluidic environment. We have successfully conducted synthesis and amplification in a
single reaction for a variety of genes and gene segments, including GFP, OR128-1, DsRed, ble
(bleomycin resistance), a Holliday junction cleavase (hjc) gene from the bacteriophage SIRV-I,
and a variant alba gene from S. solfataricus. The identity of all synthetic genes was verified by
sequencing, and extensive sequencing of DsRed enabled the determination of an error rate for
genes synthesized in a microfluidic environment, along with a comparison of error rates for genes
synthesized in standard PCR tubes. In other reports construction oligos were synthesized on the
microscale, cleaved from the surface and subsequently assembled in macroscopic (> 5 pl)
reactions 11 " 19. In contrast, we have synthesized these DNA constructs in parallel within four
500 nanoliter reactors of a microfluidic device. Furthermore, the minute construction oligo
concentrations utilized (10-25 nM each oligo) are significantly lower than concentrations
attainable (without amplification) from high density oligonucleotide microarrays. Thus, such a
microfluidic approach should be compatible with DNA microarray-derived oligonucleotides"11,
further reducing the cost of this crucial reagent.
5.2 Materials and Methods
5.2.1 Master mold fabrication
Devices utilized in this work employed "push-down" valve geometries for fluidic valve
actuation 20. Two master molds were fabricated, one from which the fluidic "flow layer" could be
cast, the other from which the fluidic "control layer" could be cast. The flow layer master was
fabricated by first rinsing a 4" silicon wafer (WaferNet) in acetone and isopropyl alcohol,
followed by wafer dehydration at 2000 C on a hot plate. Next, hexamethyldisilizane (HMDS,
Sigma) was spun on the wafer at 4000 rpm to promote adhesion of the photoresist. A layer of
18s Richmond, K.E., Li, M.H., Rodesch, M.J., Patel, M., Lowe, A.M., Kim, C., Chu, L.L.,
Venkataramaian, N., Flickinger, S.F., Kaysen, J., Belshaw, P.J., Sussman, M.R., and Cerrina, F. (2004)
Amplification and assembly of chip-eluted DNA (AACED): a method for high-throughput gene synthesis.
Nucleic Acids Res., 32, 5011-5018.
Zhou, X., Cai, S., Hong, A., You, Q., Yu, P., Sheng, N., Srivannavit, O., Muranjan, S., Rouillard,
J.M., Xia, Y., Zhang, X., Xiang, Q., Ganesh, R., Zhu, Q., Matejko, A., Gulari, E., and Gao, X. (2004)
Microfluidic PicoArray synthesis of oligodeoxynucleotides and simultaneous assembling of multiple DNA
sequences. Nucleic Acids Res., 32, 5409-5417.
20 Unger, M.A., Chou, H.P., Thorsen, T., Scherer, A., and Quake, S.R. (2000) Monolithic
microfabricated valves and pumps by multilayer soft lithography. Science. 288, 113-6.
AZP 4620 positive photoresist (AZ Electronic Materials) was then coated at 1500 rpm for 40s
followed by a one hour soft-bake at 900C. Upon completion of the soft-bake, the wafer was then
exposed for 20 seconds at 50% intensity using a UV floodlight (Uvitron, Int.), followed by
development. Next, the resist was placed on a hotplate at 150 0C for 1 minute to reflow the resist
and achieve rounded fluid channels, thus enhancing sealing during valve actuation.
The control layer master was fabricated by again employing a solvent wash followed by wafer
dehydration. A layer of SU-8 50 negative photoresist (MicroChem) was then coated at 1000 rpm,
followed by pre-exposure bake steps of 65 0C for 10 minutes and 95 0 C for 30 minutes. The resist
was then exposed for 40 seconds at 50% intensity and post-exposure baked at 650 C for 1 minute
and 950 C for 10 minutes before being developed.
Finally, both flow layer and control layer masters were briefly exposed to Chlorotrimethylsilane
(Sigma) vapors for several minutes to promote release of the elastomer from the master molds.
All transparency masks used for the various exposure steps were designed in Adobe Illustrator
and printed by PageWorks (Cambridge, MA).
5.2.2 Microfluidic device fabrication
Approximately 30 grams of liquid PDMS pre-polymer (GE, RTV 615) at a component A to B
ratio of 5:1 was poured onto the control layer master to a thickness of approximately -1 cm,
followed by partial curing in a convection oven at 80'C for 45 minutes. Liquid PDMS pre-
polymer at a component A to B ratio of 20:1 was coated onto the flow layer master at 2000 rpm
for 60 seconds and also partially cured at 800C for 45 minutes. The PDMS control layer was then
peeled from its master and individual devices were cut out with a razor blade. Holes for control
line inlet ports were cored with an 18 G needle whose tip had been beveled and sanded down for
clean coring. Next, control layer devices (typically 6 per wafer) were aligned and bonded to the
PDMS-coated flow layer master, followed by additional curing for 45 minutes at 800 C. These
two-layer devices were then cut and peeled off the flow-layer molds, cored, and bonded overnight
at 800 C to 1 mm thick glass cover slips coated with a thin layer of partially cured PDMS
(typically spun on at 2000 rpm for 40s, with a 20:1 polymer to curing agent ratio and cured at
80'C for 45 minutes).
An example of a three-layer PDMS device capable of parallel gene synthesis is shown in figure 2.
Colored food dyes are used to emphasize various features of the device, with red indicating
actuation lines in the PDMS control layer, blue (and green) indicating the four gene synthesis
reactors, and yellow indicating a mesh of fluid lines in the control layer, hereafter referred to as a
'water jacket', placed above the reactors to minimize sample evaporation during thermocycling.
Figure 5.3: Optical images of a microfluidic device capable of conducting four parallel 500 nL reactions
with various features emphasized with food coloring. Left inset: gene synthesis chamber (blue and green)
and water jacket (yellow) layers. Right inset: fluid inlet channel (blue) overlaid with red valve channel(red). Scale bars correspond to 200 jtm.
5.2.3 Parsing of genes
Several genes and gene segments were selected for synthesis and parsed utilizing the program
DNAWorks21 to generate the desired oligonucleotides sequences for assembly and amplification.
The genes selected for synthesis were: (1) a randomized amino acid sequence of the alba gene
21 Hoover, D.M. and Lubkowski, J. (2002) DNAWorks: an automated method for designing
oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res., 30, e43.
from S. solfataricus (total length 327 bp, 16 oligos); (2) a Holliday junction cleavase (hjc) gene
from the bacteriophage SIRV-1 (total length 390 bp, 16 oligos); (3) ble (bleomycin resistance,
total length 461 bp, 16 oligos); (4) DsRed (total length 733 bp, 26 oligos); (5) OR128-1 (total
length 942 bp, 32 oligos); and (6) a GFP construct including a promoter and regulatory elements
(total length 993 bp, 42 oligos), using the same sequence reported in Carr et a114. All genes were
parsed in protein-mode utilizing codon optimization with the exception of GFP, which was parsed
in DNA-only mode. Relevant parameters for the parses selected from DNAWorks for all
synthesized gene and gene segments are summarized in Table 5.1. Complete DNAWorks output
files can be found in the Appendix.
TABLE 5.1 Key parameters for the selected parses for each gene and gene segment synthesized in this
work as output by DNAWorks.
Total Number Anneal Construction Amplifying [Oligonucleo [Mg
Gene size Temp Oligo size Primer -tide]
(nt) gos (0C) (nt) sizes (nt) (nM) (MM) (mM)
alba 327 16 59 38 35, 32 25 5 2
hjc 390 16 60 48 25, 25 20 50 2
dsRed 733 26 60 50 25, 20 25 50 2
GFP 993 42 59 42 29, 29 20 50 2
5.2.4 PCA reaction mixtures
PCA reaction mixtures for each desired gene or gene segment were prepared for utilization with
the microfluidic device. Each reaction mixture contained the following concentration of reagents:
1 mM dNTPs (250 gM each), 0.15 U/glL of Pfu Hotstart Turbo Polymerase (Stratagene), 1X
cloned Pfu Buffer (Stratagene), 0.1% n-Dodecyl-p3-D-maltoside (Sigma), 10 or 25 nM of each
construction oligo depending on the construct, and 500 nM of each amplifying outside primer.
The addition of amplifying outside primers enabled the synthesis and amplification of the desired
DNA construct in a single reaction. For synthesis of the full GFP construct and dsRed, 10 nM of
each construction oligo was utilized, while for all other gene and gene segments 25 nM of each
construction oligo was used.
Two segments of the GFP gene were also synthesized; for these experiments, the first pool
consisted of oligonucleotides 1-22, with 1 and 22 used as the primers to amplify segment 1,
which was 531 bp in length. The second pool consisted of oligonucleotides 21-42, with 21 and 42
used as the primers to amplify segment 2, which was 529 bp in length. Oligonucleotides were
purchased from Integrated DNA Technologies and Operon Biotechnologies without additional
purification.
5.2.5 PDMS microchannel preparation
While PDMS has a number of superb characteristics that make it, in many cases, an ideal material
from which automated biological platforms can be built, its hydrophobicity has inhibited certain
biological processes due to a strong tendency for non-specific protein adsorption. PCR in tL and
nL volumes generally suffer from such surface effects for a variety of materials because of the
high surface area to volume ratio of reactors22, thus mandating some type of surface passivation.
To address this problem in PDMS, we have successfully employed a nonionic surfactant, n-
Dodecyl-p-D-maltoside (DDM), as a passivating agent23. DDM adsorbs strongly to hydrophobic
surfaces, and when included in reaction mixtures is capable of successfully eliminating the
majority of protein adsorption. Reaction mixtures that did not include DDM or any other
passivating reagent failed to generate desired synthesis products.
Additionally, we found that devices exhibited the most robust, reliable performance after having
been extensively thermocycled prior to conducting gene synthesis reactions. While the
mechanism for this is not yet clear, experiments have shown a substantial increase in product
yields when devices were first thermocycled with reactors containing a mixture of 0.1% DDM,
IX Pfu Buffer and water for 100 cycles utilizing the following program: 94 0C for 30 seconds,
550 C for 30 seconds, and 72'C for 60 seconds (data not shown). An Eppendorf Mastercycler
Gradient thermocycler with an in situ adapter that facilitated thermal contact between the heating
block and the glass slide was utilized for all thermocycling of microfluidic devices in this work.
5.2.6 Sample evaporation
Because of the high porosity of PDMS, during the course of thermocycling significant sample
evaporation can occur, thus altering reactant concentrations and subsequently reducing reaction
22 Shoffner, M.A., Cheng, J., Hvichia, G.E., Kricka, L.J., and Wilding, P. (1996) Chip PCR. I.
Surface passivation of microfabricated silicon-glass chips for PCR. Nucleic Acids Res, 24, 375-379.
23 Huang, B., Wu, H., Kim, S., and Zare, R.N. (2005) Coating of poly(dimethylsiloxane) with n-
dodecyl-beta-D-maltoside to minimize nonspecific protein adsorption. Lab Chip, 5, 1005-1007.
efficiency, and in some cases completely inhibiting synthesis. It has been found that the addition
of fluid reservoirs in the vicinity of reaction chambers can reduce sample evaporation17 ; thus, a
waterjacket composed of a mesh of fluid lines 50 pm wide with 300 pm spacing was designed in
the control layer above the four reactors. When filled with water and actuated during
thermocycling, the water jacket substantially decreased reactor evaporation as observed
qualitatively.
5.2.7 Device design and operation
The microfluidic device was designed with individual reactor volumes of 500 nL to facilitate
analysis of reaction products by polyacrylamide gel electrophoresis (PAGE). The overall device
architecture is quite simple, with only three control lines necessary: a single valve to address all
reactor inputs, a single valve to address all reactor outputs, and a control line for water jacket
actuation. An array of 50 pm diameter posts present in each reactor prevented chamber ceiling
collapse. Reactor input and output channels were 100 mn wide while control lines were 300 pm
wide, thus ensuring a strong seal to prevent sample evaporation from the reactor inlets and outlets
during thermocycling. Without such valving evaporation occurs almost instantaneously upon
reaching the denaturation temperature.
All control lines were dead-end loaded with water by backing with pressurized air to force any air
initially within the control lines out through the porous bulk PDMS. PCA mixes were introduced
into the device by first actuating the reactor output valve at 15 psi and then dead-end loading the
four reaction mixes at 5-10 psi into the reactor. Once all air bubbles were pushed out of the
device, the inlet valve was closed to seal the reaction mix for thermocycling. All control valves,
including the water jacket, were actuated and maintained at 15 psi for the duration of the
synthesis reaction. Fresh devices that had been extensively thermocycled as described were used
for each experiment.
Upon completion of sample loading, the device was placed on the in situ adapter of the
Eppendorf Mastercycler Gradient and adhered with a small volume of mineral oil.
Thermocycling commenced by heating first at 940C for two minutes to activate the polymerase,
followed by either 35 or 45 cycles of the subsequent program: 940 C for 30 seconds, 550C for 30
seconds, and 720C for 60 seconds. For synthesizing GFP and dsRed, 35 cycles were utilized,
while for synthesizing all other gene and gene segments 45 cycles were used. Upon completion
of cycling, a final two minute extension at 720 C was conducted. Samples were collected by
flushing with 5 pL of deionized water in preparation for analysis by PAGE.
It should be noted that while steel pins (New England Small Tube Corp) were utilized to interface
polymer control line tubing to the fluidic device, for all reaction mix introduction and collection
steps, only polymer pins were utilized to interface to device inlets and outlets, as it has been
reported that prolonged contact between reaction mixes and steel can inhibit PCR 24.
All fluid manipulations, including valving and pressure-driven flows, were controlled by
individually actuated solenoid valves (The Lee Co) connected through a custom printed circuit
board to a National Instruments DAQ card. A LabVIEW software interface allowed control over
individual valves and fluid lines, while air flow for pressure-driven fluid manipulation was
controlled by standard pressurized air regulators (McMaster).
5.2.8 Control experiments
Several sets of control experiments were conducted. For each PCA reaction mix, synthesis
reactions were performed both within the fluidic and also in vitro in standard 0.2 ml PCR tubes to
compare the performance of fluidic versus in vitro synthesis. Additionally, negative controls
where conducted where construction oligos for synthesis reactions were omitted from the mixes.
These 'primers-only' negative controls were run side-by-side in the microfluidic device with
synthesis mixtures containing construction oligos. In vitro positive control experiments were
conducted in an MWG Primus 2500 thermocycler utilizing the same thermocycle programs
described above. All 'in fluidic' control experiments were similarly conducted with the 100-
thermocycle microchannel treatment discussed previously.
5.2.9 Polyacrylamide gel electrophoresis
Reaction mixtures collected from the four 500 nL reactors for all 'in fluidic' syntheses and
negative control experiments along with 0.5 jL of each positive in vitro control were analyzed by
PAGE (4%-12% gradient TBE gel, Invitrogen) and visualized by SYBR Gold staining
(Molecular Probes). Band intensities for synthesized gene and gene segments were approximated
utilizing AlphaEaseFC software from Alpha Innotech Corporation.
24 Panaro, N.J., Lou, X.J., Fortina, P., Kricka, L.J., and Wilding, P. (2004) Surface effects on PCR
reactions in multichip microfluidic platforms. Biomedical Microdevices, 6, 75-80.
5.2.10 DNA Sequencing
Gene synthesis products were sequenced to confirm the identities of the six target genes. Upon
completion of microfluidic gene synthesis and visualization by PAGE, reaction mixtures that
demonstrated successful synthesis along with successful 'in fluidic' negative controls were
further PCR amplified for 25 or 30 cycles to produce larger quantities of DNA for sequencing.
'Primers-only' negative controls were again conducted alongside this amplification step to verify
that only gene products from the original microfluidic synthesis reaction and not a contaminant
species were amplified. Upon completion of PCR, the resultant reaction mixtures were visualized
by PAGE to verify successful amplification and the absence of product in the negative controls.
PCR products were purified using QIAquick PCR Purification Kits (QIAGEN) prior to
sequencing. It was subsequently demonstrated (with the alba and DsRed genes) that gene
assembly products taken directly from the microfluidic devices provided sufficient material for
DNA sequencing, after first using ethanol precipitation to remove salts and enzymes.
The GFP gene product was sequenced using internal sequencing primers as in Carr et a 14. All
other gene products were sequenced (top and bottom strands) using the amplifying primers as
sequencing primers, by the MIT Biopolymers Laboratory.
To quantify the errors present in these synthetic genes, one gene was chosen for further analysis.
DsRed gene synthesis products were cloned (without purification or secondary amplification) into
vector pCR4Blunt-TOPO (Invitrogen) and transformed into chemically competent DH5ca cells.
Individual colonies were picked and grown in Luria-Bertani broth. Glycerol stocks of these
cultures were sent to Cogenics for plasmid extraction and sequencing. One 96-well plate of
samples was sequenced (48 from cloned microfluidic-synthesized DsRed genes, 48 from the
positive control synthesis reactions performed in standard 0.2 ml PCR tubes). All sequence reads
were analyzed using sequence-alignment tool ClustalX, and each error was verified by direct
visual confirmation of electropherograms using Chromas (Technylesium)
5.3 Results
Parallel gene syntheses were successfully conducted in a PDMS-based microfluidic device, as
visualized in the gel shown in Figure 3 and ultimately verified by DNA sequencing. Here,
parallel synthesis of four gene and gene segments, namely GFP segment 1 (531 bp), GFP
segment 2 (529 bp), the hjc gene from bacteriophage SIRV-1 (390 bp) and the randomized alba
gene from S. solfataricus (327 bp), is demonstrated. Successful assembly was also achieved for
the four positive in vitro controls, while successful 'primers-only' negative controls were
conducted both 'in fluidic' and in vitro to confirm that the presence of desired-length product was
not a consequence of amplification of contaminant species (not shown). Strong, dominant bands
are evident for the desired products of all four fluidic syntheses, with product yields greater than
50% relative to the positive in vitro controls (i.e. in PCR tubes). The ladder of lower molecular
weight species below the product bands indicates normal levels of assembly intermediates for a
single reaction PCA.
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Figure 5.4: Polyacrylamide gel electrophoresis (PAGE) showing successful parallel synthesis of fourgene and gene segments: GFP segment 1 (531 bp), GFP segment 2 (529 bp), the hjc gene from SIR V-1(390 bp), and a variant alba gene from S. solfataricus (327 bp). Positive in vitro controls are shown side-by-side. Molecular weight markers are shown (M) with 250, 500, and 750 bp positions indicated.
Additionally, the synthesis of four additional constructs, the full length GFP construct (993 bp),
OR128-1 (942 bp), DsRed (733 bp), and ble (461 bp) was also accomplished, thus demonstrating
the generality and robustness of microfluidic gene synthesis. Lower oligonucleotide
concentrations (10 nM) were required for the longer genes (GFP, OR128-1 and DsRed), as it is
hypothesized that at higher construction oligo concentrations all dNTPs are consumed generating
intermediate products. The results of the parallel syntheses of these four genes along with their
; V ý' C, 1ý " I *h M
respective negative controls are shown in Figure 4. Again, strong, dominant product bands are
observed for all four assemblies, while the negative controls exhibit no discernable product
bands. To obtain successful negative controls as shown in Figure 4, significant care must be
taken to eliminate all contamination, as the presence of even minute quantities of template
molecules can lead to undesired amplification-and thus erroneous results--in both PCA and
PCR. These negative controls have yet to fail when appropriate care is taken to avoid
contamination (fresh reagents, thorough cleanliness of all lab surfaces and equipment-pipettors
and tips, PCR tubes, fluidic tubing, etc.).
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Figure 5.5: Polyacrylamide gel electrophoresis (PAGE) showing successful parallel synthesis of genes
along with negative controls. In the presence of construction oligos, DNA constructs GFP and dsRed(993 and 733 bp respectively, figure 4A) and OR128-1 and ble (942 and 461 bp respectively, figure 4B)
are synthesized and amplified. Without construction oligos, no product bands are generated. Molecular
weight markers are shown (M) with 500, 750, and 1000 bp positions indicated.
In all cases, direct sequencing ofmicrofluidic gene synthesis products unambiguously confirmed
the identity of each target gene. However, such sequencing does not effectively report on the rate
of error in the product material, as errors in individual molecules are effectively averaged out in
the ensemble of products. Thus, one gene product (DsRed, 733 bp) was cloned, and the resultant
clones sequenced to quantify error rates. For DsRed sequencing, purification (by length or
secondary amplification) was deliberately omitted to prevent the addition or masking of errors in
such processing. For the same reason, clones were not screened prior to sequencing other than
blue/white screening to confirm successful insertion into the cloning vector. Thus, gene synthesis
products (which include the desired full-length species along with other incomplete, intermediary
products, as seen in Figure 4) were cloned directly from the microfluidic device or PCR tube
--
upon verification of synthesis by PAGE. The results of this sequencing are shown in Table 5.3.
48 clones for both 'in fluidic' and in vitro DsRed synthesis yielded 16,250 and 13,389 bases of
sequence information, respectively. A total of 29 and 30 errors were identified for the 'in fluidic'
and in vitro DsRed syntheses, thus generating error rates, per base, of 0.0018 and 0.0022,
respectively, with an overall per-base error rate for all sequence reads of 0.0020. These values
correspond well with the 0.0018 per-base error rate for the un-purified synthesis products
reported by Carr et al. 14 and Hoover et al.21, along with the 0.0027 per-base error rate reported by
Kodumal et al.'3 Given the 0.0018 per-base error rate for 'in fluidic synthesis,' as calculated in
Carr et al. 14, approximately 9 DsRed clones are required for sequencing to have a high probability
(95%) of at least one which is error free. Ultimately, 12.5% of full-length clones were error-free,
in agreement with theoretical expectations. For detailed tabulation of sequencing results see
Appendix A.5.
Table 5.3: Summary of errors for synthesis of DsRed in the microfluidic device as compared to in a
standard PCR-tube.
Microfluidic
Error Type Device PCR tube
Deletion Single-base 19 16
Deletion Multiple-base 5 5
Transition G/C to A/T 3 6
Transition A/T to G/C 0 2
Transversion G/C to C/G 0 0
Transversion G/C to T/A 1 1
Transversion A/T to C/G 1 0
Transversion A/T to T/A 0 0
Total Errors: 29 30
Bases Sequenced: 16,250 13,389
Error Rate (per base): 0.0018 0.0022
5.4 Discussion
Currently, the cost and time required to generate long, high-fidelity DNA molecules prevents
such synthesis technology from being an extensively utilized resource. For example, at current
oligo costs of approximately lx10-' dollars per base, applications such as the de novo synthesis of
bacterial genomes 106 bp in size become prohibitively costly, requiring on the order of $100,000
in oligos alone. Similarly, the ability to generate sets of hundreds or thousands of single genes is
restricted. The costs of expensive reagents such as polymerase and oligonucleotides can be
significantly reduced by utilizing microfluidic technology to minimize reaction volumes to a
fraction of a microliter as compared to tens of microliters required in conventional syntheses.
Further reductions in oligonucleotide costs by several orders of magnitude can be achieved by
utilizing the oligos synthesized from DNA microarrays"' 18-9. In such arrays large numbers of
distinct oligos are synthesized massively in parallel (104-105 or more for a single high density
array 25'26) but in minute quantities (femtomoles or less). Thus each oligo in a microarray can cost
as little as 1x10-' to 1x10-3 dollars per base, depending upon the array, which typically cost
between a few hundred to a few thousand dollars (e.g. $420 for a 22,000 spot Agilent
microarray). These costs per base are orders of magnitude less than for conventional oligo
synthesis. Thus, the current significant contribution of oligo costs to the overall price of gene
synthesis could be reduced to an almost trivial amount if the wealth of raw building material
provided by microarrays could be successfully utilized. If maximally employed, oligo costs for
building a 106 bp genome could potentially be reduced to tens of dollars. To achieve this goal,
two difficulties must be addressed: 1) conducting synthesis from the low yields of each oligo in a
microarray; and 2) problems that arise from manipulating highly complex pools of
oligonucleotides (>104 distinct sequences). In this work, successful gene synthesis from minute
oligo quantities (femtomoles) utilizing a microfluidic device architecture has been demonstrated,
while such an architecture employed in conjunction with a microarray has the potential to
overcome the limitations associated with complex pool manipulation.
25 Cleary, M.A., Kilian, K., Wang, Y., Bradshaw, J., Cavet, G., Ge, W., Kulkami, A., Paddison, P.J.,
Chang, K., Sheth, N., Leproust, E., Coffey, E.M., Burchard, J., McCombie, R.W., Linsley, P., and Hannon,
G.J. (2004) Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide
synthesis. Nature Methods, 1, 241-248.
26 Nuwaysir, E.F., Huang, W., Albert, T.J., Singh, J., Nuwaysir, K., Pitas, A., Richmond, T., Gorski,
T., Berg, J.P., Ballin, J. et al. (2002) Gene expression analysis using oligonucleotide arrays produced by
maskless photolithography. Genome Res., 12, 1749-1755.
In prior applications, oligos synthesized in microarray format have been cleaved from the arrays
and collected in "large" volumes (e.g. 5 pl or more) 11, 18-19. The resulting low concentrations of
oligo have been below the minimum needed to perform gene synthesis. Thus, additional process
steps such as DNA concentration and/or amplification by PCR were required in order to assemble
genes from this raw material. Direct gene synthesis of microarray oligos in microfluidic reactors
such as the ones presented here can circumvent these requirements by confining synthesis
reactions to individual chambers, thus maintaining oligo concentrations at levels sufficient for
synthesis. Table 5.4 indicates the concentrations of construction oligos which are expected for
two different microarrays25 26 (Agilent, Nimblegen) for a reactor enclosing 16 oligo spots,
sufficient to build a 400 bp gene. Using a reasonable estimate for oligo yields as function of spot
area (0.1 picomoles/mm 2, as in Richmond et al.18; as much as 4 picomoles/mm2 have been
estimated27. See also Pirrung28 for further discussion of oligo density), the spot size and spacing
for the two microarrays, and assuming a chamber with the same height as the reactors used in this
work (-10 pm), we estimate that construction oligos can be confined to yield concentrations in
excess of 200 nM each. This is substantially larger than the 10-25 nM per oligo utilized for
microfluidic synthesis reported here. Thus, ample room for error is provided to account for low
oligo synthesis and/or cleavage yields, as well as chambers enclosing more oligos spots to
synthesize larger genes. Employing such direct synthesis without concentration or an initial
amplification step not only reduces the time and cost of the overall synthesis protocol, but also
eliminates the possibility that additional errors will be generated during the amplification
procedure. The oligonucleotide building blocks themselves are currently the greatest source of
error in synthesized products, so reducing the likelihood of further inaccuracies is crucial for
obtaining high quality synthetic DNA.
27 Elder, J.K., Johnson, M., Milner, N., Mir, K.U., Sohail, M., and Southern, E.M. (1999) DNA
Microarrays. A Practical Approach (Ed.: M. Schena), Oxford Press, New York, 77-99.28 Pirrung, M.C. (2002) How to make a DNA chip. Angew. Chem. Int. Ed., 41, 1276-1289.
TABLE 5.4 Calculations for expected oligonucleotide yields from a typical DNA microarray for 16
oligonucleotides, sufficient to build a 400 bp gene. Values for spot area and spot spacing are for
commercially available Agilent and Nimblegen DNA microarrays.
Resolving hundreds of thousands of oligos into reactions generating thousands of genes is a non-
trivial challenge. For example, while multiplex gene synthesis utilizing bulk-sample handling has
been impressively demonstrated from an oligo pool containing -600 distinct oligonucleotides"11,
we expect such amplifications to become unfeasible for pools of higher complexity. Just as
multiplex PCR suffers from inconsistencies such that each template may not be equally
amplified 29, similarly the simultaneous amplification and subsequent assembly of 105 or more
sequences is unlikely to proceed evenly. For gene synthesis, this is expected to be limiting; if the
pool becomes dominated by a few DNA species, the required pool diversity would be lost,
rendering assembly impossible. The absence of a single oligo prevents the assembly of its
corresponding gene, so that losses even as low as 0.1% could interfere with the production of
dozens or hundreds of genes. Correspondingly, other reagent concentrations become impacted by
the complexity of oligo pools. For example, if only 1 nM of each construction oligo were
required for synthesis (a low estimate), for a pool of 10' oligos the starting material would be 0.1
mM, meaning that virtually all the required deoxynucleotide (dNTP) precursors used by DNA
polymerase would be consumed in the first cycle of a PCA reaction, terminating the reaction
before generating the desired product.. Use of a microfluidic device architecture such as the one
presented in this work to enclose sets of oligo spots for gene synthesis would maintain reagent
concentrations at desired levels while eliminating unwanted interference between sets of
oligonucleotides in a complex pool. In the case of parallel synthesis of genes with related
29 Edwards, M.C. and Gibbs, R.A. (1994) Multiplex PCR: advantages, development, and
applications. PCR Methods Appl., 3, S65-S75.
Agilent Nimblegen
Area of spot 1.4x10 4 gpm2  2.56 xl02 pLm2
Oligo density 0.1 picomole/mm2  0.1 picomole/mm2
Maximum expected yield per spot 1.4 femtomole 0.0256 femtomole
Dimensions of spot spacing 212 ptm by 188 gpm 25 pm by 25 pm
Minimal footprint of 16 oligo spots 6.4x105 pm 2  1x10 4 pIm 2
Minimal chamber volume (10 pm height) 6.4 nanoliters 100 picoliters
Estimated concentration of each oligo 220 nM 256 nM
sequences (e.g. many variants of the same gene), avoiding undesired oligo annealing events
during assembly will be crucial.
In this work we report, to our knowledge, the first gene synthesis in a microfluidic environment.
Genes and gene segments with sizes as large as a kilobase were assembled in four parallel
reactors in a single device. Reactions were conducted in 500 nL chambers, which are reaction
volumes one to two orders of magnitude smaller than those used in conventional gene synthesis,
thus achieving substantial reductions in reagent costs. This work also demonstrates the feasibility
of utilizing such device architecture in conjunction with high-density oligonucleotide microarrays
to potentially further reduce costs by several orders of magnitude. Microfluidic syntheses were
successfully conducted at low construction oligonucleotide concentrations of 10-25 nM, values
substantially lower than the anticipated concentration attainable from microarrays. By enclosing
microarray oligos in microfluidic chambers, the currently required complex pool handling would
be eliminated while enabling researchers, in principle, to maximally harness the high density of
oligonucleotides present on a microarray. The effective use of such architecture in combination
with high density oligo microarrays would constitute a major step toward realizing the goal of
low-cost de novo gene synthesis.
While this work utilized four parallel 500 nL chambers to facilitate analysis of reaction products
via PAGE, both the number and volume of reactors can be scaled substantially. Previous work
has demonstrated PCR in volumes as small as 86 pL30 , and a 100 pL chamber with dimensions of
100 pm x 100 pm x 10 pm capable of enclosing groups of 16 oligonucleotides (described in the
calculations in table 5.4) can be fabricated with ease using existing techniques. Extension of
current work to microfluidic devices containing a high-density of reactors for massively parallel
gene synthesis is being currently investigated.
While fusion of microfluidic handling with oligo microarrays will provide the first step in making
gene synthesis more available to researchers, integration with further microfluidic functions will
allow this technology to mature. These advances will include: (1) incorporation of existing DNA
error correction techniques"1' 14-16 on-chip to improve the quality of the synthesis products. This
will help minimize the need for another substantial contribution to the cost and time of gene
30 Nagai, H., Murakami, Y., Morita, Y., Yokoyama, K., and Tamiya, E. (2001) Development of a
microchamber array for picoliter PCR. Anal. Chem. 73, 1043-1047.
synthesis: quality control (i.e. typically cloning and sequencing). While the device described in
this work does not integrate on-chip error correction, it can be used readily with existing DNA
error correction techniques both before and after synthesis. For example, construction oligos can
be first gel-purified, as demonstrated by Hutchinson et al.6, prior to conducting gene synthesis in
the microfluidic device, or alternatively the MutS error-filter described by Carr et al. 14 could be
performed on reaction mixtures collected from the device upon completion of synthesis. Thus,
the microfluidic device can complement these bench-top error correction methods while
providing the associated benefits of reduced reagent costs during synthesis. For certain in vitro
applications, cloning will not necessarily be required. Thus a second application will be (2) the
integration of in vitro protein expression using high-quality synthetic DNA as a template. (3)
Finally, assembly of constructs larger than single genes can be achieved with microfluidic
devices, employing the same types of hierarchical in vitro assembly reactions used to create 12 kb
and larger segments11-13
6 Direct Microarray Gene Synthesis
Figure 6.1 (left): A fluorescence image of a DNA microarray fabricated via Maskless Array Synthesizer (MAS) technologyFigure 6.2 (right): An optical image of a microfluidic device featuring an array of 96 reactors, each 100 picoliters in volume.
6.1 Introduction
The fluorescence micrograph shown in Figure 6.1 from Nuwaysir et al.1 displays hybridization of
biotin labeled bacterial cRNAs to a custom DNA microarray. Nearly 200,000 distinct features,
each a potentially unique probe, are present with characteristic dimensions as small as 14 pim
(seen on the left edge of the image). Currently, DNA microarray vendors boast chip capacities of
nearly one million distinct oligo sequences, which translates into a staggering wealth of raw
sequence information per array-upwards of tens of megabases. While such information density
has already been demonstrated to be an extraordinarily powerful technology for biological assays,
the potential for such arrays to be utilized as a feedstock for gene synthesis has only begun to be
realized. As discussed at length in Section 5.4, if maximally utilized, an array of even "modest"
density (100,000 features) could yield enough material for the assembly of a complete synthetic
bacterial genome at a total oligo cost in the tens of dollars-a remarkable and tantalizing
possibility.
In this chapter, I will describe progress toward realizing this vision by employing microfluidic
technology in combination with high density oligonucleotide arrays to yield hybrid, integrated
devices for the synthesis of gene-length constructs in microfluidic volumes directly at the array
surface. The strategic advantage of such an approach, as detailed in Section 5.4, lies in avoiding
the significant technical challenges associated with manipulating the highly complex
Nuwaysir, E.F., Huang, W., Albert, T.J., Singh, J., Nuwaysir, K., Pitas, A., Richmond, T., Gorski,T., Berg, J.P., Ballin, J. et al. (2002) Gene expression analysis using oligonucleotide arrays produced by
maskless photolithography. Genome Res., 12, 1749-1755.
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oligonucleotide pools produced when cleaving oligos off the array into macroscopic volumes.
Performing gene synthesis in controlled microfluidic environments at the surface of the array
circumvents this difficulty by enclosing only the oligos of interest for synthesis, keeping reactions
simple while crucially preserving the total information density present in each array.
Techniques published to date utilizing microarray oligos as building blocks for gene synthesis,
while impressive, are still modest in terms of the number of distinct oligonucleotides used-
approximately 600 at best2-highlighting the difficulties of complex pool manipulation, and also
the considerable amount of material wasted given the massive information density of
microarrays. Clearly, significant work remains to realize the awesome potential of microarray
oligos as a feedstock for gene and genome synthesis. The technology presented in this chapter
will hopefully lead to reducing that gap.
6.1.2 Hybrid microfluidic-microarray device fabrication: challenges
The type of hybrid microarray-microfluidic device envisioned would combine a DNA microarray
of complexity comparable to the one shown in Figure 6.1 with a microfluidic device of
architecture similar to the one shown in Figure 6.2. Here, 100 picoliter (pL) reactors are arranged
in a canonical 96 well-plate format; the device was fabricated via multi-layer soft lithography
techniques described in sections 5.2.1 and 5.2.2. Blue food coloring indicates fluidic lines and
reactors where gene synthesis mixture would be loaded, red food coloring indicates control-lines
In an ideal embodiment, such an array of reactors would be directly aligned and bonded to a high-
density microarray, with each reactor enclosing the oligonucleotides necessary to build a small
(several hundred bp) gene. Given chamber dimensions of 100 .m x 100 pn x 10 pm, such a 100-
picoliter reactor, as described in Table 5.2, would be sufficient to enclose 16 distinct
oligonucleotides-enough material to build a 400-bp gene. Successful gene synthesis conducted at
such reactor volumes and microarray feature sizes could yield compelling technology of the type
shown in Figure 6.3, where in the area currently devoted to a single well of a canonical,
macroscopic 96-well plate, a microarray-microfluidic 96-well "gene plate" could be synthesized.
In such a configuration, it would be possible to synthesize some ten thousand genes in a single
plate!
2 Tian, J., Gong, H., Sheng, N., Zhou, X., Gulari, E., Gao, X., and Church, G. (2004) Accurate
multiplex gene synthesis from programmable DNA microchips. Nature, 432, 1050-1054.
Figure 6.3: An optical image of a canonical 96-well plate, juxtaposed with a vision for the future: in each
well, a 96-reactor "gene plate," yielding a high-density plate featuring nearly ten thousand genes.
Let us consider an example from structural biology to again highlight the potential power of
microarray oligos. Integral membrane proteins (IMPs) such as the small multi-drug resistance
(SMR) transporters expressed by Klammt et al.3, are notoriously difficult to crystallize, thus
resulting in a startling lack of existing structures despite their significant biological relevance;
despite the fact that 20 to 25% of all cellular proteins are IMPs, they account for only -0.3% (-80
of >26,000) structures in the Protein Data Bank4. One way to increase the likelihood of obtaining
an IMP crystal is to follow the strategy of Dyda et al.5, where hydrophobic residues in the core
domain of HIV-1 integrase were systematically replaced until it was discovered, empirically, that
the single amino acid substitution of Lys for Phe s85 resulted in considerably improved protein
solubility while maintaining its biological activity. This type of systematic study could be
performed with significantly greater ease and elegance by employing gene synthesis to generate a
library of variants. Typically composed of 110 amino acids, these SMR transporters consist of
four trans-membrane segments forming a tightly packed four-helix bundle. The associated gene
for these membrane proteins would be 330 bp, a size readily amenable for single-step gene
polymerase-mediated gene assembly. Using oligo design tools such as DNAWorks, specific
amino acids of the four-helix bundle of the SMR could be systematically altered, generating a
variety of mutants. Assuming the use of 50mers, a total of 14 oligos would be required to
synthesize the full 330 bp gene. Given a Nimblegen gene chip composed of -800,000 spots,
-57,000 different mutants could be synthesized from a single microarray!
3 Klammt C et al.; High level cell-free expression and specific labeling of integral membrane proteins.
European Journal ofBiochemistry 271 586-580, 2004.
4 http://www.wwpdb.org/
Dyda et al.; Crystal structure of the catalytic domain of HIV-1 integrase; similarity to otherpolynucleotidyl transferases. Science 266 1981-1986.
While an appealing vision, numerous technical challenges need to be overcome. On the device
side, how do we align and bond the fluidic to the microarray surface? Given the variety of
microarrays available, which would be most suitable for the proposed synthesis scheme? Once
attached, how are the oligonucleotides to be liberated from the surface? Once cleaved from the
surface, what additional, if any, modifications to the microfluidic gene synthesis protocols
described in Chapter 5 are required? What are the limitations in terms of reactor volume, and
perhaps more importantly reactor surface area to volume ratio?
The remaining sections of this chapter will be devoted to addressing the above challenges. In
section 6.2, a brief overview of the various existing microarray platforms will be presented,
emphasizing spot feature size, known substrate material, and details on the microarray technology
selected for this work; strategies for aligning and bonding will be discussed in section 6.3;
methodologies for cleaving oligos from the surface of the array will be outlined in section 6.4;
and finally, sections 6.5 to 6.7 will describe experimental results to date for integrated
microarray-microfluidic devices, which will hopefully convince the reader that the vision
articulated in this section of the thesis is realizable.
6.2 DNA Microarray platforms
DNA microarrays can be fabricated a variety of different ways, as reflected in the numerous
platforms commercially available and in development6' 7. Figure 6.4, re-printed from Gao et al.,
nicely summarize a variety of processes utilized to fabricate high-density oligonucleotide arrays.
6 Pirrung, M.C. (2002) How to make a DNA chip. Angew. Chem. Int. Ed., 41, 1276-1289.
Gao, X., Gulari, E., and Zhou, X. (2004) In Situ Synthesis of Oligonucleotide Microarrays.
Biopolymers, 73, 579-596
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Figure 6.4: A summary of various techniques utilized for the fabrication of DNA microarrays. From Gao
et al.7
While each of these techniques has associated strengths and weaknesses, the characteristics of
greatest interest for the work of this thesis are: (1) frequency of errors in the synthesized oligos
(can genes even be built from these oligos?); (2) spot feature size and density (are the oligos
present in high enough concentration?); and (3) compatibility with the proposed scheme of direct
microarray gene synthesis (how easily can hybrid fluidic-array devices be constructed?).
Overall, reports of genes synthesized from DNA microarray oligos have come from three
diffeient microarray platforms: photo-generated acid deprotection in a closed fluidic
(Atactic/Xeotron)8'9; photolabile deprotection by Maskless Array Synthesizer (MAS) technology
(Nimblegen)lo; and physically addressable ink-jet based deprotection (Agilent)"1 . Crucially, the
8 Zhou, X., et al. (2004) Microfluidic PicoArray synthesis of oligodeoxynucleotides and
simultaneous assembling of multiple DNA sequences. Nucleic Acids Res., 32, 5409-5417.
9 Tian, J., Gong, H., Sheng, N., Zhou, X., Gulari, E., Gao, X., and Church, G. (2004) Accurate
multiplex gene synthesis from programmable DNA microchips. Nature, 432, 1050-1054.
10 Richmond, K.E., et al. (2004) Amplification and assembly of chip-eluted DNA (AACED): a
method for high-throughput gene synthesis. Nucleic Acids Res., 32, 5011-5018.
0IT phhop.amrddie
L- OR:
fD..•- t.
oDT pix
elc
a
PPhoaisotd WghIt pa K
asf-Mf'4by cowir*~kwff"rray "MOM"l~
Srtac sor synherel usingL Phoarbioa
0
array technologies most suitable for direct synthesis requires an 'open-face', or some access to
bonding to a fluidic, which eliminates closed systems such as the Atactic/Xeotron platform seen
in figure 6.5, unless it could be dramatically re-configured. Engineering a complete system that
allowed for both oligonucleotide synthesis and gene synthesis in a single, integrated device
leveraging the same architecture, plumbing, and fluid manipulation scheme would certainly be
the most challenging, but perhaps in the long term the most desirable. More immediately, the
goal of direct gene synthesis proposed here should be facilitated by simply taking a two-layer
PDMS-fluidic device and aligning and
MOW-- bonding it to a microarray with 'exposed'
oligos. Taking into account this design
requirement, several microarray platforms
uo•tsance were considered for fabricating integrated
fluidic-microarray devices: Agilent 12
(physical deprotection by ink-jet),
Nimblegen"' 13 (UV photocleavage using
DMD), Affmyetrix 14 (UV photocleavage
using physical masks), Combimatrix15
(electrochemical deprotection utilizing a
CMOS chip) and a photoelectrochemical
deprotection method developed by Brian Y.
Chow16. Ultimately, Agilent and Nimblegen
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Figure 6.5: Nimblegen (MAS) technology for
generating microarrays with accessible oligos. From relative to other microarray platforms in the
www.nimblegen.com case of the former", and because of the
11 Personal communication, P.A. Carr and G.M. Church
12 Hughes, T.R. et al. (2001) Expression profiling using microarrays fabricated by an ink-jet
oligonucleotide synthesizer. Nat. Biotechnol. 19, 342-347.13 Singh-Gasson, S., Green, R.D., Yue, Y., Nelson, C., Blattner, F., Sussman, M.R., and Cerrina, F.(1999) Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array.
Nature Biotechnology, 17, 974-978.
14 Fodor, S.P., et al. (1991) Light-directed, spatially addressable parallel chemical synthesis.
Science 251, 767-773.
15 Maurer, K. et al. (2006) Electrochemically Generated Acid and Its Containment to 100 Micron
Reaction Areas for the Production of DNA Microarrays. Plos one 1, e34.
16 Chow, B.Y. (2008) Photoelectrochemical Synthesis of Low-Cost DNA Microarrays. Ph.D.
Thesis.
similarly demonstrated gene synthesis and importantly high density of oligo spots in the case of
the latter. The process flow for Nimblegen (MAS) synthesis is shown in figure 6.5.
6.3 Microfluidic-microarray integration
Experiments to directly synthesize genes on the surface of microarrays in a microfluidic
environment followed a trajectory of first overcoming the microfluidic design challenges of
device integration (device design, bonding and alignment), followed by an investigation of the
molecular biology necessary to cleave oligos from the surface and assemble them into genes. In
this section, the various microfluidic-microarray integration challenges will be discussed.
6.3.1 Bonding
The major design constraint for any bonding methodology between a fluidic and microarray is the
fact that the exposed oligos on the microarray surface must survive the process unscathed. Thus,
many conventional methods for bonding PDMS and glass substrates such as plasma bonding or
corona discharge were not possible due to the inevitable DNA damage. Similarly, high-
temperature processes such as anodic bonding could not be pursued. Ultimately, several methods
that would not cause DNA damage during the bonding process were evaluated. As reported by
Liu et al. 17, for example, multi-layer fluidic devices can be successfully sealed to open-face
microarrays, such as the spotted arrays described, simply by bringing together the clean, native
glass surface of the array with a clean PDMS surface, as seen in Figure 6.5a. In this case, sealing
was performed without any surface chemistry or external pressure, and is reversible. Another
alternative involves utilizing an external pressure source of some kind to forcefully bond the
microarray with a fluidic device. In Wei et al."8, for example, a steel clamp is used to bring into
contact a spotted microarray with a fluidic device with reactor features etched in glass in a
sandwich-like structure, as seen in Figure 6.5b.
17 Liu J, Williams BA, Gwirtz RM, Wolf BJ, Quake SR. "Enhanced Signals and Fast Nucleic Acid
Hybridization By Microfluidic Chaotic Mixing " Angew. Chem. 2006 45:3618-3623
18 Wei, C.W., Cheng, J.Y., Huang, C.T., Yen, M.H., and Young, T.H. (2005) Using a microfluidic
device for 1 gL DNA microarray hybridization in 500s. Nucleic Acids Research 33, e78.
(A)
Vertical Flat Surface
Figure 6.5(a) Multi-layer PDMS device reversibly sealed to a spotted microarray without surface
chemistry or external pressure. From Liu et al.16 (b) Sealing a glass-based fluidic structure with a spotted
microarray utilizing a steel clamp. From Wei et al.' 7
Ultimately, for the work in this chapter, an adhesive bonding methodology was utilized to seal a
multi-layer PDMS device with a high-density in situ (oligos synthesized directly on the surface;
as opposed to an ex situ, or spotted array) DNA microarray. The reasons were several-fold.
Firstly, while the adhesive-free sealing from Liu et al. can in fact sustain internal pressures
sufficient for mixing by peristaltic pumping, ultimately such reversible sealing proves incapable
of surviving the internal pressures generated during PCR thermocycling (e.g. 94 0 C), and leads to
delamination. While an external pressure source of some kind was an intriguing possibility using
either clamps or, as had been previously demonstrated in our group, an air bladder"9 , ultimately
this path was abandoned due to the inability to achieve uniform pressure across the entire surface
of the device area. Given inhomogeneous sealing, valve performance was either poor or non-
functional. It should be noted that an applied force could in fact be quite a robust sealing method
in the case of single-layer fluidics using soft or hard materials (as seen by Wei et al. 17); however,
multi-layer structures prove more difficult to work with due to the more complex internal
pressures involved.
19 Personal communication, Eric Wilhelm
(B)
The bonding method utilized is shown in figure 6.6, and is a modified version of the adhesion-
transfer techniques described by Satyanarayana et al.20 and Wu et al.21 Here, a transfer substrate
(typically a glass microscope slide) is first prepared by spinning a pre-polymer solution of PDMS
(10:1, monomer:curing agent, in toluene at a mass ratio of 1:7) at 500 rpm for 3s, followed by
1500 rpm for 60s. Next, the fluidic device, with raised features indicating reactors, is gently
inked to the PDMS prepolymer-coated transfer substrate. Contact is maintained for 60s without
any additional pressure applied from above. The fluidic is then removed from the transfer
surface, leaving a thin layer of prepolymer adhesive on only the raised features of the fluidic
device. This layer has previously been measured to be several hundred nanometers thick20 , which
is negligible relative to the width (>100 pm) and height (10 pm) of the channels, thus ensuring
that none of the prepolymer adhesive will spread into the channels, thus avoiding interaction with
any of the microarray oligos. Finally, the device is aligned (described in the subsequent section)
and bonded to the DNA microarray and cured at low temperature (600C) overnight.
Spin adhesive Contact fluidic to adhesive
+
Thermal cure
Transfer adhesive to microarray
Figure 6.6: Methodology for bonding fluidic devices to DNA microarrays.
Using this type of bonding process, irreversibly sealed fluidic-microarray devices could be
fabricated where the DNA was unperturbed during the bonding itself. Internal pressures in the
10-15 psi range were tolerated and thermocycling was possible without causing device
delamination, thus enabling all of the necessary device functions.
20 Satyanarayana S., Karnik R.N., and Majumdar, A. (2005) Stamp-and-Stick Room-Temperature
Bonding Technique for Microdevices. Journal ofMicroelectromechanical Systems 14, 392-399.21 Wu, H., Huang, B., and Zare, R.N. (2005) Construction of microfluidic chips using polydimethylsiloxane
for adhesive bonding. Lab on a Chip, 5, 1393-1398.
This adhesive bonding technique worked best for bare glass substrates as would be the case with
ex situ, or spotted microarrays. In the case of in situ DNA microarrays, however, typically large-
scale, homogeneous surface functionalization is utilized (e.g. capping), thus rendering the surface
chemically different from native glass. This points to an inherent disadvantage of adhesive
bonding; it is not general and must be compatible with the surface chemistry of the exposed
microarray surface. To that point, Agilent chips were tested for bonding utilizing adhesive
transfer and delaminated easily, due to incompatibility with the proprietary surface coating. DNA
microarrays fabricated via Nimblegen technology from Professor Franco Cerrina were ultimately
utilized for the various tests described in this chapter. Bonding to these arrays was successful
given a regiment of three washes in Tween 20 prior to adhesive transfer.
6.3.2 Device Design
For this first generation set of devices and experiments, the ultimate goal was to demonstrate the
synthesis of a gene-length construct, from microarray oligos, in an integrated fluidic-microarray
chamber. Assuming success, even in a large volume relative to ultimate desired volumes (e.g.
100 pL), scaling-up should proceed readily. Thus, initial device designs were borrowed to the
extent possible from the previously successful designs shown in Chapter 5. The microfluidic
device designed for integration with DNA microarrays is shown in figure 6.7, with food coloring
used to illustrate the various components: two 500 nL reactors are featured, shown in blue; each
reactor has an inlet and outlet with bifurcation channels to evenly distribute flows entering and
exiting the reactors. In the control layer, there are two valves, one addressing all inlets and the
other addressing all outlets, shown in red. Finally, there is also a water jacket, shown in yellow,
which sits atop both reactors to help minimize sample evaporation during thermocycling. "Push-
down" valving geometry was also employed (and required).
Figure 6.7: Optical image of the two-layer microfluidic device to be aligned and bonded to the DNA
microarray. Food coloring is utilized to highlight various components.
The device is fabricated using the same protocol described in section 5.2.2, with the important
difference being that instead of bonding to a third layer of PDMS that would ultimately serve as
the 'floor' of the device, the two-layer device was bonded to the DNA microarray according to
the protocol described in 6.3.1. In order to achieve the most reproducible, strongest bonds, the
device needed to undergo the adhesive-transfer protocol while still in a partially-cured state, i.e.
immediately after trimming and coring the bonded control and flow layers after their 45 minute
back at 80 0C.
6.3.3 Alignment
For these first generation devices, alignment was accomplished by hand, aided by optical
microscopy, using the edge of the microarray itself as the alignment marker. From array to array,
the location of the oligo spots themselves is nearly identical-at the center of each microscope
slide, covering a total area of 10.5 mm x 14.0 mm. Three alignment pins set the position of the
microscope slide upon which the array is fabricated, and such positioning is sufficient for array
placement accuracy in the tens of microns. As can be seen in figure 6.8, two layers of photoresist
were exposed 'blindly' using the DMD system, the first layer leaving an outer cross, the second
layer leaving an inner cross. Given that the only alignment used between resist processing steps
was the pin positioning, the accuracy of such placement resulted in a misalignment error of +/- 10
to 20 jpm. Thus, the predominant source of error in terms of array placement comes from
differences in the dimensions of each slide (25 +/- 0.2mm x 76 +/- 0.3mm). These several
hundred micron differences in slide dimension ultimately determine the alignment tolerance when
using the microscope slide edge as the registration mark.
Figure 6.8 Image showing alignment error from two resist layers exposed with the DMD system utilized
for array DNA microarray fabrication. Misalignment between inner and outer crosses is approximately ten
to twenty microns. Image courtesy of Mike Bassetti.
The initial device was designed such that the two 500 nL reactors would sit directly above the
10.0 mm x 14.0 mm array area, with the total footprint of the two reactors being sufficiently small
enough that they would be surrounded by more than 1 mm of DNA on all sides, as seen in Figure
6.9a. Here, the dashed line indicates the DNA array area. Given this geometry, the several
hundred micron alignment error present from the variation in microscope slide dimension would
be more than offset, ensuring that the reaction chambers would be enclosing the desired oligo
spots.
Figure 6.9 (a) Optical image of the designed microfluidic device overlaying the DNA array, with the DNA
array area indicated by a dashed line. (b) Optical image of the two-layer PDMS microfluidic aligned and
bonded to a DNA microarray.
For future device designs, registration markers on both the microfluidic device and the array itself
will be utilized to ensure alignment accuracy below 10 microns.
6.4 Oligonucleotide cleavage
The next major technical challenge involved deciding upon the methodology for releasing the
anchored oligonucleotides, which are bound covalently to the microscope slide surface, into
solution in the microfluidic chamber, whereupon they could be assembled into genes via PCA.
Three techniques were initially considered: chemical cleavage8s 10, enzymatic cleavage by type II
restriction enzymes, enzymatic cleavage by Uracil DNA glycosylase (UDG) and an
endonuclease, or finally enzymatic cleavage by Ribonuclease A (RNase A)9. In evaluating these
options, as has been the theme, simplicity in adaptation to microfluidics was forefront in mind.
Cleavage alternatives requiring purification or separation steps were eliminated due to the
required additional on-chip functionality. An ideal cleavage method would have a high cleavage
yield and be compatible with the molecular biology necessary to perform PCA, thus allowing for
single-pot syntheses and simplified microfluidic operation. Even moderate yield should be
sufficient given the high expected concentrations of oligos (section 5.4). Chemical cleavage by
ammonium hydroxide (NH40H), despite its high cleavage yield, was eliminated for these reasons
of necessary on-chip purification. Ultimately enzymatic cleavage by type II restriction enzymes
and a blend of UDG and endonuclease was explored.
6.4.1 Type II restriction enzymes
Type II restriction enzymes, which have previously been demonstrated to be successful at
cleaving micro oligos (e.g. Bulyk et al.22), were first examined as a cleavage mechanism. The
mechanism for such cleavage is shown schematically in Figure 6.10. Because Type II restriction
enzymes require a double-stranded DNA substrate, for this type of cleavage, in addition to the
enzyme itself a separate single-stranded DNA molecule is required to hybridize with the anchored
microarray oligo for the appropriate recognition site to be formed. This additional oligo, or
'helper oligo,' is shown as an orange arrow, which hybridizes to a complementary region of DNA
on the anchored microarray oligo, as seen in stage 2. All microarray oligos were designed such
that every oligo shared a common distance from the array surface (in terms of nucleotide spacing
and strand length), and also a common recognition sequence to which the helper oligo, and
subsequently restriction enzyme, can bind. After annealing, the restriction enzyme then binds to
the double-stranded recognition site (stage 3), cutting and liberating the microarray oligos, now
ready for construction by PCA, into solution (stage 4).
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Figure 6.10. A schematic depicting the enzymatic cleavage method to release construction oligos from a
microarray surface using type II restriction enzyme digestion. Initially (stage 1) the oligos are anchored
by their 3' ends (arrowheads) to the array surface. Enzymes (blue circles) and helper oligos (short
orange arrows) are also in solution. Helper oligos hybridize to complementary regions, indicated in
orange, on the anchored oligos (stage 2). The restriction enzyme binds to the recognition site (stage 3)
and cleaves the oligo (stage 4).
In order to assess whether type II restriction enzymes were a viable option for microarray oligo
cleavage, first, in vitro tests were performed, whereby this cleavage methodology would be tested
with un-anchored oligos in solution. Mlyl, an 'outside cutter,' was the type II restriction enzyme
selected for initial testing, and recognizes the 10-base sequence shown below:
22 Bulyk, M.L., Gentalen, E., Lockhard, D.J., and Church, G.M. (1999) Quantifying DNA-protein
interactions by double-stranded DNA arrays. Nature Biotechnology, 17, 573-577
•'/////////////,/////J////////•
5' AGGTGGACTC 3'
3' TCCACCTGAG 5'
A randomized amino acid sequence of the alba gene from S. solfataricus (total length 327 bp)
was parsed using DNAWorks to yield a design consisting of.16 oligos, of which the 14
construction oligos were 38 bases long each. A randomized protein sequence was used for in
vitro tests while the wild type protein sequence was utilized for the design of oligos to be
synthesized on the microarray itself, thus keeping with an appropriate level of stringency to
ensure that any contamination from in vitro tests would not impact tests with actual microarrays.
Parse and full sequence information for both alba variants is available in Appendix A6. As we
have seen throughout our work in gene synthesis, amplification on contaminant DNA can be a
non-trivial source of error during experimentation. The full-length design for each oligo, as it
would appear on the microarray surface, consisted of (5' to 3'): the 38 base 'payload' to be
utilized in PCA, a universal (across all 14 oligos) 10-base sequence for helper oligo annealing and
enzyme recognition, and finally a poly-T segment 12 bases long to yield a final oligo 60 bases in
length. 60-mer oligos were ordered from Integrated DNA Technologies (IDT).
In vitro cleavage tests were performed by incubating, at 370 C, a mixture of the 60 base oligos (14
oligos, 25 nM each), the 15 base helper oligo (500 nM) complementary to the Mlyl recognition
site, and finally the restriction enzyme itself. 500 nM of the helper oligo was chosen to ensure
saturation of the 350 nM of 60-mers. Digestion products were visualized by denaturing PAGE, as
is seen in Figure 6.11, and are as expected: bands for the full-length 60-mer and 15-mer helper
oligo are evident for undigested product (lane 2) but, after digestion with Mlyl, yield the 38-mer
construction payload and 22-mer 'waste' products.
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Figure 6.11 Denaturing PAGE showing the products of the in vitro digestion of sixteen 60-mers, facilitated
by a 15-mer helper oligo. The sixteen released 38-mers are the construction oligos to be used in DNA
assembly. Lane 1 shows the digested product; lane 2 the original undigested mix.
A more rigorous characterization of oligo cleavage efficiency as a function of Mlyl concentration
(units/pL) and helper oligo relative to 60-mer (reactant) concentration is shown in Figure 6.12.
As might be anticipated, when the concentration of helper oligo is only a fraction of the reactant
concentration, cleavage does not proceed fully; however, once those ratios are equivalent or
greater, all reactions with an Mlyl concentration greater than 0.5 U/pL proceed to completion
(i.e., all 60-mer reactants are consumed). Reactant/product ratios were calculated by measuring
gel band intensities utilizing AlphaEaseFC software from Alpha Innotech Corporation.
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Figure 6.12 Graph showing digestion of 60-mer reactants as a function of Mlyl concentration and also the
concentration of helper oligo relative to reactant concentration.
6.4.2 USER mix, UDG and endo IV
The second type of enzymatic cleavage tested utilized a blend of UDG and endonuclease, either
endonuclease IV or endonuclease VIII. All enzymes were purchased from New England Biolabs
(NEB), with the UDG and endonuclease VIII coming in a commercially available mix, sold as
USER (Uracil-Specific Excision Reagent) by NEB. The cleavage mechanism is shown
schematically in figure 6.13. Here, each microarray oligo is synthesized with at least a single
Uracil base present. The UDG works by excising Uracil, leaving an abasic site which the
endonuclease recognizes and cleaves, thus releasing the construction payload into solution.
Endonuclease IV and VIII operate slightly differently, however, in that after cleaving the abasic
site, endo IV leaves a hydroxyl group at the 3' terminus and a deoxyribose 5'-phosphate at the 5'
terminus, while endo VIII leaves phosphate groups at both 3' and 5' termini. It was thought that
the 3' hydroxyl group would be necessary for gene synthesis, but as we shall see in the
subsequent section, USER still enables gene synthesis. One general advantage of using this
enzyme blend is that no 'helper oligo' is required and all protein-DNA interaction is with single-
stranded DNA, thus potentially eliminating some of the steric issues involved when using Mlyl.
i 0 A h,
0
- -*
->~(
1 2 3 5
Figure 6.13. A schematic depicting the enzymatic cleavage method to release construction oligos from a microarray
surface utilizing UDG and endonuclease. Initially (stage 1) the oligos are anchored by their 3' ends (arrowheads) to
the array surface. Each oligo features a Uracil base. UDG (red circles) and endonuclease (green circles) are also in
solution. UDG binds to Uracil bases in the single stranded DNA (stage 2), excising the base and leaving an
apyrimidinic site (asterisk, stage 3). Endonuclease then binds (stage 4), cleaving at the abasic site and liberating the
construction payload (black lines) into solution (stage 5).
As with Mlyl, cleavage by UDG/endonuclease was first characterized in vitro with un-anchored
60-mer oligos. An antifreeze gene (300 bp) was parsed utilizing DNAWorks into 12 oligos, and
the 10 construction oligos were synthesized with a single Uracil base present in each. The design
for each oligo, as it would appear on the microarray surface, consisted of (5' to 3'): a 44 base
construction payload, a single Uracil base, and a poly-T segment 15 bases long serving as a
spacer. An example of such a sequence is shown below for oligo "b2," with the full parse and
sequence information for all oligos found in Appendix A6:
Anti-b2 GCAGCACAAACAGCAGGCCGGTCAGTATTACGCTTTTCATATGC/ ideoxyU/TTTTTTTTTTTTTTT
In vitro cleavage characterization was accomplished for both sets of enzymes by incubating the
10 construction oligos (each at 25 nM) at 370 C for 1 hour, viewing the digested products with
denaturing gel electrophoresis, and tabulating the resultant band intensities. As can be seen in
figure 6.14, in the case of UDG with endonuclease IV, the concentration of endonuclease has the
most significant impact; for three separate UDG concentrations, endonuclease IV concentration
greater than 0.2 U/pL leads to almost complete digestion of the 60-mer reactants. Utilizing the
USER mix, for concentrations greater than 0.1 U/pL, similarly all products are digested.
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Figure 6.14 Graphs showing digestion of reactant antifreeze oligos as a function of (a) UDG and
endonuclease IV and (b) USER mix.
6.5 Single pot cleavage and synthesis in vitro and in fluidic
Because microarrays are an expensive commodity, to the extent possible, experiments that would
proof the essential concepts without using arrays were conducted. So, upon completion of
characterizing the cleavage reactions in vitro, the next step involved performing single pot
cleavage followed by gene synthesis, both in vitro and also in a microfluidic environment, again
using un-anchored oligos (no microarray). Reaction mixes testing the Mlyl cleavage system
were prepared containing 1 mM dNTPs (250 pM each), 0.15 U/gL of Pfu Hotstart Turbo
Polymerase (Stratagene), IX cloned Pfu Buffer (Stratagene), 0.1% n-Dodecyl-[3-D-maltoside
(Sigma), 25 nM of each construction oligo of the 'shuffled' alba gene, 500 nM of amplifying
primers, 350 nM of the helper oligo, and 1 U/pL of Mlyl. This mixture was kept on ice until
placed either in a PCR tube or loaded into a microfluidic device such as the one described in
section 5.2.2. The reaction proceeded by first incubating at 370 C, where cleavage of the 60-mers
into 22-mers and the desired 38-mer construction oligo occurred, followed by thermocycling
whereby the 327 bp gene are subsequently assembled and amplified. This one-pot cleavage,
assembly, and amplification is successfully verified in the gel shown in Figure 6.15 for the in
vitro case.
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Figure 6.15 PAGE showing the single-pot, in vitro cleavage and synthesis of the 327 bp 'shuffled' alba
gene.
For the influidic case, the 4-reactor microfluidic device (500 nL each reactor) was loaded with
three separate reaction mixes; in reactor 1 only oligos are present; in reactor 2 MlyI was
introduced in addition, facilitating cleavage; in lane 3
+ + + 60-mers polymerase is present, thus enabling PCA. These
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- 327-mer For the UDG and endonuclease blends, similar
experiments were carried out. Each combined cleavage
and synthesis reaction contained the same reaction mix as
indicated previously, with Mlyl and the helper oligo
exchanged for either UDG (0.1 U/pL) and endo IV (0.2
U/pLL) or USER (0.1 U/pL). As seen in figure 6.15, again,
both conditions do in fact yield the desired full-length 300
bp antifreeze gene, for both in vitro and also influidic
cases. It is of interest to note here that, despite the
presence of a 3'-phosphate for oligos cleaved via USER,
synthesis still proceeds; this could be explained by the
Figure 6.16 Denaturing PAGE
demonstrating the in situ cleavage of inherent exonuclease activity of the polymerase. It is also
60-mers yielding construction oligos possible that the endonuclease VIII generates 3' hydroxylswhich are subsequently assembled to
the desired 327-mer gene and instead of 3' phosphates at some low frequency. While
amplified in a single-step PCA, all in
one microfluidic device. such a process yields successful gene synthesis for the
small number of construction oligos seen here (10 oligos), for larger oligo pools such inefficient
generation of 3' hydroxyls could adversely affect the concentration of even a single oligo, thus
disrupting the assembly process and causing the synthesis to fail.
tube in fluidic M tube in fluidic MM
300 base pair
gene
500
300 base pair
250 gene
coU 
r
uIuIJIU4IU !J IIIMbUU IJI I
s + - + + o + - + +
UDG/endolV USER
Figure 6.17 PAGE showing the single-pot, cleavage and synthesis of the 300 bp antifreeze gene both in
vitro and influidic.
6.6 Microfluidic-microarray direct cleavage of oligos
Once these various in vitro and influidic tests were completed, the next step was to verify
whether the enzymatic cleavage methods would work for microarrays. DNA microarrays were
fabricated via a custom Maskless Array Synthesizer (MAS) 1 from the lab of Professor Franco
Cerrina. For the Mlyl-based array, 60-mers were synthesized for the alba gene (not randomized)
with sequences shown in Appendix A6.6, while for the arrays tested for UDG and endonuclease
cleavage, 60-mers for alba featuring an individual Uracil base were synthesized. These
sequences can also be found in A6.6. The oligo layout is shown in figure 6.18, where the
fourteen construction oligos (top strand oligos with prefix 't' and bottom strand oligos with prefix
'b') are tiled throughout the 10.0 mm x 14.0 mm area. Each oligo spot has a 13 pm feature size.
Oligos were synthesized with a "1 in 4" format, where only one out of every four spot areas is
used for oligo synthesis with the remaining areas capped; such a strategy helps to reduce errors
that occur at the edge of each oligo spot exposure23
23 Kim, C., Kaysen, J., Richmond, K., Rodesch, M., Binkowski, B., Chu, L., Li, M., Heinrich, K., Blair, S.,
Belshaw, P., Sussman, M., and Cerrina, F. (2006) Progress in gene assembly from a MAS-drive DNA
microarray. Microelectronic Engineering 83, 1613-1616.
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Figure 6.18 Layout for alba construction oligos on the array surface. The dimension of each spot is 13 gtm.
Integrated microfluidic-microarray devices were fabricated as described in section 6.3. To test
for the various cleavage schemes with microarrays, the following reaction mixes were prepared:
IX cloned Pfu Buffer (Stratagene), 0.1% n-Dodecyl-3-D-maltoside (Sigma), and 0.4%
Polyvinylpyrrolidone (PVP), combined with either: (a) helper oligo (2 pM) and Mlyl (2 U/pjL);
(b) UDG (0.3 U/pLL) and endo IV (2 U/gL); or (c) USER mix (0.5 U/pL). The PVP was added as
it has previously been shown to be effective as a dynamic passivating agent in the case of glass-
PDMS systems24. Each of these mixes was loaded into the two 500 nL reactors of 3 different
microarrays (one for Mlyl digestion and two featuring Uracil bases) and incubated at 370 C for 1
hour. The sample was collected from the device reactors with 4.5 pL of dH20 (into a 5 pL total
volume), and was further diluted 20-fold before three PCR reactions were carried out to assay
whether certain individual oligos were successfully liberated from the microarray surface within
each reactor. PCR reactions that amplify top strand oligos t03, t07, and tO 11 (see Appendix A6.6
for primer sequences) were prepared with standard concentrations of polymerase, buffer, and
dNTPs and thermocycled for 30 cycles according to the following protocol: 94 0C for 2 minutes;
30 cycles of 940C for 30s, 55 0 C for 30s, 72 0C for 30s; 720 C for 1 minute; and finally down to
40 C. The presence of PCR bands (along with successful negative controls) would indicate that
that particular oligo was successfully cleaved from the device. Denaturing PAGE as seen in
6.19a reveals that for Mlyl, only oligo t3 yielded a PCR band, while oligos t7 and tl 1 were not
cleaved in sufficient quantity to be assayable by PCR. The "double band" present is a common
artifact of denaturing PAGE25. For UDG/endoIV and USER cleavage, however, PCR bands of
varying intensity were observed for all three sets of assayed oligos (figure 6.19b and c). The
band intensities for each experiment are inhomogeneous, however, which is of course not
24 Xia, Y-M., Hua, Z-S., Srivannavit, O., Ozel, A.B., and Gulari, E. (2007) Minimizing the surface effect ofPDMS-glass microchip on polymerase chain reaction by dynamic polymer passivation. Journal of
Chemical Technology & Biotechnology, 1, 33-38.
25 Peter Carr, personal communication
desirable given the fickle nature of oligo concentration as it relates to gene synthesis; however,
these initial tests verify that, at a minimum, the enzymatic cleavage methods, without any
optimization, do in fact yield cleaved products. The next set of experiments will involve the
ultimate step of influidic cleavage and gene synthesis from the microarray surface.
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Figure 6.19 Denaturing PAGE showing PCR
products assaying for the presence of three
different top-strand microarray oligos (t3, t7,
tl 1) in the case of(a) Mlyl cleavage, (b)
UDG/endo IV cleavage, and (c) USER
cleavage.
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Figure 6.1 "Leapfrog" gene synthesis from microarray oligos. Image courtesy of Brian Chow.
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7 Integrated microfluidic gene and protein synthesis
Figure 7.1 (left): Structure of green fluorescent
protein (GFP). From Tsien'.
Figure 7.2 (right): Confocal image of GFP
synthesized in a microfluidic device. Scale bar
indicates 300 pm. .
7.1 Introduction
Large-scale, high throughput integrated gene and protein synthesis would be an invaluable
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proteins would be useful to researchers synthesizing novel
proteins, while the potential exists even for those working
on constructing genetic circuits in vitro. Many of the in vivo
tests of genetic circuits could be replaced with influidic
examinations2 and directed evolution 3.
Figure 7.2
1 http://www.tsienlab.ucsd.edu/Images.htm
2 Sprinzak D. and Elowitz, M.B. (2005) Reconstruction of genetic circuits. Nature, 438, 443-448.
3 Griffiths, A.D., and Tawfik, D.S. (2000) Man-made enzymes - from design to in vitro
compartmentalization. Current Opinion in Biotechnology, 11, 338-353.
7.2 In vitro gene and protein synthesis
In order to realize this vision of an integrated gene and protein synthesis device, as has been the
guiding philosophy throughout much of this thesis work, steps were first taken to proof the
essential concepts in vitro before moving to the more challenging microfluidic environment. The
first steps in this regard were selection of target fluorescent proteins, then the design of gene
expression constructs, followed by the synthesis and expression of these genes in vitro.
Functioning protein could then be assayed by fluorometer.
7.2.1 Fluorescent Protein Selection
In selecting fluorescent proteins (FPs), several factors were examined: compatibility with the
laser lines of the available confocal scope (Zeiss LSM Pascal confocal microscope); intrinsic
brightness (i.e. product of extinction coefficient and quantum yield); and lastly compatibility with
cell-free transcription/translation systems (e.g. will the protein fold properly?). Tsien et al.4 was a
valuable reference in evaluating the various available fluorescent proteins. The proteins initially
selected for gene and protein synthesis are shown in Table 7.1. eGFP, eYFP, and mOrange5 were
well-suited because of their brightness and compatibility with the laser lines of the available
confocal scope (488 nm Argon, 514 nm Argon, 548 nm Helium Neon). DsRed was initially
tested as well because of its already demonstrated microfluidic gene synthesis from previous
work (chapter 5), and Cerulean 6 was later synthesized to add a relatively bright blue fluorescent
protein that was also an Aequorea Victoria GFP mutant, as those proteins expressed well in initial
tests.
Table 7.1: The various fluorescent proteins selected for gene and protein synthesis along with associated
characteristics of note.
Fluorescent Organism Excitation Emission Brightness
Protein (nm) (nm) (% of
fluorescein)
4 Shaner, N.C., Steinbach, P.A., and Tsien, R.Y. (2005) A guide to choosing fluorescent proteins. Nature
Methods, 2, 905-909.
5 Shaner, N.C., Campbell, R.E., Steinbach, P.A., Giepmans, B.N.G., Palmer, A.E., and Tsien, R.Y. (2004)
Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red
fluorescent protein. Nature Biotechnolol., 22, 1567-1572.
6 Rizzo, M.A., Springer, G.H., Granada, B. and Piston, D.W. (2004) An improved cyan fluorescent protein
variant useful for FRET. Nature Biotechnol., 22, 445-449.
Cerulean Aequorea victoria 433 475 39%
eGFP Aequorea victoria 484 511 49%
eYFP Aequorea victoria 514 527 74%
mOrange Discosoma sp. 548 562 71%
DsRed Discosoma sp. 556 586 5.1%
As an aside, the methods of directed evolution employed to generate these various mutant
fluorescent proteins are ones of great interest for miniaturization and automation, and could be a
strong application for the technology described in this thesis given sufficient technological
maturation and advancement. For example, for the development of both mOrange[ref] and
Cerulean [ref], a combined rational and combinatorial design was employed, where select amino
acid residues were targeted for mutation and mutants were then randomly generated (e.g., two
hydrophobic residues in the case of Cerulean). Such an approach would be well-suited for
microfluidic gene synthesis (generation of mutant library) and subsequent protein synthesis
(prototyping mutants, selecting winners) given the relatively small combinatorial parameter
space.
7.2.2 Cell-free protein synthesis with circular and linear templates
Initially, in addition to protein selection, testing of cell-free protein synthesis was also
accomplished. While a variety of commercially available cell-free expression systems exist,
ultimately the Rapid Translation System (RTS) 100 E. coli HY Kit from Roche was chosen for
initial tests due to its widespread use in the literature and also its robustness in the hands of other
lab members. Initial experiments were performed to assess firstly, whether linear constructs of
the type generated during gene synthesis could be successfully expressed, and secondly, whether
unpurified products post-gene synthesis could yield functional protein. To assess both of these
factors, firstly T7 regulatory elements that would enable gene expression were added to the 993
bp eGFP construct built in Chapter 5 by the "RTS E. coli Linear Template Generation Set, His-
tag" Kit from Roche. This entails two PCR reactions: one for the additions of overlap regions
using custom primers, and a second for the addition of the T7 regulatory elements (downstream
promoter, upstream terminator). Addition of T7 regulatory elements to generate linear constructs
was also performed for a circular eGFP plasmid (pEGFP, BD Biosciences). Negative controls
were also run for these PCR reactions without any template and only primers present.
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Figure 7.3 Protocol for adding T7 regulatory elements for in vitro expression. From the Roche manual for
"Rapid Translation System RTS E. coli Linear Template Generation Set, His-tag."
Upon completion of regulatory element addition, linearized samples were purified utilizing a
QIAquick PCR purification kit. Next, protein synthesis was performed utilizing the RTS 100 E.
coli HY Kit from Roche. 20 pL reactions containing kit master mix (E. coli lysate, Reaction Mix,
Amino Acids, Methionine, and Reconstitution Buffer) along with 4 pL of PCR product (linear
template from plasmid or PCA, clean and unclean, primer-only negative control, 20% of the
reaction volume) was incubated at 300C for 6 hours in an Eppendorf Mastercycler Gradient
thermocycler and maintained at 40C (either on the thermocycler or in a 4°C refrigerator) prior to
being imaged by a Spex Fluoromax fluorometer. Fluorometer measurements were taken in a 120
pL total volume (20 pL protein synthesis + 100 pL dH20) with 1-nm steps, a 1 second integration
time, entrance/exit slits 2.0 nm, xcittion = 488 nm. Signals were averaged 3 times per sample.
The fluorometer scans are shown in figure 7.4
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As can be seen from the fluorometer scans, all eGFP samples yielded functional, fluorescent
protein; however, purified samples gave 1.3 and 1.7 times greater fluorescence for linear pEGFP
and linear PCA eGFP samples, respectively. The presence of fluorescent protein without
purification was a promising result in that, for microfluidic integration, such an on-chip
purification step would not be necessary. However, clearly purification has a substantial benefit
in terms of increasing signal intensity; thus, future device designs could include some on-chip
refinement (e.g. via microfluidic affinity columns7).
7.2.3 Design of linear FP gene expression constructs
Given the success of linear constructs in yielding functional FPs, the next step was to design and
parse gene expression constructs into oligos for synthesis by PCA. Because the T7 regulatory
elements from the Roche linear template generation kit worked well, those exact sequences were
added to the coding regions of Cerulean, eGFP, eYFP, and mOrange; the DsRed construct
already featured previously designed regulatory elements. DNAWorks was used to generate
oligos with these regulatory DNA sequences fixed while codon optimization was utilized for the
protein sequences. Complete parses for these constructs can be found in Appendix A.7.2. A
schematic depicting the approximate break-up of the oligo design relative to the position of
regulatory elements is shown in figure 7.5. Because initial gene synthesis did not fare well for
the full length, 30 oligo constructs (Cerulean, eGFP, eYFP, and mOrange were all parsed into 30
oligos as shown in figure 7.5), constructs shorter than the full length were generated. A set of
constructs was generated that would preserve functionality of essential regulatory elements for
protein synthesis (promoter, RBS). Because oligos tl and b30 contained potentially unnecessary
sequence information (again, these sequences originated from the Roche kit), the following sets
of additional constructs were pooled and synthesized for Cerulean and eYFP: tl to b28 (all
regulatory elements), tl to b26 (no terminator), t3 to b30 (all regulatory elements), t3 to b28 (all
regulatory elements), t3 to b26 (no terminator). For eGFP and mOrange, the following sets of
additional constructs were pooled and synthesized: tl to b28 (all regulatory elements), tl to b24
(no terminator), t3 to b30 (all regulatory elements), t3 to b28 (all regulatory elements), t3 to b24
(no terminator).
7 Hong JW, Studer V, Hang G, Anderson WF, Quake SR. 2004. A nanoliter-scale nucleic
acid processor with parallel architecture. Nat. Biotechnol. 22(4):435-39
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Figure 7.5 Schematic of a gene expression construct for (a) Cerulean and eYFP and (b) mOrange and
eGFP, with oligo positions relative to regulatory elements indicated. Promoter, RBS, and Terminator are
labeled, with the blue and green regions indicating the open reading frame for Cerulean and eGFP,
respectively.
7.2.4 Analysis of in vitro gene and protein synthesis by PAGE and fluorometer
Once some problematic reagents were eliminated (a bad stock of dNTPs), all variants were
eventually generated by PCA, as seen in figures 7.6 and 7.7. PCA reaction mixtures contained: 1
mM dNTPs (250 pM each), 0.05 U/pL of Pfu Hotstart Turbo Polymerase (Stratagene), IX cloned
Pfu Buffer (Stratagene), 10 nM of each construction oligo depending on the construct, and 500
nM of each amplifying outside primer. Negative controls were also conducted where
construction oligos were excluded (primers only). Thermocycling was performed on an
Eppendorf Mastercycler Gradient thermocycler according to the following protocol: 940C for two
minutes to activate the polymerase; 45 cycles of 94'C for 30 seconds, 55 0C for 30 seconds, and
720 C for 60 seconds; and finally, a final extension period of no less than 2 minutes.
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Figure 7.6 PAGE showing synthesis of mOrange variants
(1-30) and (1-24) along with primers-only negative
controls.1000750
Upon completion of gene synthesis by PCA, cell-free protein synthesis was attempted for all
constructs. Protein synthesis and fluorometer scans were conducted as described in section 7.2.2.
While all gene expression constructs were in fact synthesized via PCA, ultimately only the
Aequorea Victoria mutants of GFP yielded functional protein, as seen in figure 7.7. The
Discosoma sp.FPs (DsRed and mOrange) did not yield fluorescence above background levels; it
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Figure 7.7 Fluorometer and PAGE results for Cerulean, eGFP, and eYFP. Excitation frequencies are
indicated for fluorometer scans, while PAGE images for all constructs, including primers-only negative
controls, are also shown.
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is unknown during what stage of the protein synthesis that failure occurred. Poor synthesis for
Discosoma sp.FPs could be affected by a variety of factors, including reaction temperature and
duration, or the lack of chaperones, for example. The strongest sets of potential concerns,
however, deal with a lack of generality in regards to the RTS protein synthesis system. For the
proposed integrated gene and protein synthesis tool to be maximally effective, a robust, widely
applicable cell-free expression system is highly desirable.
Of particular note for the results shown in figure 7.7 is that significant fluorescence signal was
measured for FPs expressed from all constructs despite the lack of a purification step in between
gene and protein synthesis. This result boded well for the prospect of miniaturization in
microfluidic devices as, again, incorporation of on-chip purification would have been a non-
trivial addition. This also highlights the power and ease of gene synthesis; it is possible within a
24 to 48 hour period to go from protein design (virtual) to protein on-hand (physical) via mail
order oligos and two simple reactions, thus eliminating the need for any of the laborious steps
associated with traditional DNA manipulation (e.g. cloning).
When examining the fluorescence data for this set of experiments, one notable feature in terms of
correlating content of the DNA construct to fluorescence intensity (and thus efficiency of
expression) was the substantial decrease in fluorescence for all constructs that did not feature
terminators. The utility of a highly parallelized gene to protein synthesis device would depend
greatly upon its ability to generate similar data sets which could lead to conclusions linking
genotype and phenotype. Again, such a tool could be invaluable for large scale comparative
structural studies (e.g. biobrick prototyping: do I get better expression with terminator A or
terminator B?).
7.3 Gene and protein synthesis in microfluidic devices
Given successful in vitro gene and protein synthesis results, the next step involved miniaturizing
each of these processes in a microfluidic environment, first separately and finally in an integrated
system. Given the already successful microfluidic gene synthesis results of chapters 5 and 6, the
next major step was the demonstration ofmicrofluidic protein synthesis. Several other research
groups have recently demonstrated synthesis of proteins in microfabricated volumes 8' 9,10 ,1 1,12
notably all in a well-based format (no on-chip fluid manipulations; all automation must come
from external agents, e.g. fluid dispensing robots). Key characteristics of each of these works are
shown in table 7.2; device images from Yamomoto, Mei, and Kinpara can be seen in figure 7.8.
The most impressive demonstration was the work of Kinpara et al., where GFP synthesis from 10
DNA molecules was measured in 1 pL wells, a volume only -100 larger than an E. coli cell (tens
of femtoliters). The use of a glass and PDMS material set for that work also bodes well in terms
of gauging the potential ultimate limits of minimum reactor volume and maximum reactor density
for the work presented in this thesis. Both microfluidic gene and protein synthesis reaction
volumes should scale down well from the tens to hundreds of nLs used in this work. As an aside,
it would also be interesting to test via a system such as Kinpara's reactors how reactor volume
(and ultimately surface effects) affects the resolution of gene expression. At what point would I
be unable to compare the performance between two terminators with known performance
differences? At what point do we start to sacrifice resolution for throughput?
Table 7.2: A comparison of various in vitro protein syntheses performed in miniaturized systems.
Reference Year Expression Microchip Reactor Protein
System material Volume
Tabuchi Adipose-type fatty acid
[REF] 2002 RTS PMMA 10 gL binding protein (A-
FABP)
Glass, ITO, GFP, Blue FluorescentYamamoto 2002 RTS 125 nLPDMS Protein (BFP)
Angenendt 2004 RTS glass 1.5 gL to 100 GFP, -galactosidase
nL
Kinpara 2004 RTS PDMS, glass 150, 5, and GFP
Mei 2005 RTS Acrylic 13 pL GFP, CAT, luciferase
Mei 2005 RTS Acrylic 13 gL GFP, CAT, luciferase
8 Tabuchi M, Hino M, Shinohara Y, Baba Y (2002) Cell-free protein synthesis on a microchip.
Proteomics, 2, 430-435
9 Yamamoto T, Nojima T, Fujii T (2002) PDMS-glass hybrid microreactor array with embedded
temperature control device. Application to cell-free protein synthesis. Lab on a Chip, 2, 197-202
10 Angenendt P, Nyarsik L, SzaflarskiW, Glokler J, Nierhaus KH, Lehrach H, Cahill DJ, Lueking A (2004)
Cell-free protein expression and functional assay in nanowell chip format. Anal Chem 76, 1844-1849.
l Kinpara T, Mizuno R, Murakami Y, KobayashiM, Yamaura S, Hasan Q, Morita Y, Nakano H, Yamane
T, Tamiya E (2004) A picoliter chamber array for cell-free protein synthesis. J Biochem 136, 149-154
12 Mei Q, Fredrickson CK, Jin SG, Fan ZH (2005) Toxin detection by a miniaturized in vitro protein
expression array. Anal Chem 77, 5494-5500.
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Figure 7.8 Images from of various microchips utilized for in vitro protein synthesis, including: 125 nL
reactors integrated with ITO heaters from Yamamoto (upper left); 13 pL wells in acrylic from Mei (upper
right); and 150 pL (a), 5 pL (b), and 1 pL (c) PDMS-on-glass well arrays from Kinpara.
7.3.1 Design and fabrication of microfluidic devices for gene and protein synthesis
Microfluidic devices for gene and protein synthesis were designed and fabricated for conducting
initial experiments testing out the individual modules. The microfluidic device presented in
section 5.2.2 was modified by adding two additional 500 nL reactors (7 total) and also bifurcation
channels to evenly distribute flow at the inlets and outlets of the device, as seen in figure 7.9.
Other slight modifications on the wafer-level in terms of device spacing and placement were
made to facilitate easier fabrication.
Figure 7.9 Optical image of an updated device design for microfluidic- gene synthesis featuring 7 parallel
500 nL reactors. Insets show bifurcation channels at inlets and exits.
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Microfluidic devices for protein synthesis were designed and fabricated by multi-layer soft
lithography (section 5.2.2) as shown in figure 7.10. The devices feature 14 parallel reactors, each
15 nL in volume (excluding the dead volume from the device inlet), with channel widths of 100
pim. The devices were designed such that all fourteen reactors could be viewed within a single
field of view of the confocal scope (Zeiss LSM Pascal confocal microscope) at the center of the
chip. The reactors also have no outlets; they are designed to be dead-end pressure loaded and
imaged, so protein is never extracted from the device.
The device shown in figure 7.10a is a single-layer device, while the one in figure 7. 10b features
two-layers. The 'control' layer here does not feature valves, but instead channels from which air
or oxygen can be supplied to nearby reaction channels. The presence or absence of molecular
oxygen has a significant impact upon the maturation of FPs, as 02 is required to dehydrogenate
amino acids during chromophore formation13 . Because fluorescence formation is prevented by
anoxic conditions, it was thought that, despite the porosity of PDMS, maturation efficiency could
be enhanced by an increased oxygen flux. In an ideal case, such oxygen channels could
potentially increase the signal from each reactor in a tunable fashion (as a function of oxygen
flux), which would of course be a welcome outcome. Such experiments will be the subject of
future work.
A B
Figure 7.10 Optical image of two microfluidic devices designed for protein synthesis, with food coloring
utilized to highlight features: (a) a single-layer device featuring 14 parallel reactors (blue), each 15 nL in
volume and (b) a two-layer device with channels to supply oxygen to potentially improve protein
maturation.
13 Hansen, M.C., Palmer, R.J., Jr, Udsen, C., White, D.C. & Molin, S. (2001) Assessment of GFP
fluorescence in cells of Streptococcus gordonii under conditions of low pH and low oxygen concentrations.
Microbiology, 147, 1383-1391.
7.3.2 Gene and protein synthesis in microfluidic devices
Upon completion of device fabrication, the next step was to demonstrate successful microfluidic
gene synthesis for the linear FP gene expression constructs detailed in section 7.2.3. Reaction
mixes were prepared as described in section 7.2.4, and microfluidic gene synthesis was performed
as described in sections 5.2.5 and 5.2.7. The results of PAGE (section 5.2.9) are shown in figure
7.11 for Cerulean, eYFP, and eGFP constructs, indicating that microfluidic gene synthesis yielded
FP gene expression constructs of the appropriate length.
Cerulean u M eYFP eGFP
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Figure 7.11 PAGE results for microfluidic synthesis of Cerulean, eYFP, and eGFP.
Upon completion of microfluidic gene synthesis, microfluidic protein synthesis was then tested.
Initial experiments were performed with the original microfluidic device design of section 5.2.5.
Protein synthesis mixtures were prepared as in section 7.2.2; the DNA template utilized was the
pIVEX GFP expression vector included with the Roche kit, which was diluted to a concentration
of 0.01 p.g/pL in the final reaction mix. This mixture was then loaded into the 500 nL reactors of
the microfluidic device and incubated for 6 hours at 300C, followed by storage at 40C prior to
imaging via confocal microscopy. Scanning was accomplished utilizing the 488 nm Argon line
with a 505 nm long pass (LP) filter. The results of the imaging are shown in figure 7.12, with
green false coloring. As can be seen, the microfluidic protein synthesis yielded strong
fluorescence relative to the background bulk PDMS. Given this successful result, the next step
was to assess whether the linear FP gene expression constructs assembled via PCA could
similarly yield functional protein in a microfluidic environment.
Iri
Figure 7.12 Confocal microscopy image of GFP
synthesized in a 500 nL microfluidic reactor. Excitation
was performed at 488 nm while imaging was
accomplished a 505 nm long-pass filter.
Microfluidic protein synthesis experiments were first conducted with linear gene synthesis
constructs assembled in vitro. eGFP construct (1-24, no terminator) was synthesized via PCA
(section 7.2.4) and then prepared as the DNA template in a standard protein synthesis mixture
(section 7.2.2). Negative controls with protein synthesis mixture and primers-only (negative
control from PCA) were also prepared. Mixes were then dead-end loaded into the 15 nL reaction
channels of the protein synthesis device at 10 psi for 5 minutes to ensure complete reactor filling
(i.e. no air bubbles). Again, given the device design, channels with protein synthesis experiments
and negative controls could be compared side-by-side in a single field of view of the confocal
scope. Incubation was performed at 300C for 6 hours on the Eppendorf Mastercycler Gradient
thermocycler with in situ adapter suitable for four devices; following incubation, chips were
maintained at 40C either until imaging via confocal microscopy. Scanning was accomplished
utilizing the 488 nm Argon line with a 505 nm long pass (LP) filter; images are shown in figure
7.13, with the autofluorescence negative control labeled. All other channels giving fluorescent
signal contained protein synthesis mixture with the eGFP (1-24) construct, indicating successful
synthesis of functional protein from PCA assembled linear gene expression constructs.
Autofluorescence
Figure 7.13 Confocal microscope images showing strong fluorescent signal relative to
autofluorescence indicating successful synthesis of eGFP from linear templates assembled by PCA.
Excitation was performed at 488 nm while imaging was accomplished a 505 nm long-pass filter.
Scalebars represent 300 gtm.
While strong fluorescence is observable relative to autofluorescence indicating the successful
synthesis of functional protein, some notable and potentially undesirable features include the
presence of what are believed to be concentrated agglomerations of protein, as seen in figure
7.13. While not characterized as a function of time for this work, over long periods (many hours)
protein progressively agglomerates until fairly regularly spaced islands are resolved, as seen for
example in Figure 7.14. Here, eYFP (constructed by PCA) was synthesized in the microfluidic
device and imaged after approximately 30 hours of storage at 40C post-synthesis. While such
aggregation may not be an issue for assay and prototyping applications (e.g. comparing effects of
terminator function on expression), it may prove problematic for applications requiring long-term
protein stability, storage or on-chip utilization (e.g. olfactory sensing on a chip). Protein
aggregation could potentially be reduced via improved surface passivation; as shall be seen in
subsequent sections, several passivating agents were tested to improve device bio-compatibility.
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Figure 7.14 Confocal microscopy
image of microfluidic synthesis of
eYFP. Imaging was performed at
approximately 30 hours of storage
at 4'C, showing regularly spaced
islands.
Upon completion of microfluidic protein synthesis from linear FP gene expression constructs
assembled by in vitro PCA, the next step toward proofing the full integration paradigm involved
first synthesizing the constructs in a microfluidic environment followed by microfluidic protein
synthesis. For this procedure gene synthesis devices shown in section 7.3.1 were first utilized to
construct eYFP and eGFP constructs (section 7.3.2). Upon completion of synthesis, protein
synthesis mixture (2 jtL) was utilized to collect the 500 nL gene synthesis volumes, thus yielding
a reaction mix of the appropriate concentration for protein synthesis, and this mix was then
loaded into the protein synthesis channels. The reaction mixture containing protein synthesis mix
and eluted microfluidic gene synthesis mix (-2.5 pL) was sufficient to load several protein
synthesis channels. Once loaded, the devices were then incubated at 300C for 6 hours followed
by storage at 40C prior to imaging. The results of such an experiment are shown in figure 7.15,
where eYFP and eGFP were synthesized in parallel (following parallel microfluidic gene
synthesis). Three channels were utilized for the synthesis of both fluorescent proteins, as
indicated. Scans were taken utilizing 488 nm and 514 nm excitation for eGFP and eYFP
excitation along with 505 nm and 514 nm long pass filters, respectively. As can be seen from
figure 7.15, strong fluorescent signal relative to autofluorescence was detected, indicating the
successful synthesis of fluorescent protein. There is, however, again the presence of regularly-
spaced aggregates, including in the autofluorescence for this particular sample, indicating that
components of the cell-free expression kit can also agglomerate over time and may also be
mediating the aggregation effects observed during synthesis of fluorescent protein.
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Figure 7.15 Confocal microscope images of eYFP and eGFP synthesized in a microfluidic environment
following parallel microfluidic synthesis of gene expression constructs.
One major challenge for future work will be the optimization of microfluidic protein synthesis
such that robust, reliable data can be consistently generated. Consistency is important not only
from reactor to reactor, but also for within a single microchannel. As can be seen from figure
7.16, for even the same reaction mix within a single microfluidic channel significant variation is
evident. Here, an eYFP gene expression construct was first synthesized in a microfluidic
environment followed by microfluidic protein synthesis in channels 2 and 5, from left to right.
Channel 4 is an autofluorescence negative control. Such inhomogeneity could have arisen from a
variety of sources, from non-uniformly mixed reaction mixtures to variability in the composition
of the PDMS microchannels. Particularly because PDMS is an elastomer, its surface properties
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can be dynamic; as such, surface functionalization, coatings, and highly standardized device
manufacture should be explored to increase the homogeneity of surface properties.
While for the previous microfluidic protein synthesis results in this chapter utilized no surface
coatings, the results shown in figure 7.16 relied upon a 100 cycle pre-treatment with 0.1% n-
Dodecyl-3-D-maltoside (Sigma) as described in section 5.2.5. More extensive studies are
required to establish the potential benefit of such treatment, but anecdotally protein aggregation
appeared to be diminished, though artifacts such as inhomogeneous expression in microchannels
is of course still evident.
Figure 7.16 Inhomogeneous expression in a microfluidic channel for eYFP synthesis (channels 2 and 5
from left to right). Autofluorescence (channel 4 from left to right) is also shown.
The successful demonstration of microfluidic protein synthesis utilizing gene expression
constructs similarly synthesized in a microfluidic environment strongly implies that the proposed
integrated system should work. These experiments in and of themselves, however, are already a
non-trivial demonstration of the power of miniaturization. The Roche cell-free expression system
utilized provides enough reaction mix for conducting twenty-four 50 pL reactions, or, a total of
1.2 mL worth of mix, at a cost of $475 (-$24/reaction); in comparison, given the 15 nL reaction
volumes utilized here, approximately 80,000 reactions could be performed given the same
amount of starting material (0.6 cents/reaction)! While the simple design and substantial dead-
volume at the reaction inlet (-0.5 pL) for each reaction channel of the protein synthesis device
utilized here prevents maximal use of 80,000 reactions, given a more sophisticated design with
better amortization of reagents (e.g. a single reaction inlet addressing multiple reactors, such as in
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the designed integrated system shown in the next section. Liu et al. 14 provides a good example of
efficient reagent amortization in microfluidics), such efficient use of reaction mixture should be
realizable. Other simple advancements in dead volume reduction have also been demonstrated
for fluidic inlets utilizing inert filler materials'5 . Even with the substantial dead-volume
requirement for channel loading in the design shown in figure 7.10, volumes are still small
enough to yield approximately 2,400 reactions for the Roche kit ($0.20/reaction). Combined with
the similarly minimal reagent costs associated with de novo microfluidic gene synthesis, use of
these two sets of microfluidic processes already represents a low-cost protocol for allowing
researchers to rapidly transition from biological design to physical molecule. For assay and
prototyping applications, such high throughput devices should prove to be a useful enabling
technology given the minimal reagent input per information output.
7.4 Integrated gene and protein synthesis in a microfluidic device
Having proofed the core technologies for both gene and protein synthesis, I then designed the
integrated device shown schematically in figure 7.16. The device features several core elements,
notably three parallel serpentine gene synthesis reactors (45 nL each) and also three protein
synthesis reactors (12 nL each). Device operation is described in figure 7.17.
14 Liu, J., Hansen, C., and Quake, S.R. (2003) Solving the "world-to-chip" interface problem with a
microfluidic matrix. Anal. Chem., 75, 4718-4723.
15 Will Grover, personal communication.
Figure 7.17 Denaturing PAGE showing the products of the in vitro digestion of sixteen 60-mers,
facilitated by a 15-mer helper oligo. The sixteen released 38-mers are the construction oligos to be used
in DNA assembly. Lane 1 shows the digested product; lane 2 the original undigested mix.
Device Fabrication
Devices were fabricated utilizing multi-layer soft lithography with "push-up" geometry. In such
a configuration, the control valves are positioned beneath the flow channels instead of above, thus
reducing the required sealing pressure by as much as a factor of three [ref]. Utilizing "push-up"
geometry proved to be particularly crucial as the high sealing pressures (--15 psi) required for
"push-down" valving, along with the long sealing times and high temperatures required during
device pre-treatment and thermocycling, sometimes resulted in permanent valve sealing, thus
rendering devices useless.
Pump characterization
EFigure 6.11 Denaturing PAGE showing the
products of the in vitro digestion of sixteen 60-
mers, facilitated by a 15-mer helper oligo. The
sixteen released 38-mers are the construction
oligos to be used in DNA assembly. Lane 1
shows the digested product; lane 2 the original
undigested mix.
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*protein could be pulled off the chip.
Figure 6.11 Denaturing PAGE showing the products of the in vitro digestion of sixteen 60-mers, facilitated
by a 15-mer helper oligo. The sixteen released 38-mers are the construction oligos to be used in DNA
assembly. Lane 1 shows the digested product; lane 2 the original undigested mix.
Figure 6.11 Denaturing PAGE showing the products of the in vitro digestion of sixteen 60-mers, facilitated
by a 15-mer helper oligo. The sixteen released 38-mers are the construction oligos to be used in DNA
assembly. Lane 1 shows the digested product; lane 2 the original undigested mix.
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Figure 7.X: Integrated Device
Operation. Initially (a), the device is
loaded with PCA mixture capable of
synthesizing DNA constructs for the
expression of, for example, three
fluorescent proteins (e.g. red, green,
and blue) (b). Upon completion of
thermocycling and the assembly of
these protein expression constructs, the
material in the 45 nL reactors can be
collected off the chip for further
analysis (c, d). Next, in vitro transcription/translation mix, seen in yellow, is loaded into the remaining portion of each of the
three mixers (e), followed by the introduction of an auto-fluorescence negative control (f). Finally, each of the three mixer
rings is operated (g), mixing the in vitro transcription/translation mix with each synthesized DNA construct. Upon
completion of mixing (h), the device can be incubated at 300 C to initiate the synthesis of fluorescent protein.
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Below, showing 45 nL synthesis of eGFP in reactor 2.
4-12% GPS gel
1. kb ladder
2. eYFP (+)
3. eYFP (-)
4. eGFP (+)
5. eGFP (-)
6. GPS8/13/07C-eYFP
reactor 1
7. GPS8/13/07C- eGFP
reactor 2
8. GPS8/13/07C- eYFP
reactor 3
9. 10 bp ladder
1 2 3 4 5 6 7 R 9
Surface Treatment of the Chip. At the beginning of each
experiment, Pluronic F-127 (Sigma-Aldrich Corp., St. Louis, MO;
0.2% w/w in PBS, filter-sterilized) was incubated for 1 h inside
the entire network of flow channels except the culture chambers.
This passivated the PDMS surfaces and therefore prevented
adsorption of proteins and adherence of the cells to the channels.
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Figure 7.8 Images from of various microchips utilized for in vitro protein synthesis, including: 125
nL reactors integrated with ITO heaters from Yamamoto (upper left); 13 pL wells in acrylic from
Mei (upper right); and 150 pL (a), 5 pL (b), and 1 pL (c) PDMS-on-glass well arrays from Kinpara.
Scaling up
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DNAWorks output file for the alba gene from S. solfataricus. The amino acid
sequence was randomized prior to conducting the parse.
PARAMETERS FOR TRIAL 9
Total Size Of Gene ......... 327 nt
Protein Residues ........... 101
Mutatable Residues ......... 98
Fixed Nucleotides .......... 33 nt
Oligo Size ................. 38 nt
Annealing Temp ............. 59 +/- 1*C
Oligo Concentration ........ 2.50E-8 M
Sodium Concentration ....... 5.00E-2 M
Mg2+ Concentration ......... 2.00E-3 M
Codon Frequency Threshold .. 10%
Repeat Threshold ........... 8 nt
Mispriming Threshold ....... 8/18 (6 exact) nt
The DNA sequence # 9 is:
1 CGCAGGCTTGCTGATGGTGGTGTACATCAAAGTGCGCCGTGCTGACATTATGCAAGAATC
61 TCAGCCGCGTCGTCGCGGTGTGGAAAAGAAAACGATCGGTTTCAAGGACCAGCTCGAAAT
121 CGGCAAAGTCAGCAACTCCAAGGGCATCATCATCTCCGTTGGCATGAAGGAGGCGAACAC
181 CATCTCTGCCGTCAGCCTGACGAGCGTGCAGATTAACACCCTGGTCAAGCTGTCTAACAT
241 CGTTATCACCCGCGGCAAACGTCTGGAGGTGCTGGCGGCAAGCGTTACTCCGCCTCGTGT
301 TGACGAACCGGCGTAAGCAAGAACTAC
The oligonucleotide assembly is:
1 10 20 30 40 50 60
1 ---> 3 --->
1 CGCAGGCTTGCTGATGGTGGTGTACATCAAAGTGCgccgtgctgacattatgcaagaatc
CCACCACATGTAGTTTCACGCGGCACGACTGTAATACG tag
<--- 2
M V V Y I K V R R A D I M Q E S
5 --- > 7 --- >
61 tcagccgcgtcgt CGGTGTGGAAAAGAAAACGATCGGTTTCAAGGACCAGC cgaaat
agtcggcgcagcagcgccacaccttttcttttgctAGCCAAAGTTCCTGGTCGAGCTTTA
<--- 4
Q P R R R G V E K K T I G F K D Q L E I
9 --- >
121 cggcaaagtcagcaactccaagggcatcatca CTCCGTTGGCATGAAGGAGGCGAACAC
GCCGTTTCAGTCGttgaggttcccgtagtagtagaggcaaccgtacttcct GCTTGTG
<--- 6 <--- 8
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11 ---> 13 --->
181 CATCTCTGCCG cctgacgagcgtgcagattaacaccctggtcaagctgtCTAACAT
GTAGAGACGGCAGTCGGACTGCTCGCACGTC tgtgggaccagttcgacagattgta
<--- 10
I S A V S L T S V Q I N T L V K L S N I
15 --- >
241 CGTTATCACCCGCGGCAAACGTCTGGAGGTG gcggcaagcgttactccgcctcgtgt
gcaatagtgggcgCCGTTTGCAGACCTCCACGACCGCCGTTCGCAATGAGG gcaca
<--- 12 <--- 14
V I T R G K R L E V L A A S V T P P R V
301 tgacgaaccggc
actgcttggccgcattcgttcttgatg
<--- 16
D E P A X
total
total
total
total
total
total
total
total
total
codon usage score ..........
length score ................
hairpin score ...............
melting temperature score ...
repeat score ................
pattern score ...............
mispriming score ............
AT content score ............
GC content score ............
The OVERALL score ......
< GC rich
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.489
0.489
DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence I
0.29
0.71
0.03
0.06
0.06
0.08
0.01
0.77
TCT
TCC
TCA
TCG
CCT
CCC
CCA
CCG
0.32
0.27
0.05
0.07
0.11
0.02
0.15
0.72
TAT
TAC
TAA
TAG
CAT
CAC
CAA
CAG
0.35
0.65
0.63
0.08
0.30
0.70
0.19
0.81
TGT
TGC
TGA
TGG
CGT
CGC
CGA
CGG
0.39
0.61
0.35
1.00
0.64
0.33
0.01
0.01
ATT I 0.34
ATC I 0.66
ACT T 0.29
ACC T 0.54
AAT N 0.17
AAC N 0.83
AGT S 0.05
AGC S 0.24
The
The
The
The
The
The
The
The
The
TTT
TTC
TTA
TTG
CTT
CTC
CTA
CTG
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ATA I 0.01 0 ACA T 0.05 0 AAA K 0.79 4 AGA R 0.01 0
ATG M 1.00 3 ACG T 0.13 2 AAG K 0.22 5 AGG R 0.00 0
GTT V 0.40 4 GCT A 0.28 1 GAT D 0.46 0 GGT G 0.51 2
GTC V 0.14 3 GCC A 0.16 1 GAC D 0.54 3 GGC G 0.43 4
GTA V 0.20 0 GCA A 0.24 1 GAA E 0.75 4 GGA G 0.02 0
GTG V 0.27 6 GCG A 0.32 3 GAG E 0.25 2 GGG G 0.04 0
Frequency Range Number of Codons
0% - 4% 0
5% - 9% 1
10% - 14% 6
15% - 19% 2
20% - 24% 12
25% - 29% 10
30% - 34% 11
35% - 39% 4
40% - 44% 4
45% - 49% 0
>= 50% 51
Total Codons Used = 101
Tm Range # of Overlaps
<47^C 0
47-49^C 0
50-52^C 0
53-55^C 0
56-58^C 8
59-61^C 7
62-64^C 0
65-67^C 0
68-70^C 0
71-73^C 0
>=74^C 0
Tm Range = 1.9
Ovrlap Len Range # of Oligos
<10 0
10-11 0
12-13 0
14-15 0
16-17 4
18-19 8
20-21 3
22-23 0
24-25 0
26-27 0
28-29 0
>=30 0
115
Lowest Overlap = 16
Length Range # of Oligos
<20
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
>=60
Longest = 38
Sequence Patterns Screened (As Supplied By User)
None found
16 oligonucleotides need to be synthesized
CGCAGGCTTGCTGATGGTGGTGTACATCAAAGTGC 35
GCATAATGTCAGCACGGCGCACTTTGATGTACACCACC
GCCGTGCTGACATTATGCAAGAATCTCAGCCGCGTCGT
TCGTTTTCTTTTCCACACCGCGACGACGCGGCTGAGAT
CGGTGTGGAAAAGAAAACGATCGGTTTCAAGGACCAGC
GCTGACTTTGCCGATTTCGAGCTGGTCCTTGAAACCGA
CGAAATCGGCAAAGTCAGCAACTCCAAGGGCATCATCA
TCCTTCATGCCAACGGAGATGATGATGCCCTTGGAGTT
CTCCGTTGGCATGAAGGAGGCGAACACCATCTCTGCCG
CTGCACGCTCGTCAGGCTGACGGCAGAGATGGTGTTCG
CCTGACGAGCGTGCAGATTAACACCCTGGTCAAGCTGT
GCGGGTGATAACGATGTTAGACAGCTTGACCAGGGTGT
CTAACATCGTTATCACCCGCGGCAAACGTCTGGAGGTG
GGAGTAACGCTTGCCGCCAGCACCTCCAGACGTTTGCC
GCGGCAAGCGTTACTCCGCCTCGTGTTGACGAACCGGC
GTAGTTCTTGCTTACGCCGGTTCGTCAACACG 32
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TABLE IIb
DNAWorks output file for the Holliday junction cleavase (hjc) gene from
bacteriophage SIRV-I.
PARAMETERS FOR TRIAL 14
Total Size Of Gene ......... 390 nt
Protein Residues ........... 122
Mutatable Residues ......... 121
Fixed Nucleotides .......... 27 nt
Oligo Size ................. 48 nt
Annealing Temp ............. 60 +/- 1*C
Oligo Concentration ........ 2.00E-8 M
Sodium Concentration ....... 5.00E-2 M
Mg2+ Concentration ......... 2.00E-3 M
Codon Frequency Threshold .. 10%
Repeat Threshold ........... 8 nt
Mispriming Threshold ....... 8/18 (6 exact) nt
The DNA sequence # 14 is:
1 CAGGTAATTCCATATGAACATCCGTCAGTCTGGTAAATACTACGAGTACAAAACTCTGGA
61 GATCCTGGAAAAGAATGGTTTCAAAGCGCTGCGTATCCCGGTTTCTGGTACCGGCAAACA
121 GGCGCTGCCGGACCTGATCGCGACCAAAAACACCATCTACCCTATTGAAGTTAAATC
181 TACCTCTAAAGACGTTGTTACCGTTCGTAATTTCCAGATCGAAAAACTGTTCAAATTCTG
241 CGAAATCTTCAACTTCTGTGAATGCCACCCGCTGGTAACCGTTTACTACAAGAAATACAA
301 AATCGTTATCGTTTATGAACTGTCTCAGGACGTTCGCACCAAAGAAAAAATCAAGTTCAA
361 GTACGGCATCAACTCCTAACTCGAGCGGAC
The oligonucleotide assembly is:
1 10 20 30 40 50 60
I I I I I I 1
1 ---> 3 --->
1 CAGGTAATTCCATATGAACATCCGTcagtctggtaaatactacgagtacaaaactctgga
CCATTAAGGTATACTTGTAGGCAGTCAGACCATTTATGATGCTCATGT ttgagacct
<--- 2
M N I R Q S G K Y Y E Y K T L E
5 --- >
61 gatcctggaaaag CAAAGCGCTGCGTATCCCGGTTTCTGGTACCGGCAAACA
ctaggaccttttcttaccaaagtttcgcgacgcataggg CGTTTGT
<--- 4
I L E K N G F K A L R I P V S G T G K Q
7 --- >
117
121 GGCGCTGCC cgaccaaaaacaacaccatctaccctattgaagttaaatc
CCGCGACGGCCTGGACTAGCGCTGGTTTTTGTTGTGGTAGA gggataacttcaatttag
<--- 6
A L P D L I A T K N N T I Y P I E V K S
9 ---> 1
181 tacctcta AGACGTTGTTACCGTTCGTAATTTCCAGATCGAAAAACTGTTCAAATT g
atggagatttctgcaacaatggcaagcatt GGTCTAGCTTTTTGACAAGTTTAAGAC
<--- 8
T S K D V V T V R N F Q I E K L F K F C
II I I I I I
1 --- > 13 --- >
241 cgaaatcttcaacttctgtgaatgccacccgctggtaaccgtttact CAAGAAATACAA
GCTTTAGAAGTTGAAGACACT ggcgaccattggcaaatgatgttctttatgtt
<--- 10
E I F N F C E C H P L V T V Y Y K K Y K
15 --- >
301 AATCGTTATCGTTTATGAACTGTCTCAGGACGTTCG ccaaagaaaaaatcaagttcaa
ttagcaatagcaaataCTTGACAGAGTCCTGCAAGCGTGGTTTCTTTTTTAGTTCAAGTT
<--- 12 <--
I V I V Y E L S Q D V R T K E K I K F K
361 gtacggcatcaactcctaactcgagc
CATG cgtagttgaggattgagctcgcctg
- 14 <--- 16
Y G I N S X
The total codon usage score ........... 0.000
The total length score ................ 0.000
The total hairpin score ............... 0.000
The total melting temperature score ... 0.000
The total repeat score ................ 0.000
The total pattern score ............... 0.718
The total mispriming score ............ 0.000
The total AT content score ............ 0.000
The total GC content score ............ 0.000
The OVERALL score ...... 0.718
DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence ]
TTT F 0.29 0 TCT S 0.32 5 TAT Y 0.35 1 TGT C 0.39 1
TTC F 0.71 7 TCC S 0.27 1 TAC Y 0.65 8 TGC C 0.61 2
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TTA L 0.03
TTG L 0.06
CTT L
CTC L
CTA L
CTG L
ATT I
ATC I
ATA I
ATG M
GTT V
GTC V
GTA V
GTG V
TCA S 0.05
TCG S 0.07
0.06
0.08
0.01
0.77
0.34
0.66
0.01
1.00
0.40
0.14
0.20
0.27
CCT
CCC
CCA
CCG
ACT
ACC
ACA
ACG
GCT
GCC
GCA
GCG
0.11
0.02
0.15
0.72
0.29
0.54
0.05
0.13
0.28
0.16
0.24
0.32
TAA X 0.63
TAG X 0.08
CAT
CAC
CAA
CAG
AAT
AAC
AAA
AAG
GAT
GAC
GAA
GAG
0.30
0.70
0.19
0.81
0.17
0.83
0.79
0.22
0.46
0.54
0.75
0.25
TGA X 0.35
TGG W 1.00
CGT R
CGC R
CGA R
CGG R
AGT S
AGC S
AGA R
AGG R
GGT G
GGC G
GGA G
GGG G
0.64
0.33
0.01
0.01
0.05
0.24
0.01
0.00
0.51
0.43
0.02
0.04
Frequency Range Number of Codons
0% - 4%
5% - 9%
10%
15%
20%
25%
30%
35%
40%
45%
- 14%
- 19%
- 24%
- 29%
- 34%
- 39%
- 44%
- 49%
>= 50%
Total Codons Used = 122
Tm Range # of Overlaps
<47^C
47-49^C
50-52^C
53-55^C
56-58^C
59-61^C
62-64^C
65-67^C
68-70^C
71-73^C
>=74^C
Tm Range = 1.9
Ovrlap Len Range # of Oligos
<10
10-11
12-13
119
14-15
16-17
18-19
20-21
22-23
24-25
26-27
28-29
>=30
Lowest Overlap = 16
Length Range # of Oligos
<20
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
>=60
Longest = 48
Sequence Patterns Screened (As Supplied By User)
Name
NdeI
XhoI
Seq
CATATG
CTCGAG
Pos Notes
11 forward
380 forward
16 oligonucleotides need to be synthesized
1 CAGGTAATTCCATATGAACATCCGT 25
2 TGTACTCGTAGTATTTACCAGACTGACGGATGTTCATATGGAATTACC
3 CAGTCTGGTAAATACTACGAGTACAAAACTCTGGAGATCCTGGAAAAG
4 GGGATACGCAGCGCTTTGAAACCATTCTTTTCCAGGATCTCCAGAGTT
5 CAAAGCGCTGCGTATCCCGGTTTCTGGTACCGGCAAACAGGCGCTGCC
6 AGATGGTGTTGTTTTTGGTCGCGATCAGGTCCGGCAGCGCCTGTTTGC
7 CGACCAAAAACAACACCATCTACCCTATTGAAGTTAAATCTACCTCTA
8 TTACGAACGGTAACAACGTCTTTAGAGGTAGATTTAACTTCAATAGGG
9 AGACGTTGTTACCGTTCGTAATTTCCAGATCGAAAAACTGTTCAAATT
10 TCACAGAAGTTGAAGATTTCGCAGAATTTGAACAGTTTCGATCTGG
11 GCGAAATCTTCAACTTCTGTGAATGCCACCCGCTGGTAACCGTTTACT
12 ATAAACGATAACGATTTTGTATTTCTTGTAGTAAACGGTTACCAGCGG
13 CAAGAAATACAAAATCGTTATCGTTTATGAACTGTCTCAGGACGTTCG
14 GTACTTGAACTTGATTTTTTCTTTGGTGCGAACGTCCTGAGACAGTTC
15 CCAAAGAAAAAATCAAGTTCAAGTACGGCATCAACTCCTAACTCGAGC
16 GTCCGCTCGAGTTAGGAGTTGATGC 25
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TABLE IIc
DNAWorks output file for DsRed.
PARAMETERS FOR TRIAL 33
Total Size Of Gene ......... 733 nt
Protein Residues ........... 225
Mutatable Residues ......... 216
Fixed Nucleotides .......... 85 nt
Oligo Size ................. 50 nt
Annealing Temp .............
Oligo Concentration ........
Sodium Concentration .......
Mg2+ Concentration .........
Codon Frequency Threshold ..
Repeat Threshold ...........
Mispriming Threshold .......
60 +/- 1*C
2.50E-8 M
5.00E-2 M
2.00E-3 M
10%
8 nt
8/18 (6 exact) nt
The DNA sequence # 33 is:
CTAATACGACTCACTATAGGGAGACACAACGGTAAGGAGATATACATATGGATAACACGG
AAGACGTTATCAAAGAATTCATGCAGTTCAAGGTTCGTATGGAAGGCTCTGTTAACGGCC
ACTACTTCGAAATCGAAGGTGAAGGCGAAGGTAAGCCGTATGAAGGTACCCAGACCGCGA
AACTGCAAGTTACGAAAGGTGGCCCGCTGCCGTTTGCGTGGGACATCCTCTCTCCACAGT
TCCAGTACGGCTCTAAAGCGTACGTTAAACACCCAGCGGACATTCCGGACTACATGAAGC
TCTCTTTCCCGGAAGGTTTCACCTGGGAACGCTCTATGAACTTTGAAGATGGTGGTGTTG
TTGAAGTGCAGCAGGACTCTTCTCTGCAAGACGGTACTTTCATCTACAAGGTAAAATTCA
AAGGTGTCAACTTCCCGGCTGACGGTCCGGTTATGCAGAAAAAAACGGCGGGTTGGGAAC
CGTCTACCGAAAAACTGTACCCTCAGGACGGCGTTCTGAAAGGCGAGATTTCTCACGCGC
TGAAACTGAAAGACGGCGGTCACTACACCTGCGACTTTAAAACCGTTTACAAAGCTAAAA
AGCCGGTTCAGCTGCCGGGTAACCACTACGTTGACTCTAAACTGGACATCACCAACCACA
ATGAAGACTATACCGTAGTTGAGCAGTATGAACACGCGGAAGCGCGTCACTCTGGTTCTC
AACTCGAGCGGAC
The oligonucleotide assembly is:
1 --- > 3 --- >
1 CTAATACGACTCACTATAGGGAGAC aacggtaaggagatatacatatggataacacgg
TTATGCTGAGTGATATCCCTCTGTGTTGCCATTCCTCTATATGTATACCT gtgcc
<--- 2
M D N T
5 --- >
61 aagacgttatcaaagaa CAGTTCAAGGTTCGTATGGAAGGCTCTGTTAACGGCC
ttctgcaatagtttcttaagtacgtcaagttccaagcataccttc ATTGCCGG
<--- 4
121
1
61
121
181
241
301
361
421
481
541
601
661
721
E D V I K E F M Q F K V R M E G S V N G
7 --- >
121 ACTACTTCGAAAT ggcgaaggtaagccgtatgaaggtacccagaccgcga
TGATGAAGCTTTAGCTTCCACTTCCGCTTCCATTCGGCATAC ggcgct
<--- 6
H Y F E I E G E G E G K P Y E G T Q T A
9 --- >
181 aactgcaagttac GCCGTTTGCGTGGGACATCCTCTCTCCACAGT
ttgacgttcaatgctttccaccgggcgacggcaaacgcaccctg TCA
<--- 8
K L Q V T K G G P L P F A W D I L S P Q
11 --- >
241 TCCAGTACGGCTCTAAAG acccagcggacattccggactacatgaagc
AGGTCATGCCGAGATTTCGCATGCAATTTGTGGGTCGCCTGTAAGGC g
<--- 10
F Q Y G S KAYVK H PAD I P DYMK
13 --- >
301 tctctttcccggaaggtttc GAACGCTCTATGAACTTTGAAGATGGTGGTGTTG
agagaaagggccttccaaagtggacccttgcgagatacttgaaacttct AAC
<--- 12
L S F P E G F T W E R S M N F E D G G V
15 --- >
361 TTGAAGTGCAGCAGGA gcaagacggtactttcatctacaaggtaaaattca
AACTTCACGTCGTCCTGAGAAGAGACGTTCTGCCATGAAAGTAGATG cattttaagt
<--- 14
V E V Q Q D S S L Q D G T F I Y K V K F
17 --- >
421 aaggtgtcaacttcc ACGGTCCGGTTATGCAGAAAAAAACGGCGGGTTGGGAAC
ttccacagttgaagggccgactgccaggccaatacgtctt AACCCTTG
<--- 16
K G V N F P A D G P V M Q K K T A G W E
19 --- >
481 CGTCTACCGAA caggacggcgttctgaaaggcgagatttctcacgcgc
GCAGATGGCTTTTTGACATGGGAGTCCTGCCGCAAGACTTTC tgcgcg
<--- 18
122
P S T E K L Y P Q D G V L K G E I S H A
21 --- >
541 tgaaactgaaaga CTACACCTGCGACTTTAAAACCGTTTACAAAGCTAAAA
actttgactttctgccgccagtgatgtggacgctgaaattttgg CGATTTT
<--- 20
L K L K D G G H Y T C D F K T V Y K A K
23 --- >
601 AGCCGGTTCAGC accactacgttgactctaaactggacatcaccaaccaca
TCGGCCAAGTCGACGGCCCATTGGTGATGCAACTGAGATTTGA gtggttggtgt
<--- 22
K P V Q L P G N H Y V D S K L D I T N H
25 --- >
661 atgaagactat AGCAGTATGAACACGCGGAAGCGCGTCACTCTGGTTCTC
tacttctgatatggcatcaactcgtcatacttgtgcgcc CCAAGAG
<--- 24
N E D Y T V V E Q Y E H A E A R H S G S
I I I I I 1 1
721 AACTCGAGCGG
TTGAGCTCGCCTG
<--- 26
Q
The total codon usage score ........... 0.000
The total length score ................ 0.000
The total melting temperature score ... 0.000
The total repeat score ................ 0.000
The total pattern score ............... 0.382
The total mispriming score ............ 0.000
The total AT content score ............ 0.000
The total GC content score ............ 0.000
The OVERALL score ...... 0.382
DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence ]
TTT F 0.29 3 TCT S 0.32 12 TAT Y 0.35 3 TGT C 0.39 0
TTC F 0.71 9 TCC S 0.27 0 TAC Y 0.65 9 TGC C 0.61 1
TTA L 0.03 0 TCA S 0.05 0 TAA X 0.63 0 TGA X 0.35 0
TTG L 0.06 0 TCG S 0.07 0 TAG X 0.08 0 TGG W 1.00 3
CTT L 0.06 0 CCT P 0.11 1 CAT H 0.30 0 CGT R 0.64 2
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CCC P
CCA P
CCG P
0.08
0.01
0.77
0.34
0.66
0.01
1.00
0.40
0.14
0.20
0.27
0.02
0.15
0.72
0.29
0.54
0.05
0.13
A 0.28
A 0.16
A 0.24
A 0.32
Frequency Range
CAC H
CAA Q
CAG Q
AAT N
AAC N
AAA K
AAG K
GAT D
GAC D
GAA E
GAG E
0.70
0.19
0.81
0.17
0.83
0.79
0.22
0.46
0.54
0.75
0.25
Number of Codons
0% - 4%
5% - 9%
10%
15%
20%
25%
30%
35%
40%
45%
- 14%
- 19%
- 24%
- 29%
- 34%
- 39%
- 44%
- 49%
= 50% 147
Total Codons Used = 225
Tm Range # of Overlaps
<57
57
59
60
61
62
63
64
>=65
Tm Range = 1.8
Ovrlap Len Range # of Oligos
<17
17
18
19
20
21
22
23
124
CTC L
CTA L
CTG L
ATT
ATC
ATA
ATG
GTT V
GTC V
GTA V
GTG V
ACT
ACC
ACA
ACG
GCT
GCC
GCA
GCG
CGC R
CGA R
CGG R
AGT
AGC
AGA
AGG
GGT
GGC
GGA
GGG
0.33
0.01
0.01
0.05
0.24
0.01
0.00
0.51
0.43
0.02
0.04
25 2
26 0
>=27 0
Lowest Overlap = 16
Length Range # of Oligos
<39 2
39-40 0
41-42 0
43-44 0
45-46 0
47-48 0
49-50 24
51-52 0
53-54 0
55-56 0
57-58 0
>=59 0
Longest = 50
Sequence Patterns Screened (As Supplied By User)
Name Seq Pos Notes
NdeI CATATG 45 forward
XhoI CTCGAG 723 forward
26 oligonucleotides need to be synthesized
1 CTAATACGACTCACTATAGGGAGAC 25
2 TCCATATGTATATCTCCTTACCGTTGTGTCTCCCTATAGTGAGTCGTATT 50
3 AACGGTAAGGAGATATACATATGGATAACACGGAAGACGTTATCAAAGAA 50
4 CTTCCATACGAACCTTGAACTGCATGAATTCTTTGATAACGTCTTCCGTG 50
5 CAGTTCAAGGTTCGTATGGAAGGCTCTGTTAACGGCCACTACTTCGAAAT 50
6 CATACGGCTTACCTTCGCCTTCACCTTCGATTTCGAAGTAGTGGCCGTTA 50
7 GGCGAAGGTAAGCCGTATGAAGGTACCCAGACCGCGAAACTGCAAGTTAC 50
8 GTCCCACGCAAACGGCAGCGGGCCACCTTTCGTAACTTGCAGTTTCGCGG 50
9 GCCGTTTGCGTGGGACATCCTCTCTCCACAGTTCCAGTACGGCTCTAAAG 50
10 CGGAATGTCCGCTGGGTGTTTAACGTACGCTTTAGAGCCGTACTGGAACT 50
11 ACCCAGCGGACATTCCGGACTACATGAAGCTCTTTCCCGGAAGGTTTC 50
12 TCTTCAAAGTTCATAGAGCGTTCCCAGGTGAAACCTTCCGGGAAAGAGAG 50
13 GAACGCTCTATGAACTTTGAAGATGGTGGTGTTGTTGAAGTGCAGCAGGA 50
14 GTAGATGAAAGTACCGTCTTGCAGAGAAGAGTCCTGCTGCACTTCAACAA 50
15 GCAAGACGGTACTTTCATCTACAAGGTAAAATTCAAAGGTGTCAACTTCC 50
16 TTCTGCATAACCGGACCGTCAGCCGGGAAGTTGACACCTTTGAATTTTAC 50
17 ACGGTCCGGTTATGCAGAAAAAAACGGCGGGTTGGGAACCGTCTACCGAA 50
18 CTTTCAGAACGCCGTCCTGAGGGTACAGTTTTTCGGTAGACGGTTCCCAA 50
19 CAGGACGGCGTTCTGAAAGGCGAGATTTCTCACGCTGAAACTGAAAGA 50
20 GGTTTTAAAGTCGCAGGTGTAGTGACCGCCGTCTTTCAGTTTCAGCGCGT 50
21 CTACACCTGCGACTTTAAAACCGTTTACAAAGCTAAAAAGCCGGTTCAGC 50
125
22 AGTTTAGAGTCAACGTAGTGGTTACCCGGCAGCTGAACCGGCTTTTTAGC 50
23 ACCACTACGTTGACTCTAAACTGGACATCACCAACCACAATGAAGACTAT 50
24 CCGCGTGTTCATACTGCTCAACTACGGTATAGTCTTCATTGTGGTTGGTG 50
25 AGCAGTATGAACACGCGGAAGCGCGTCACTCTGGTTCTCAACTCGAGCGG 50
26 GTCCGCTCGAGTTGAGAACC 20
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TABLE IId
DNAWorks output file for an eGFP construct with a promoter and regulatory elements.
The DNA sequence # 5 is:
1 GGGGACCACTTTGTACAAGAAAGCTGGGTCGCAACGCAATTAATGTGAGTTAGCTCACTC
61 ATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGA
121 GCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCTAGCTTGCATGCC
181 TGCAGGTCGACTCTAGAGGATCCCCGGGTACCGGTCGCCACCATGGTGAGCAAGGGCGAG
241 GAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCAC
301 AAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAG
361 TTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACC
421 TACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAG
481 TCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAAC
541 TACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
601 AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTAC
661 AACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTC
721 AAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAAC
781 ACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCC
841 GCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACC
901 GCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGA
961 ATTCAGCCTGCTTTTTTGTACAAACTTGTGGGG
The oligonucleotide assembly is:
1 10 20 30 40 50 60
I I I I I I
1 --- > 3 --->
1 GGGGACCACTTTGTACAAGAAAGCTGGGT gcaacgcaattaatgtgagttagctcactc
********** < repeat
****************** < misprime
GAAACATGTTCTTTCGACCCAGCGTTGCGTTAATTACACTCA gagtgag
<--- 2
5 ---> 7 ---
61 attaggcacccc GGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATtgtga
******** < repeat
****************** < misprime
taatccgtggggtccgaaatgtgaaatacgaaggcCGAGCATACAACACACCTTAACACT
<--- 4
> 9 --- >
121 gcggataacaatttcacacaggaaacagctatgacca ACGCCTAGCTTGCATGCC
** < repeat
************ < misprime
127
CGCCTATTGTTAAAGTGtgtcctttgtcgatactggtactaatgcggatcgaacgtacg
<--- 6 <--- 8
11 --- >
181 TGCAGGTCGACTCTAGAGGATCCC ccggtcgccaccatggtgagcaagggcgag
****** *********** ********** ********
CCAGCTGAGATCTCCTAGGGGCCCATGGCCAGCGGTGGTACC cgctc
<--- 10
241 gagctgttcacc
ctcgacaagtggcc
13 --- >
CCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCAC
******** **************** ******** ***
ccaccacgggtaggaccagctcg CTGCATTTGCCGGTG
<--- 12
15 --- >
301 AAG ccggcgagggcgagggcgatgccacctacggcaagctgaccc
*** **************** *************** *****
TTCAAGTCGCACAGGCCGCTCCCGCTC ggatgccgttcgactgggacttc
<--- 14
< repeat
< misprime
< repeat
< misprime
< repeat
< misprime
17 --->
361 ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC
**** ********************* **
aagtagacgtggtggccgt GGGACCGGGTGGGAGI
<--- 16
--> 21
421 tacggcgtgcagtgcttcagccgctaccccgaccacat AG'
****************
ATGCCGCACGTC gcgatggggctggtgtacttcgtc
<--- 18
19 -
gacc
CACT T ACT**
CACTGGTGGGACTGG
--- >
CACGACTTCTTCAAG
**** **********
gtgctgaagaagttc
<---
< repeat
< misprime
< repeat
< misprime
128
481 TCCGCCATGCCCGAAGGCTACGTCC
*******
agg GGGCTTCCGATGCAGGF
20
23 --->
gcaccatcttcttcaaggacgacggcaac
************ ********
***~*********
TCCTCGCGTGGTAGAAGAAGTTCCTG
<--- 22
< repeat
< misprime
cgttg
541 tacaagacccgcg
*****
25 --- >
TGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
**************** ******** < repeat
< misprime
< GC rich
atgttctgggcgcggctccacttcaagctcccgctgt
<--- 24
ACTTGGCGTAGCTCGAC
27 ---> 29 --->
601 A catcgacttcaaggaggacggcaacatcctggggcacaagct TACAACTAC
* *********************************
TTCCCGTAGCTGAAGTTCCTCCTGC taggaccccgtgttcgacctcatgttgatg
<--- 26
< repeat
< misprime
31 --- >
661 AACAGCCACAACGTCTATATCATGGCCGACAAG gaagaacggcatcaaggtgaacttc
** ******** ******** < repeat
* < misprime
ttgtcggtgttgCAGATATAGTACCGGCTGTTCGTCTTCTTGCCGTAGTTCCAC
<--- 28 <--- 30
33 --->
721 aagatccgccacaacat GCAGCGTGCAGCTCGCCGACCACTACCAGCAGAAC
*** ********** ****************** ***********
ttctaggcggtgttgtagctcctgccgtcgcacgtcgagc
<--- 32
781 ACCCCCA
*** *******
GGTCGTCTTG
35 --- >
ccccgtgctgctgcccgacaaccactacctgagcacccagtc
******** ************** *************** *****
< repeat
< misprime
< repeat
< misprime
< GC rich
129
TGGGGGTAGCCGCTGCCGGGGCACGACGACGG
<--- 34
tgatggactcgtgggtcagg
37 ---> 39
TGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGC acc
********~****~******
cgggactcgtttctggggttgc
<--- 36
**T
CGCTAGTGTACCAGGACGACCTCAAGCACTGG
>901 gccgccgggatcactctcggcatggacgagctgtacaag
901 gccgccgggatcactctcggcatggacgagctgtacaag
~*t*~**~**************
CGGCGGCCCT
<--- 38
41 --- >
CGGCCGCGACTCTAGA
******~******X*****
cgtacctgctcgacatgttcatttcgccggcgctgagatct
<--- 4
< repeat
< misprime
< GC rich
< repeat
< misprime
< GC rich
961 ATTCAGCCTGCTTTTTTGTACAAACT
t TCGGACGAAAAAACATGTTTGAACACCCC
0 <--- 42
total
total
total
total
total
total
total
total
total
codon usage score ........
length score .............
hairpin score ............
melting temperature score
repeat score .............
pattern score ............
mispriming score .........
AT content score .........
GC content score .........
The OVERALL score ...
Tm Range # of Overlaps
<47^C 0
47-49^C 0
50-52^C 0
53-55^C 0
56-58^C 23
59-61^C 18
< repeat
0.000
0.000
0.000
0.038
14.340
0.000
9.426
0.000
1.450
25.255
841
The
The
The
The
The
The
The
The
The
130
62-64^C 0
65-67^C 0
68-70^C 0
71-73^C 0
>=74^C 0
Tm Range = 5.1
Ovrlap Len Range # of Oligos
<10 0
10-11 0
12-13 1
14-15 4
16-17 11
18-19 11
20-21 11
22-23 3
24-25 0
26-27 0
28-29 0
>=30 0
Lowest Overlap = 13
Length Range # of Oligos
<20 0
20-24 0
25-29 1
30-34 0
35-39 0
40-44 39
45-49 0
50-54 0
55-59 0
>=60 0
Longest = 42
There are 13 potential misprimings with <= 8 non-identical nts:
Oligo Type 5'-start Sequence 3'-start Identical
39 DS 922 ATGGACGAGCTGTACAAG 939 10/18
I I II I I I I I
2 ggGacCacttTGTACAAG 19
31 IS 720 CAAGATCCGCCACAACAT 737 13/18
II II 11111111
119 CAcaATtCcaCACAACAT 102
27 IS 630 CATCCTGGGGCACAAGCT 647 11/18
I I I II III
186 CcTgCaGGcatgCAAGCT 169
131
11 IA 235
599
12 DA 253
340
13 DS 286
628
25 DS 584
335
16 DA 355
436
18 DA 408
595
40 IA 937
473
39 DS 922
529
31 DS 720
615
34 IS 788
872
GGCGAGGAGCTGTTCACC
I I II I 11111
aGCtcGatGCgGTTCACC
CGGTGAACAGCTCCTCGC
aGGTGgcatcgcCCTCGC
GACGTAAACGGCCACAAG
I I II 111111
aACaTcctgGGgCACAAG
TGAACCGCATCGAGCTGA
I I I I I I I I
ccAcCtaCggCaAGCTGA
GGGTCAGCTTGCCGTAGG
I I I II IIII
aGcaCtGCacGCCGTAGG
CACGAGGGTGGGCCAGGG
I III I 111
CgatgcGGTtcaCCAGGG
TGTACAGCTCGTCCATGC
I I I I I 1111 I
TcTtCAagTCcgCCATGC
ATGGACGAGCTGTACAAG
I I 1 II I I
gacGACGgcaacTACAAG
CAAGATCCGCCACAACAT
I I I I ll II
CAAGgaggaCggCAACAT
ATGGGGGTGTTCTGCTGG
i 11 IIIII 1
ATcacatgGTcCTGCTGG
There are 41 repeats greater than 8 nt:
DR Posl = 10 Pos2 = 975 Size = 9 Seql = TTTGTACAA
Seq2 = TTTGTACAA
IR Posl = 10 Pos2 = 976 Size = 9 Seql = TTTGTACAA
Seq2 = TTGTACAAA
PR Posl = 11 Pos2 = 11 Size = 8 Seql = TTGTACAA
Seq2 = TTGTACAA
DR Posl = 12 Pos2 = 932 Size = 8 Seql = TGTACAAG
Seq2 = TGTACAAG
IR Posl = 102 Pos2 = 730 Size = 8 Seql = ATGTTGTG
Seq2 = CACAACAT
PR Posl = 179 Pos2 = 179 Size = 8 Seql = CCTGCAGG
Seq2 = CCTGCAGG
132
252
582
236
323
303
645
601
352
338
419
391
578
920
490
939
546
737
632
771
889
12/18
10/18
11/18
10/18
12/18
10/18
12/18
10/18
11/18
11/18
DR Posl =
PR Posl =
PR Posl =
DR Posl =
IR Posl =
DR Posl =
DR Posl =
DR Posl =
IR Posl =
DR Posl =
DR Posl =
DR Posl =
DR Posl =
DR Posl =
DR Posl =
IR Posl =
DR Posl =
DR Posl =
DR Posl =
DR Posl =
IR Posl =
DR Posl =
DR Posl =
DR Posl =
DR Posl =
DR Posl =
IR Posl =
DR Posl =
188
191
219
233
255
264
272
282
297
316
318
324
337
342
356
356
381
404
425
449
461
471
479
522
532
537
Pos2 = 951 Size = 10 Seql = CGACTCTAGA
Seq2 = CGACTCTAGA
Pos2 = 191 Size = 8 Seql = CTCTAGAG
Seq2 = CTCTAGAG
Pos2 = 219 Size = 10 Seql = CACCATGGTG
Seq2 = CACCATGGTG
Pos2 = 320 Size = 9 Seql = AGGGCGAGG
Seq2 = AGGGCGAGG
Pos2 = 368 Size = 8 Seql = GGTGGTGC
Seq2 = GCACCACC
Pos2 = 630 Size = 8 Seql = CATCCTGG
Seq2 = CATCCTGG
Pos2 = 593 Size = 8 Seql = TCGAGCTG
Seq2 = TCGAGCTG
Pos2 = 789 Size = 8 Seql = CGGCGACG
Seq2 = CGGCGACG
Pos2 = 983 Size = 9 Seql = CCACAAGTT
Seq2 = AACTTGTGG
Pos2 = 322 Size = 11 Seql = GGCGAGGGCGA
Seq2 = GGCGAGGGCGA
Pos2 = 567 Size = 9 Seql = CGAGGGCGA
Seq2 = CGAGGGCGA
Pos2 = 567 Size = 9 Seql = CGAGGGCGA
Seq2 = CGAGGGCGA
Pos2 = 418 Size = 9 Seql = ACCTACGGC
Seq2 = ACCTACGGC
Pos2 = 375 Size = 10 Seql = CGGCAAGCTG
Seq2 = CGGCAAGCTG
Pos2 = 560 Size = 8 Seql = TGAAGTTC
Seq2 = TGAAGTTC
Pos2 = 713 Size = 9 Seql = TGAAGTTCA
Seq2 = TGAACTTCA
Pos2 = 807 Size = 8 Seql = GCTGCCCG
Seq2 = GCTGCCCG
Pos2 = 893 Size = 8 Seql = TCGTGACC
Seq2 = TCGTGACC
Pos2 = 749 Size = 8 Seql = GCGTGCAG
Seq2 = GCGTGCAG
Pos2 = 761 Size = 8 Seql = CCGACCAC
Seq2 = CCGACCAC
Pos2 = 801 Size = 9 Seql = AGCAGCACG
Seq2 = CGTGCTGCT
Pos2 = 519 Size = 10 Seql = CTTCTTCAAG
Seq2 = CTTCTTCAAG
Pos2 = 836 Size = 8 Seql = AGTCCGCC
Seq2 = AGTCCGCC
Pos2 = 612 Size = 9 Seql = CTTCAAGGA
Seq2 = CTTCAAGGA
Pos2 = 622 Size = 9 Seql = GACGGCAAC
Seq2 = GACGGCAAC
Pos2 = 654 Size = 9 Seql = CAACTACAA
Seq2 = CAACTACAA
Pos2 = 714 Size = 8 Seql = TGAAGTTC
Seq2 = GAACTTCA
Pos2 = 716 Size = 8 Seql = ACTTCAAG
Seq2 = ACTTCAAG
560
611
133
DR Posi = 619 Pos2 = 739 Size = 10 Seqi = GAGGACGGCA
Seq2 = GAGGACGGCA
DR Posl = 645 Pos2 = 885 Size = 8 Seqi = GCTGGAGT
Seq2 = GCTGGAGT
DR Posl = 665 Pos2 = 728 Size = 8 SeqI = GCCACAAC
Seq2 = GCCACAAC
DR Posl = 764 Pos2 = 818 Size = 9 Seql = ACCACTACC
Seq2 = ACCACTACC
DR Posl = 825 Pos2 = 843 Size = 8 Seql = CCTGAGCA
Seq2 = CCTGAGCA
PR Posl = 944 Pos2 = 944 Size = 8 SeqI = GCGGCCGC
Seq2 = GCGGCCGC
PR Posl = 975 Pos2 = 975 Size = 10 Seql = TTTGTACAAA
Seq2 = TTTGTACAAA
Sequence Patterns Screened (As Supplied By User)
None found
42 oligonucleotides need to be synthesized
1 GGGGACCACTTTGTACAAGAAAGCTGGGT 29
2 ACTCACATTAATTGCGTTGCGACCCAGCTTTCTTGTACAAAG 42
3 GCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCC 42
4 CGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAG 42
5 GGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAT 42
6 GTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGC 42
7 TGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCA 42
8 GCATGCAAGCTAGGCGTAATCATGGTCATAGCTGTTTCCTGT 42
9 ACGCCTAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATCCC 42
10 CCATGGTGGCGACCGGTACCCGGGGATCCTCTAGAGTCGACC 42
11 CCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACC 42
12 GCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGC 42
13 CCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAG 42
14 CTCGCCCTCGCCGGACACGCTGAACTTGTGGCCGTTTACGTC 42
15 CCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCC 42
16 TGCCGGTGGTGCAGATGAACTTCAGGGTCAGCTTGCCGTAGG 42
17 ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC 42
18 CTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGGG 42
19 GACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACAT 42
20 GGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCG 42
21 AGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCC 42
22 GTCCTTGAAGAAGATGGTGCGCTCCTGGACGTAGCCTTCGGG 42
23 GCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCG 42
24 TGTCGCCCTCGAACTTCACCTCGGCGCGGGTCTTGTAGTTGC 42
25 TGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGA 42
26 CGTCCTCCTTGAAGTCGATGCCCTTCAGCTCGATGCGGTTCA 42
27 CATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCT 42
28 GTTGTGGCTGTTGTAGTTGTACTCCAGCTTGTGCCCCAGGAT 42
29 TACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAG 42
30 CACCTTGATGCCGTTCTTCTGCTTGTCGGCCATGATATAGAC 42
31 GAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACAT 42
32 CGAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGA 42
134
33 GCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCA 42
34 GGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCTGG 42
35 CCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTC 42
36 CGTTGGGGTCTTTGCTCAGGGCGGACTGGGTGCTCAGGTAGT 42
37 TGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGC 42
38 TCCCGGCGGCGGTCACGAACTCCAGCAGGACCATGTGATCGC 42
39 ACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG 42
40 TTCTAGAGTCGCGGCCGCTTTACTTGTACAGCTCGTCCATGC 42
41 CGGCCGCGACTCTAGAATTCAGCCTGCTTTTTTGTACAAACT 42
42 CCCCACAAGTTTGTACAAAAAAGCAGGCT 29
135
A.6 Chapter 6 appendix
Helper oligos:
MlyI-helpl5 AAAAAGAGTCCACCT
MlyI-helpl 6 AAAAAAGAGTCCACCT
MlyI-helpl8 AAAAAAAAGAGTCCACCT
MlyI-help20 AAAAAAAAAAGAGTCCACCT
MlyI-help22 AAAAAAAAAAAAGAGTCCACCT
136
A.7 Chapter 7 Appendix
A.7.1 custom primers for T7 regulatory element addition
-custom primers for T7 addition to...pEGFP/eGFP?
A.7.2. DNAworks output files for fluorescent protein gene expression constructs
mOrange
PARAMETERS FOR TRIAL 42
Total Size Of Gene ......... 1079 nt
Protein Residues ........... 237
Mutatable Residues ......... 224
Fixed Nucleotides .......... 407 nt
Oligo Size ................. 58 nt
Annealing Temp ............. 61 +/- 1*C
Oligo Concentration ........ 2.00E-8 M
Sodium Concentration ....... 5.00E-2 M
Mg2+ Concentration ......... 2.00E-3 M
Codon Frequency Threshold .. 10%
Repeat Threshold ........... 8 nt
Mispriming Threshold ....... 8/18 (6 exact) nt
The DNA sequence # 42 is:
1 GATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATA
61 CGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAA
121 GAAGGAGATATACCATGGTTTCCAAAGGCGAGGAAAATAACATGGCGATCATCAAAGAGT
181 TCATGCGTTTCAAAGTTCGTATGGAAGGCTCTGTTAACGGTCACGAATTTGAAATCGAAG
241 GTGAGGGCGAGGGCCGTCCGTACGAAGGTTTTCAAACCGCTAAACTGAAAGTTACCAAGG
301 GTGGTCCGCTGCCGTTTGCGTGGGACATCCTGTCTCCGCAGTTCACCTACGGCTCTAAGG
361 CGTACGTCAAACACCCAGCAGACATCCCTGACTACTTCAAACTGTCTTTCCCAGAAGGCT
421 TCAAGTGGGAGCGTGTTATGAACTTCGAGGATGGTGGCGTGGTTACCGTTACGCAGGACT
481 CTTCTCTGCAAGACGGTGAATTTATCTACAAGGTTAAACTGCGCGGTACCAACTTCCCGT
541 CTGATGGCCCAGTTATGCAGAAAAAAACGATGGGTTGGGAAGCGTCTTCTGAACGTATGT
601 ACCCGGAAGATGGTGCCCTGAAGGGTGAGATCAAAATGCGTCTGAAGCTCAAAGACGGCG
661 GTCACTACACCTCTGAAGTTAAGACTACCTATAAAGCCAAAAAGCCGGTTCAGCTGCCAG
721 GCGCGTACATCGTTGGTATCAAACTCGACATCACTTCTCACAACGAGGACTACACGATTG
781 TTGAACAGTACGAACGTGCCGAAGGTCGCCACTCTACCGGTGGTATGGATGAACTGTACA
841 AATGAGGGGGGGGTTCTCATCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACA
901 CTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGC
961 TGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAG
1021 GGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCC
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The oligonucleotide assembly is
1 --- >
1 GATGCCGGCCACGATGCGTCCGG
3 --- >
atcccgcgaaattaata
****************** < repeat
********* < AT rich
CGGTGCTACGCAGGCCGCATCTCCTAGCTCTAGAGCTAGGGCGCTTTAATTAT
61 cgactcactatagggagaccacaacggtttccctctagaaa
GCTGA
-- 2
5 --- >
GTTTAACTTTAA
gtgttgccaaagggagatctttattaaaacaaattgaaatt
121 GAAGGAGATATACCATGGTTTCCAAAGGCGAGGAAAATAACATGGC
cttcctctatatggtac
<--- 4
< repeat
TCCGCTCCTTTTATTGTACCGCTAGTAGTTTCTCA
M V S K G E E N N M A I I K E
7 --- >
181 tcatgcgtttcaaagttcgtatggaaggctctgttaacggtcacgaatttgaaatcga
AGTACGCAAAGTTTCAAGCATAC tgccagtgcttaaactttagcttc
<--- 6
F M R F K V R M E G S V N G H E F E I E
I I I I I I 1
9 ---
241 CGTCCGTACGAAGGTTTTCAAACCGCTAAACTGAAAGTTACCAAGG
cactcccgctcccggcaggcatgcttccaaaagt GTTCC
<--- 8
G E G E G R P Y E G F Q T A K L K V T K
11 --- >
301 GTGGTCCGCTGC ccgcagttcacctacggctctaagg
CACCAGGCGACGGCAAACGCACCCTGTAGGACAGAGGCGTCAAGTGGATGCCG
<--- 10
G G P L P F A W D I L S P Q F T Y G S K
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< AT rich
13 --- >
361 cgtacgtcaaacacccagcagacatccctgact AGAAGGCT
ggtcgtctgtagggactgatgaagtttgacagaaagggtcttccga
AYVK H PAD I PD Y F K L SF P E G
421 TCAAGTGGGAGCGTGTTATGAACTTCGAGGATGGTGGCGTGGTTACCGTT
agttcaccctcg CCACCGCACCAATGGCAATGCGTCCTGA
<--- 12
F K W E R V M N F E D G G V V T V T Q D
15 I I I I
15 --- >
481 tgcaagacggtgaatttatctacaaggttaaactgcgcggtaccaacttcccgt
GAAGAGACGTTCTGCCACTTAAATAGATGT ccatggttgaagggca
<--- 14
S S L Q D G E F I Y K V K L R G T N F P
17 --- >
541 ctga AAAAAAACGATGGGTTGGGAAGCGTCTTCTGAACGTATGT
gactaccgggtcaatacgtctttttttgctacccaacccttc
<--- 16
S D G P V M Q K K T M G W E A S S E R M
19 --- >
601 ACCCGGAAGATGGTGCCC gtctgaagctcaaagacggcg
GGGCCTTCTACCACGGGACTTCCCACTCTAGTTTTACGCAGACTTCGAGTTTCTGCCG
<--- 18
Y P E D G A L K G E I K M R L K L K D G
21 --- >
661 gtcactacacctctgaagttaagactacctataaagc GCTGCCAG
gagacttcaattctgatggatatttcggtttttcggccaagtcgacggtc
G H Y T S E V K T T Y K A K K P V Q L P
I I I I I 1 1
721 GCGCGTACATCGTTGGTATCAAACTCGACATCACTTCTCACAACGAGGAC
cgcgcatg GTAGTGAAGAGTGTTGCTCCTGATGTGCTAAC
<--- 20
G A Y I V G I K L D I T S H N E D Y T I
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23 --- >
gtacgaacgtgccgaaggtcgccactctaccggtggtatggatgaactgtaca
AACTTGTCATGCTTGCACGGCTTCCA accatacctacttgacatgt
<--- 22
V E Q Y E RA E G R H ST G GM D E L Y
25 --- >
GGTTCTCATCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACA
***~**~************* < repeat
< GC rich
< AT rich
ttactccccccccaagagtagtagtagtagtagtaatt
<--- 24
K X
GTCGTGT
901 CTGGCGGCC
·k********
27 --->
taacaaagcccgaaaggaagctgagttggc
GACCGCCGGCAATGATCACCTAGGCCGACGATTGTTTCGGGCTTTCCTTCG
<--- 26
29 --->
961 tgctgccaccgctgagcaataactagca TAAACGGGTCTTGAG
ggcgactcgttattgatcgtattggggaaccccggagatttgcccagaactc
< GC rich
1021 GGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAG
**t**R***X******
cccaaa
--- 28
total
total
total
total
total
total
total
total
< repeat
CCTTGATATAGGCCTATAGGTGTCCTGCCCACACCAGCGG
<--- 30
codon usage score ...........
length score ................
melting temperature score ...
repeat score ................
pattern score ...............
mispriming score ............
AT content score ............
GC content score ............
The OVERALL score ......
0.000
0.000
0.002
2.298
0.000
0.000
1.186
0.297
3.783
781
841 aatga
The
The
The
The
The
The
The
The
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DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence ]
TTT F 0.29
TTC F 0.71
TTA L 0.03
TTG L 0.06
CTT L 0.06
CTC L 0.08
CTA L 0.01
CTG L 0.77
ATT I 0.34
ATC I 0.66
ATA I 0.01
ATG M 1.00
GTT V 0.40
GTC V 0.14
GTA V 0.20
GTG V 0.27
TCT S
TCC S
TCA S
TCG S
CCT P
CCC P
CCA P
CCG P
ACT T
ACC T
ACA T
ACG T
GCT A
GCC A
GCA A
GCG A
0.32
0.27
0.05
0.07
0.11
0.02
0.15
0.72
0.29
0.54
0.05
0.13
0.28
0.16
0.24
0.32
TAT Y 0.35
TAC Y 0.65
TAA X 0.63
TAG X 0.08
CAT H 0.30
CAC H 0.70
CAA Q 0.19
CAG Q 0.81
AAT N 0.17
AAC N 0.83
AAA K 0.79
AAG K 0.22
GAT D 0.46
GAC D 0.54
GAA E 0.75
GAG E 0.25
TGT C 0.39
TGC C 0.61
TGA X 0.35
TGG W 1.00
CGT R 0.64
CGC R 0.33
CGA R 0.01
CGG R 0.01
AGT S 0.05
AGC S 0.24
AGA R 0.01
AGG R 0.00
GGT G 0.51
GGC G 0.43
GGA G 0.02
GGG G 0.04
Frequency Range Number of Codons
0% - 4%
5% - 9%
10% - 14%
15% - 19%
20% - 24%
25% - 29%
30% - 34%
35% - 39%
40% - 44%
45% - 49%
>= 50%
10
4
145
Total Codons Used = 237
Tm Range # of Overlaps
<59
59
60
61
62
63
64
65
66
>=67
141
Tm Range = 2.0
Ovrlap Len Range # of Oligos
<17 3
17 2
18 2
19 2
20 5
21 3
22 5
24 2
25 1
26 0
>=27 2
Lowest Overlap = 16
Length Range # of Oligos
<48 2
48-49 0
50-51 0
52-53 0
54-55 0
56-57 0
58-59 28
60-61 0
62-63 0
64-65 0
66-67 0
>=68 0
Longest = 58
There are 5 repeats greater than 8 nt:
PR Posl = 30 Pos2 = 30 Size = 18 Seql = GGATCGAGATCTCGATCC
Seq2 = GGATCGAGATCTCGATCC
PR Posl = 132 Pos2 = 132 Size = 8 Seql = ACCATGGT
Seq2 = ACCATGGT
DR Posl = 857 Pos2 = 860 Size = 16 Seql = TCATCATCATCATCAT
Seq2 = TCATCATCATCATCAT
PR Posl = 1046 Pos2 = 1046 Size = 12 Seql = ATATCCGGATAT
Seq2 = ATATCCGGATAT
PR Posl = 1052 Pos2 = 1052 Size = 8 Seql = GGATATCC
Seq2 = GGATATCC
Sequence Patterns Screened (As Supplied By User)
None found
142
30 oligonucleotides need to be synthesized
1 GATGCCGGCCACGATGCGTCCGG 23
2 AGTCGTATTAATTTCGCGGGATCGAGATCTCGATCCTCTACGCCGGACGCATCGTGGC 58
3 ATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAA 58
4 CATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGAAACCGTTGTG 58
5 GTTTAACTTTAAGAAGGAGATATACCATGGTTTCCAAAGGCGAGGAAAATAACATGGC 58
6 CATACGAACTTTGAAACGCATGAACTCTTTGATGATCGCCATGTTATTTTCCTCGCCT 58
7 TCATGCGTTTCAAAGTTCGTATGGAAGGCTCTGTTAACGGTCACGAATTTGAAATCGA 58
8 TGAAAACCTTCGTACGGACGGCCCTCGCCCTCACCTTCGATTTCAAATTCGTGACCGT 58
9 CGTCCGTACGAAGGTTTTCAAACCGCTAAACTGAAAGTTACCAAGGGTGGTCCGCTGC 58
10 GCCGTAGGTGAACTGCGGAGACAGGATGTCCCACGCAAACGGCAGCGGACCACCCTTG 58
11 CCGCAGTTCACCTACGGCTCTAAGGCGTACGTCAAACACCCAGCAGACATCCCTGACT 58
12 GCTCCCACTTGAAGCCTTCTGGGAAAGACAGTTTGAAGTAGTCAGGGATGTCTGCTGG 58
13 AGAAGGCTTCAAGTGGGAGCGTGTTATGAACTTCGAGGATGGTGGCGTGGTTACCGTT 58
14 TGTAGATAAATTCACCGTCTTGCAGAGAAGAGTCCTGCGTAACGGTAACCACGCCACC 58
15 TGCAAGACGGTGAATTTATCTACAAGGTTAAACTGCGCGGTACCAACTTCCCGTCTGA 58
16 CTTCCCAACCCATCGTTTTTTTCTGCATAACTGGGCCATCAGACGGGAAGTTGGTACC 58
17 AAAAAAACGATGGGTTGGGAAGCGTCTTCTGAACGTATGTACCCGGAAGATGGTGCCC 58
18 GCCGTCTTTGAGCTTCAGACGCATTTTGATCTCACCCTTCAGGGCACCATCTTCCGGG 58
19 GTCTGAAGCTCAAAGACGGCGGTCACTACACCTCTGAAGTTAAGACTACCTATAAAGC 58
20 GTACGCGCCTGGCAGCTGAACCGGCTTTTTGGCTTTATAGGTAGTCTTAACTTCAGAG 58
21 GCTGCCAGGCGCGTACATCGTTGGTATCAAACTCGACATCACTTCTCACAACGAGGAC 58
22 ACCTTCGGCACGTTCGTACTGTTCAACAATCGTGTAGTCCTCGTTGTGAGAAGTGATG 58
23 GTACGAACGTGCCGAAGGTCGCCACTCTACCGGTGGTATGGATGAACTGTACAAATGA 58
24 TTAATGATGATGATGATGATGAGAACCCCCCCCTCATTTGTACAGTTCATCCATACCA 58
25 GGTTCTCATCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCC 58
26 GCTTCCTTTCGGGCTTTGTTAGCAGCCGGATCCACTAGTAACGGCCGCCAGTGTGCTG 58
27 TAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCA 58
28 AAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTATTGCTCAGCGG 58
29 TAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAG 58
30 GGCGACCACACCCGTCCTGTGGATATCCGGATATAGTTCC 40
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eGFP
PARAMETERS FOR TRIAL 11
Total Size Of Gene ......... 1160 nt
Protein Residues ........... 264
Mutatable Residues ......... 255
Fixed Nucleotides .......... 395 nt
Oligo Size ................. 60 nt
Annealing Temp ............. 58 +/- 1*C
Oligo Concentration ........ 2.00E-8 M
Sodium Concentration ....... 5.00E-2 M
Mg2+ Concentration ......... 2.00E-3 M
Codon Frequency Threshold .. 10%
Repeat Threshold ........... 8 nt
Mispriming Threshold ....... 8/18 (6 exact) nt
The DNA sequence # 11 is:
1 GATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATA
61 CGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAA
121 GAAGGAGATATACCATGACCATGATCACCCCGTCTCTCCACGCTTGCCGTTCCACTCTCG
181 AAGATCCGCGTGTTCCGGTTGCTACGATGGTCTCTAAAGGTGAAGAACTGTTTACGGGCG
241 TTGTTCCGATCCTGGTTGAGCTGGACGGCGATGTTAACGGTCACAAGTTCTCTGTTTCTG
301 GTGAGGGCGAGGGTGACGCGACCTACGGTAAGCTGACCCTCAAATTCATCTGCACCACCG
361 GCAAACTCCCGGTCCCGTGGCCTACCCTGGTTACTACGCTGACTTACGGTGTTCAATGCT
421 TCTCTCGTTACCCGGACCATATGAAACAGCACGACTTCTTTAAATCTGCTATGCCGGAAG
481 GTTACGTTCAGGAACGTACCATCTTTTTCAAAGACGACGGCAATTACAAAACCCGTGCGG
541 AAGTTAAGTTCGAAGGTGACACGCTGGTGAACCGTATCGAGCTGAAGGGTATCGACTTCA
601 AGGAAGACGGTAACATCCTGGGCCACAAACTGGAATACAACTACAACTCTCACAACGTTT
661 ACATCATGGCGGATAAACAGAAAAACGGTATCAAAGTAAACTTCAAAATCCGTCACAACA
721 TCGAGGACGGTTCTGTTCAGCTGGCGGACCACTATCAACAAAACACCCCTATCGGTGATG
781 GTCCTGTTCTGCTCCCGGACAACCACTACCTGTCTACGCAATCTGCGCTGTCTAAGGACC
841 CGAACGAAAAGCGTGACCACATGGTGCTGCTCGAATTTGTTACGGCAGCGGGTATCACCC
901 TGGGCATGGACGAACTCTACAAATAAGGGGGGGGTTCTCATCATCATCATCATCATTAAT
961 AAAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGC
1021 CCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG
1081 GGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCC
1141 ACAGGACGGGTGTGGTCGCC
The oligonucleotide assembly is:
1 10 20 30 40 50 60
1 I I I I I I
1 --- > 3 --->
1 GATGCCGGCCACGATGCGTCCGGCGTAGAGGAT aaattaata
****************** < repeat
********* < AT rich
GCAGGCCGCATCTCCTAGCTCTAGAGCTAGGGCGCTTTAATTAT
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61 cgactcactatagggagaccacaacggtttccctctagaaataattttgtt
*******•*•* < AT rich
GCTGAGTGATATCCCT
<--- 2
caaagggagatctttattaaaacaaattgaaatt
5 --- >
121 GGAGATATACCATGACCATGATCACCCCGTCTCTCCACGCTTGCCGTTCCACTCTCG
cttcctctatatggtactggtactag CGGCAAGGTGAGAGC
<---- 4
M T M I T P S L H A C R S T L
7 --- >
181 AAG cgatggtctctaaaggtgaagaactgtttacgggcg
TTCTAGGCGCACAAGGCCAACGATGCTACCAGAGATTTCCACTTC
<--- 6
E D P R V P V A T M V S K G E E L F T G
9 --- >
241 ttgttccgatcctggttgagctgg GTTCTCTGTTTCTG
gctaggaccaactcgacctgccgctacaattgccagtgttcaagagacaaagac
V V P I L V E L D G D V N G H K F S V S
301 GTGAGGGCGAGGGTGACGCGACCTACGGTAAGCTGACCCTCAAATT
cactcc CCATTCGACTGGGAGTTTAAGTAGACGTGGTGGC
8
G E G E G D A T Y G K L T L K F I C T T
11 --- >
361 ggtcccgtggcctaccctggttactacgctgacttacggtgttcaatgct
CGTTTGAGGGCCAGGGCACCGGATGG acaagttacga
<--- 10
G K L P V P W P T L V T T L T Y G V Q C
13 --- >
421 tctctcgtta GCACGACTTCTTTAAATCTGCTATGCCGGAAG
agagagcaatgggcctggtatactttgtcgtgctgaagaaatttagacg
<--- 12
F S R Y P D H M K Q H D F F K S A M P E
145
15 --- >
481 GTTACGTTCAGGAACGTACCATCTTTTT aacccgtgcgg
AGTCCTTGCATGGTAGAAAAAGTTTCTGCTGCCGTTAATGTTTTGGGCACGCC
G Y V Q E R T I F F K D D G N Y K T R A
541 aagttaagttcgaaggtgacacgctggtgaaccgtatcgagctgaaggg
TTCAATT ggcatagctcgacttcccatagctgaagt
<--- 14
E V K F E G D T L V N R I E L K G I D F
I I 17 I I I I I
17 --- >
601 CATCCTGGGCCACAAACTGGAATACAACTACAACTCTCACAACGTTT
tccttctgccattgtaggacccggtgtttga TGCAAA
<--- 16
K E D G N I L G H K L E Y N Y N S H N V
19 --- >
661 ACATCATGGCGGA caaagtaaacttcaaaatccgtcacaaca
TGTAGTACCGCCTATTTGTCTTTTTGCCATAGTTTCATTTGAAGTTTTAGGCAG
<--- 18
Y I M A D K Q K N G I K V N F K I R H N
21
721 tcgaggacggttctgttcagctggcggacca ATG
aagtcgaccgcctggtgatagttgttttgtggggatagccactac
I E D G S V Q L A D H Y Q Q N T P I G D
781 GTCCTGTTCTGCTCCCGGACAACCACTACCTGTCTACGCAATCTGCGCTGTCTAAGG
caggacaagacgagg GTTAGACGCGACAGATTCCTGG
<--- 20
G P V L L P D N H Y L S T Q S A L S K D
841
23 --- >
catggtgctgctcgaatttgttacggcagcgggtatcaccc
GCTTGCTTTTCGCACTGGTGTACCACGACGAGCTTAAA
<--- 22
P N E K R D H M V L L E F V T A A G I T
146
901 tgggcatggacgaactcta
25 --- >
TCTCATCATCATCATCATCATTAAT
"******************* < repeat
< GC rich
****** < AT rich
cccgtacctgcttgagatgtttattccccccccaagagtagtagtagtagtagtaatta
<--- 2
L G M D E L Y K X
961 AAAAGGGCGAATTCCAGCACACTGGCGGCCGTTAC
*Jr*·k**** < GC rich
< AT rich
GTGACCGCCGGCAATGATCACCTAGGCCGACGATTGTTTCG
27 --- >
1021 ccgaaaggaagctgagttggctgctgccaccgctgagcaataactagcataaccccttgg
GGCTTTCCTTCGACTCAAC tattgatcgtattggggaacc
<--- 26
29 --- >
AGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCC
**************
ccggagatttgcccagaactccccaaaaaacgactttcc
<--- 28
< repeat
1141 ACAGGACGGGTGTGGTCGC
CTGCCCACACCAGCGG
<--- 30
total
total
total
total
total
total
total
total
codon usage score ..........
length score ................
melting temperature score ...
repeat score ................
pattern score ...............
mispriming score ............
AT content score ............
GC content score ............
0.000
0.000
0.002
1.862
0.000
0.000
1.103
0.276
1081
The
The
The
The
The
The
The
The
147
The OVERALL score ...... 3.243
DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence ]
0.29
0.71
0.03
0.06
0.06
0.08
0.01
0.77
0.34
0.66
0.01
1.00
0.40
0.14
0.20
0.27
TCT S
TCC S
TCA S
TCG S
CCT P
CCC P
CCA P
CCG P
ACT T
ACC T
ACA T
ACG T
GCT A
GCC A
GCA A
GCG A
0.32
0.27
0.05
0.07
0.11
0.02
0.15
0.72
0.29
0.54
0.05
0.13
0.28
0.16
0.24
0.32
TAT Y
TAC Y
TAA X
TAG X
CAT H
CAC H
CAA Q
CAG Q
AAT N
AAC N
AAA K
AAG K
GAT D
GAC D
GAA E
GAG E
0.35
0.65
0.63
0.08
0.30
0.70
0.19
0.81
0.17
0.83
0.79
0.22
0.46
0.54
0.75
0.25
TGT
TGC
TGA
TGG
CGT
CGC
CGA
CGG
AGT
AGC
AGA
AGG
GGT
GGC
GGA
GGG
0.39
0.61
0.35
1.00
0.64
0.33
0.01
0.01
0.05
0.24
0.01
0.00
0.51
0.43
0.02
0.04
Frequency Range Number of Codons
0% - 4%
5% - 9%
10% - 14%
15% - 19%
20% - 24%
25% - 29%
30% - 34%
35% - 39%
40% - 44%
45% - 49%
>= 50%
4
169
Total Codons Used = 264
Tm Range # of Overlaps
<55
55
56
57
58
59
60
61
62
>=63
148
TTT
TTC
TTA
TTG
CTT
CTC
CTA
CTG
ATT
ATC
ATA
ATG
GTT
GTC
GTA
GTG
Tm Range = 2.4
Ovrlap Len Range # of Oligos
<16 1
16 3
17 1
18 7
19 4
20 3
21 5
22 0
23 2
24 0
25 2
>=26 1
Lowest Overlap = 15
Length Range # of Oligos
<49 2
49-50 0
51-52 0
53-54 0
55-56 0
57-58 0
59-60 28
61-62 0
63-64 0
65-66 0
67-68 0
>=69 0
Longest = 60
There are 4 repeats greater than 8 nt:
PR Posl = 30 Pos2 = 30 Size = 18 Seql = GGATCGAGATCTCGATCC
Seq2 = GGATCGAGATCTCGATCC
DR Posl = 938 Pos2 = 941 Size = 16 Seql = TCATCATCATCATCAT
Seq2 = TCATCATCATCATCAT
PR Posl = 1127 Pos2 = 1127 Size = 12 Seql = ATATCCGGATAT
Seq2 = ATATCCGGATAT
PR Posl = 1133 Pos2 = 1133 Size = 8 Seql = GGATATCC
Seq2 = GGATATCC
Sequence Patterns Screened (As Supplied By User)
None found
30 oligonucleotides need to be synthesized
149
1 GATGCCGGCCACGATGCGTCCGGCGTAGAGGAT 33
2 TCCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATCTCGATCCTCTACGCCGGACG 60
3 AAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTT 60
4 GATCATGGTCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGAAAC 60
5 GGAGATATACCATGACCATGATCACCCCGTCTCTCCACGCTTGCCGTTCCACTCTCGAAG 60
6 CTTCACCTTTAGAGACCATCGTAGCAACCGGAACACGCGGATCTTCGAGAGTGGAACGGC 60
7 CGATGGTCTCTAAAGGTGAAGAACTGTTTACGGGCGTTGTTCCGATCCTGGTTGAGCTGG 60
8 CCTCACCAGAAACAGAGAACTTGTGACCGTTAACATCGCCGTCCAGCTCAACCAGGATCG 60
9 GTTCTCTGTTTCTGGTGAGGGCGAGGGTGACGCGACCTACGGTAAGCTGACCCTCAAATT 60
10 GGTAGGCCACGGGACCGGGAGTTTGCCGGTGGTGCAGATGAATTTGAGGGTCAGCTTACC 60
11 GGTCCCGTGGCCTACCCTGGTTACTACGCTGACTTACGGTGTTCAATGCTTCTCTCGTTA 60
12 GCAGATTTAAAGAAGTCGTGCTGTTTCATATGGTCCGGGTAACGAGAGAAGCATTGAACA 60
13 GCACGACTTCTTTAAATCTGCTATGCCGGAAGGTTACGTTCAGGAACGTACCATCTTTTT 60
14 TTAACTTCCGCACGGGTTTTGTAATTGCCGTCGTCTTTGAAAAAGATGGTACGTTCCTGA 60
15 AACCCGTGCGGAAGTTAAGTTCGAAGGTGACACGCTGGTGAACCGTATCGAGCTGAAGGG 60
16 AGTTTGTGGCCCAGGATGTTACCGTCTTCCTTGAAGTCGATACCCTTCAGCTCGATACGG 60
17 CATCCTGGGCCACAAACTGGAATACAACTACAACTCTCACAACGTTTACATCATGGCGGA 60
18 GACGGATTTTGAAGTTTACTTTGATACCGTTTTTCTGTTTATCCGCCATGATGTAAACGT 60
19 CAAAGTAAACTTCAAAATCCGTCACAACATCGAGGACGGTTCTGTTCAGCTGGCGGACCA 60
20 GGAGCAGAACAGGACCATCACCGATAGGGTGTTTTGTTGATAGTGGTCCGCCAGCTGAA 60
21 ATGGTCCTGTTCTGCTCCCGGACAACCACTACCTGTCTACGCAATCTGCGCTGTCTAAGG 60
22 AAATTCGAGCAGCACCATGTGGTCACGCTTTTCGTTCGGGTCCTTAGACAGCGCAGATTG 60
23 CATGGTGCTGCTCGAATTTGTTACGGCAGCGGGTATCACCCTGGGCATGGACGAACTCTA 60
24 TATTAATGATGATGATGATGATGAGAACCCCCCCCTTATTTGTAGAGTTCGTCCATGCCC 60
25 TCTCATCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTTAC 60
26 CAACTCAGCTTCCTTTCGGGCTTTGTTAGCAGCCGGATCCACTAGTAACGGCCGCCAGTG 60
27 CCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG 60
28 CCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTAT 60
29 AGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGC 60
30 GGCGACCACACCCGTC 16
150
eYFP
PARAMETERS FOR TRIAL 44
Total Size Of Gene ......... 1125 nt
Protein Residues ........... 239
Mutatable Residues ......... 232
Fixed Nucleotides .......... 429 nt
Oligo Size ................. 60 nt
Annealing Temp ............. 61 +/- 1*C
Oligo Concentration ........ 2.00E-8 M
Sodium Concentration ....... 5.00E-2 M
Mg2+ Concentration ......... 2.00E-3 M
Codon Frequency Threshold .. 10%
Repeat Threshold ........... 8 nt
Mispriming Threshold ....... 8/18 (6 exact) nt
The DNA sequence # 44 is:
1 CGGTCACGCTTGGGACTGCCATAGGCTGGCCCGGTGATGCCGGCCACGATGCGTCCGGCG
61 TAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAAC
121 GGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGTTAGCAA
181 GGGTGAAGAACTCTTCACGGGTGTTGTTCCGATCCTGGTTGAACTGGACGGTGACGTAAA
241 CGGTCATAAGTTCTCTGTTTCTGGTGAAGGTGAGGGTGACGCGACTTACGGTAAGCTGAC
301 CCTGAAATTCATCTGCACCACCGGTAAACTGCCGGTTCCGTGGCCTACCCTGGTTACCAC
361 CTTTGGTTACGGTCTGCAGTGCTTCGCGCGCTACCCGGATCACATGAAACAGCACGACTT
421 CTTCAAGAGCGCGATGCCTGAGGGTTACGTTCAGGAACGTACCATCTTTTTCAAAGACGA
481 TGGTAACTACAAAACCCGTGCGGAAGTTAAGTTCGAAGGCGATACCCTCGTGAACCGTAT
541 CGAGCTCAAGGGCATCGATTTTAAGGAAGACGGTAACATTCTGGGTCACAAACTGGAATA
601 CAACTATAATTCTCACAACGTTTATATCATGGCGGACAAGCAGAAAAACGGTATCAAAGT
661 GAACTTCAAAATCCGTCACAACATCGAGGACGGTAGCGTTCAGCTCGCGGACCATTATCA
721 ACAAAACACCCCTATCGGCGACGGTCCGGTCCTTCCTGACAACCACTATCTGTCTTA
781 CCAGTCTGCGCTGTCTAAAGACCCAAACGAGAAACGTGACCACATGGTTCTGCTGGAGTT
841 TGTTACTGCAGCGGGTATCACCCTGGGTATGGACGAACTGTACAAAGGGGGGGGTTCTCA
901 TCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTG
961 GATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAA
1021 TAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGA
1081 GGAACTATATCCGGAGCGACTCCCACGGCACGTTGGCAAGCTCGA
----------------------------------------------------------------
The oligonucleotide assembly is:
----------------------------------------------
1 10 20 30 40 50 60
1 --- > 3 --
1 CGGTCACGCTTGGGACTGCCATAGGCTGGCCCG ggcg
CGGTATCCGACCGGGCCACTACGGCCGGTGCTACGCAGGCCGC
151
61 tagaggatcgagatctcgatcccgcgaaattaatacgactcactatagggagacca
******************
ATCTCCTAGCTCTAGAG
<--- 2
< repeat
< AT rich
gctgagtgatatccctctggtgttg
5 --- >
TCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGTTAGCAA
*J*******
ccaaagggagatctttattaaaacaaattgaaatt
<--- 4
< repeat
< AT rich
CTATATGGTACCAATCGTT
M V S K
7 --- >
181 GGGT gtgttgttccgatcctggttgaactggacggtgacgtaaa
CCCACTTCTTGAGAAGTGCCCACAACAAGGCTAGGACCAAC cattt
<--- 6
G E E L F T G V V P I L V E L D G D V N
9 --- >
241 cggtcataagttctctgttt GTGACGCGACTTACGGTAAGCTGAC
gccagtattcaagagacaaagaccacttccactcccactgcgctgaatgccattc
<--- 8
G H K F S V S G E G E G D A T Y G K L T
11
301 CCTGAAATTCATCTGCACCACCGGTAAACTGCCGG cac
GGTGGCCATTTGACGGCCAAGGCACCGGATGGGACCAATGGTG
L K F I C T T G K L P V P W P T L V T T
361 ctttggttacggtctgcagtgcttcgcgcgctacccggatcacatgaaacagcacga
GAAACCAATGCCAGACG cctagtgtactttgtcgtgctgaa
<--- 10
F G Y G L Q C F A R Y P D H M K Q H D F
13 I I I
13 --- >
CCTGAGGGTTACGTTCAGGAACGTACCATCTTTTTCAAAGACGA
gaagttctcgcgctacggactcccaatgcaagtcct GTTTCTGCT
<--- 12
F K S A M P E G Y V Q E R T I F F K D D
121
421
152
15 --- >
481 TGGTAACTACAAAACC cgaaggcgataccctcgtgaaccgtat
ACCATTGATGTTTTGGGCACGCCTTCAATTCAAGCTTCCGCTATGGGAGCA
<--- 14
G N Y K T R A E V K F E G D T L V N R I
17 --- >
541 cgagctcaagggcatcgattttaaggaagacgg GTCACAAACTGGAATA
cgtagctaaaattccttctgccattgtaagacccagtgtttgaccttat
E L K G I D F K E D G N I L G H K L E Y
601 CAACTATAATTCTCACAACGTTTATATCATGGCGGACAAGCAGA
gttgatattaa TATAGTACCGCCTGTTCGTCTTTTTGCCATAGTTTCA
<--- 16
N Y N S H N V Y I M A D K Q K N G I K V
I I I I I
19 --- >
661 gaacttcaaaatccgtcacaacatcgaggacggtagcgttcagctcgcggaccattatca
CTTGAAGTTTTAGGCAGTGTTGT tcgagcgcctggtaatagt
<--- 18
721
N F K I R H N I E D G S V Q L A D H Y Q
21 --- >
TCCGGTCCTCCTGCCTGACAACCACTATCTGTCTTA
tgttttgtggggatagccgctgccaggccaggaggacggac
<--- 20
Q N T P I G D G P V L L P D N H Y L S Y
23 --- >
781 CCAGTCTGCGCTGTCTAAAGACCC atggttctgctggagtt
AGACGCGACAGATTTCTGGGTTTGCTCTTTGCACTGGTGTACCAAGACGACCTCAA
Q S A L S K D P N E K R D H M V L L E F
841 tgttactgcagcgggtatcaccctgggtatggacgaactgtac
ACAA
25 --->
GTTCTCA
*** < repeat
k* < GC rich
gacccatacctgcttgacatgtttccccccccaagagt
153
- 22
V T A A G I T L G M D E L Y K
901 TCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTT
**************** < repeat
< GC rich
< AT rich
agtagtagtagtagtaattatt
<--- 24
GTGTGACCGCCGGCAATGATCAC
27 --- >
gcccgaaaggaagctgagttggctgctgccaccgctgagcaa
CTAGGCCGACGATTGTTTCGGGCTTTCCTTCGACTCA tcgtt
<--- 26
29 --->
1021 taactagcataacccctt TCTTGAGGGGTTTTTTGCTGAAAGGA
attgatcgtattggggaaccccggagatttgcccagaactccccaaaaaacgact
<--- 28
1081 GGAACTATATCCGGAGCGACTCCCACGGCACGTT
CTGAGGGTGCCGTGCAACCGTTCGAGCT
<--- 30
The
The
The
The
The
The
The
The
total
total
total
total
total
total
total
total
codon usage score ...........
length score ................
melting temperature score ...
repeat score ................
pattern score ...............
mispriming score ............
AT content score ............
GC content score ............
The OVERALL score ......
0.000
0.000
0.000
1.493
0.000
0.000
1.138
0.284
2.916
DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence ]
TTT F 0.29
TTC F 0.71
TCT S 0.32
TCC S 0.27
TAT Y 0.35
TAC Y 0.65
TGT C 0.39
TGC C 0.61
961
154
TTA L 0.03
TTG L 0.06
CTT
CTC
CTA
CTG
ATT
ATC
ATA
ATG
GTT
GTC
GTA
GTG
0.06
0.08
0.01
0.77
0.34
0.66
0.01
1.00
0.40
0.14
0.20
0.27
TCA S 0.05
TCG S 0.07
CCT P
CCC P
CCA P
CCG P
ACT T
ACC T
ACA T
ACG T
GCT A
GCC A
GCA A
GCG A
TAA X 0.63
TAG X 0.08
0.11
0.02
0.15
0.72
0.29
0.54
0.05
0.13
0.28
0.16
0.24
0.32
CAT
CAC
CAA
CAG
AAT
AAC
AAA
AAG
GAT
GAC
GAA
GAG
0.30
0.70
0.19
0.81
0.17
0.83
0.79
0.22
0.46
0.54
0.75
0.25
TGA X 0.35
TGG W 1.00
CGT R
CGC R
CGA R
CGG R
AGT S
AGC S
AGA R
AGG R
GGT G
GGC G
GGA G
GGG G
0.64
0.33
0.01
0.01
0.05
0.24
0.01
0.00
0.51
0.43
0.02
0.04
Frequency Range Number of Codons
0% - 4%
5%
10%
15%
20%
25%
30%
35%
40%
45%
- 9%
- 14%
- 19%
- 24%
- 29%
- 34%
- 39%
- 44%
- 49%
>= 50%
Total Codons Used =
4
155
239
Tm Range # of Overlaps
<58
58
59
60
61
62
63
64
65
>=66
Tm Range = 2.0
Ovrlap Len Range # of Oligos
<18
18
19
20
155
22
23
24
25
26
27
>=28
Lowest Overlap = 16
Length Range # of Oligos
<50
50-51
52-53
54-55
56-57
58-59
60-61
62-63
64-65
66-67
68-69
>=70
Longest = 60
There are 3 repeats greater than 8 nt:
PR Posl = 65
PR Posl = 167
DR Posl = 898
Pos2 = 65
Pos2 = 167
Pos2 = 901
Size = 18
Size = 8
Size = 16
Seql = GGATCGAGATCTCGATCC
Seq2 = GGATCGAGATCTCGATCC
Seql = ACCATGGT
Seq2 = ACCATGGT
Seql = TCATCATCATCATCAT
Seq2 = TCATCATCATCATCAT
Sequence Patterns Screened (As Supplied By User)
None found
30 oligonucleotides need to be synthesized
1 CGGTCACGCTTGGGACTGCCATAGGCTGGCCCG 33
2 GAGATCTCGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGGCCAGCCTATGGC
3 GGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCA
4 TTAAAGTTAAACAAAATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCG
5 TCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGTTAGCAAGGGT
6 CAACCAGGATCGGAACAACACCCGTGAAGAGTTCTTCACCCTTGCTAACCATGGTATATC
7 GTGTTGTTCCGATCCTGGTTGAACTGGACGGTGACGTAAACGGTCATAAGTTCTCTGTTT
8 CTTACCGTAAGTCGCGTCACCCTCACCTTCACCAGAAACAGAGAACTTATGACCGTTTAC
9 GTGACGCGACTTACGGTAAGCTGACCCTGAAATTCATCTGCACCACCGGTAAACTGCCGG
10 GCAGACCGTAACCAAAGGTGGTAACCAGGGTAGGCCACGGAACCGGCAGTTTACCGGTGG
156
11 CACCTTTGGTTACGGTCTGCAGTGCTTCGCGCTACCCGGATCACATGAAACAGCACGA 60
12 TCCTGAACGTAACCCTCAGGCATCGCGCTCTTGAAGAAGTCGTGCTGTTTCATGTGATCC 60
13 CCTGAGGGTTACGTTCAGGAACGTACCATCTTTTTCAAAGACGATGGTAACTACAAAACC 60
14 ACGAGGGTATCGCCTTCGAACTTAACTTCCGCACGGGTTTTGTAGTTACCATCGTCTTTG 60
15 CGAAGGCGATACCCTCGTGAACCGTATCGAGCTCAAGGGCATCGATTTTAAGGAAGACGG 60
16 AATTATAGTTGTATTCCAGTTTGTGACCCAGAATGTTACCGTCTTCCTTAAAATCGATGC 60
17 GTCACAAACTGGAATACAACTATAATTCTCACAACGTTTATATCATGGCGGACAAGCAGA 60
18 TGTTGTGACGGATTTTGAAGTTCACTTTGATACCGTTTTTCTGCTTGTCCGCCATGATAT 60
19 GAACTTCAAAATCCGTCACAACATCGAGGACGGTAGCGTTCAGCTCGCGGACCATTATCA 60
20 CAGGCAGGAGGACCGGACCGTCGCCGATAGGGTGTTTTGTTGATAATGGTCCGCGAGCT 60
21 TCCGGTCCTCCTGCCTGACAACCACTATCTGTCTTACCAGTCTGCGCTGTCTAAAGACCC 60
22 AACAAACTCCAGCAGAACCATGTGGTCACGTTTCTCGTTTGGGTCTTTAGACAGCGCAGA 60
23 ATGGTTCTGCTGGAGTTTGTTACTGCAGCGGGTATCACCCTGGGTATGGACGAACTGTAC 60
24 TTATTAATGATGATGATGATGATGAGAACCCCCCCTTTGTACAGTTCGTCCATACCCAG 60
25 GTTCTCATCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTT 60
26 ACTCAGCTTCCTTTCGGGCTTTGTTAGCAGCCGGATCCACTAGTAACGGCCGCCAGTGTG 60
27 GCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT 60
28 TCAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTATTGCT 60
29 TCTTGAGGGGTTTTTTGCTGAAAGGAAACTATATCCGGAACTCCCACGGCACGTT 60
30 TCGAGCTTGCCAACGTGCCGTGGGAGTC 28
157
Cerulean
PARAMETERS FOR TRIAL 44
Total Size Of Gene ......... 1125 nt
Protein Residues ........... 239
Mutatable Residues ......... 232
Fixed Nucleotides .......... 429 nt
Oligo Size ................. 60 nt
Annealing Temp ............. 61 +/- 1*C
Oligo Concentration ........ 2.00E-8 M
Sodium Concentration ....... 5.00E-2 M
Mg2+ Concentration ......... 2.00E-3 M
Codon Frequency Threshold .. 10%
Repeat Threshold ........... 8 nt
Mispriming Threshold ....... 8/18 (6 exact) nt
The DNA sequence # 44 is:
1 CGGTCACGCTTGGGACTGCCATAGGCTGGCCCGGTGATGCCGGCCACGATGCGTCCGGCG
61 TAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAAC
121 GGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGTTAGCAA
181 GGGTGAAGAACTGTTCACCGGCGTTGTTCCGATCCTGGTTGAACTCGACGGCGATGTTAA
241 CGGTCATAAATTCTCTGTTTCTGGTGAAGGTGAGGGTGACGCGACCTACGGCAAACTGAC
301 CCTGAAATTCATCTGTACCACCGGTAAGCTGCCGGTTCCGTGGCCAACCCTGGTTACCAC
361 CCTGACCTGGGGTGTTCAGTGCTTCGCGCGTTACCCGGATCACATGAAACAACACGATTT
421 TTTCAAATCTGCGATGCCTGAAGGTTACGTTCAGGAACGTACCATTTTCTTCAAAGATGA
481 TGGCAATTACAAAACCCGTGCGGAAGTCAAATTCGAAGGCGATACGCTCGTTAACCGTAT
541 CGAGCTCAAGGGTATTGATTTTAAGGAAGACGGCAATATCCTGGGCCACAAACTGGAATA
601 CAACGCGATCTCTGACAACGTTTATATCACGGCGGACAAACAGAAAAACGGTATCAAAGC
661 GAACTTCAAAATCCGTCACAACATCGAGGACGGCTCTGTTCAGCTGGCAGACCACTATCA
721 GCAGAATACTCCTATCGGTGACGGTCCGGTTCTCCTCCCTGACAATCACTACCTGTCTAC
781 TCAATCTGCCCTGTCCAAGGACCCAAACGAGAAACGTGACCACATGGTGCTGCTGGAGTT
841 TGTTACCGCGGCAGGTATCACCCTGGGTATGGACGAACTGTACAAAGGGGGGGGTTCTCA
901 TCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTG
961 GATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAA
1021 TAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGA
1081 GGAACTATATCCGGAGCGACTCCCACGGCACGTTGGCAAGCTCGA
The oligonucleotide assembly is:
1 10 20 30 40 50 60
I I I I I I I
1 --- > 3 --->
1 CGGTCACGCTTGGGACTGCC cgatgcgtccggcg
AGTGCGAACCCTGACGGTATCCGACCGGGCCACTACGGCCGGTGCTACGCAGGCCGC
158
61 tagaggatcgagatctcgatcccgcgaaattaatacgactcactat
********W*********
5 -
AAC
gcgctttaattatgctgagtgatatccctctggtgttg
121 GGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGTTAG
***r*****
ccaaagggagatctttattaaa
<--- 4
< repeat
< AT rich
GAAATTCTTCCTCTATATGGTACCAATCGTT
M V S K
7 --- >
ctgttcaccggcgttgttccgatcctggttgaactcgacggcgatgttaa
CCCACTTCTTGACAAGTGGCCGCAACAAG gccgctacaatt
<--- 6
G E E L F T G V V P I L V E L D G D V N
9 --- >
241 cggtcataaa TGAGGGTGACGCGACCTACGGCAAACTGAC
gccagtatttaagagacaaagaccacttccactcccactgcgctggat
<--- 8
G H K F S V S G E G E G D A T Y G K L T
11 --- >
301 CCTGAAATTCATCTGTACCACCGGTAAGCT ctggttaccac
GTAGACATGGTGGCCATTCGACGGCCAAGGCACCGGTTGGGACCAATGGTG
L K F I C T T G K L P V P W P T L V T T
I I I I I I 1
361 cctgacctggggtgttcagtgcttcgcgcgttacccggatcacatgaaa
GGACTGGAC gcaatgggcctagtgtactttgttgtgctaaa
<--- 10
L T W G V Q C F A R Y P D H M K Q H D F
13 --->
CTGCGATGCCTGAAGGTTACGTTCAGGAACGTACCATTTTCTTCAAAGATGA
aaagtttagacgctacggacttccaatg GTAAAAGAAGTTTCTACT
ATC
< repeat
< AT rich
181
421
159
<--- 12
F K S A M P E G Y V Q E R T I F F K D D
15 --- >
481 TGGCAATT ggaagtcaaattcgaaggcgatacgctcgttaaccgtat
ACCGTTAATGTTTTGGGCACGCCTTCAGTTTAAGCTTCCGCT ata
<--- 14
G N Y K T R A E V K F E G D T L V N R I
17 --- >
541 cgagctcaagggtattgattt CCTGGGCCACAAACTGGAATA
gctcgagttcccataactaaaattccttctgccgttataggacccggtgtttgacct
<--- 16
E L K G I D F K E D G N I L G H K L E Y
19
601 CAACGCGATCTCTGACAACGTTTATATCACGGCGGACAA agc
GCAAATATAGTGCCGCCTGTTTGTCTTTTTGCCATAGTTTCG
N A I S D N V Y I T A D K Q K N G I K A
I I I I I I I
661 gaacttcaaaatccgtcacaacatcgaggacggctctgttcagctggcagaccacta
CTTGAAGTTTTAGGCAGT caagtcgaccgtctggtgatagt
<--- 18
N F K I R H N I E D G S V Q L A D H Y Q
21 --- >
721 GACGGTCCGGTTCTCCTCCCTGACAATCACTACCTGTCTAC
cgtcttatgaggatagccactgccaggccaagaggag
<--- 20
Q N T P I G D G P V L L P D N H Y L S T
23 --- >
781 TCAATCTGCCCTGTCCAAG cacatggtgctgctggagtt
AGTTAGACGGGACAGGTTCCTGGGTTTGCTCTTTGCACTGGTGTACCACGACGACCTCA
<--- 22
Q S A L S K D P N E K R D H M V L L E F
841 tgttaccgcggcaggtatcaccctgggtatggacgaactg
25 --->
GTTCTCA
*** < repeat
160
gggacccatacctgcttgacatgtttccccccccaagagt
V T A A G I T L G M D E L Y K
< GC rich
901 TCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTT
***********~***** < repeat
< GC rich
< AT rich
agtagtagtagtagtaatta
<--- 24
GTGTGACCGCCGGCAATGATCAC
27 --->
961 gcccgaaaggaagctgagttggctgctgccaccgctgagcaa
CTAGGCCGACGATTGTTTCGGGCTTTCCTTCGACTCA tcgtt
<--- 26
29 --->
1021 taactagcataacccctt TCTTGAGGGGTTTTTTGCTGAAAGGA
attgatcgtattggggaaccccggagatttgcccagaactccccaaaaaacgact
<--- 28
1081 GGAACTATATCCGGAGCGACTCCCACGGCACGTT
CTGAGGGTGCCGTGCAACCGTTCGAGCT
<--- 30
The
The
The
The
The
The
The
The
total
total
total
total
total
total
total
total
codon usage score ...........
length score ................
melting temperature score ...
repeat score ................
pattern score ...............
mispriming score ............
AT content score ............
GC content score ............
The OVERALL score ......
0.000
0.000
0.000
1.493
0.000
0.000
1.138
0.284
2.916
DETAILED CODON FREQUENCY REPORT
[ Codon, AA, Frequency, # of times used in coding sequence ]
161
TTT F 0.29
TTC F 0.71
TTA L 0.03
TTG L 0.06
CTT L 0.06
CTC L 0.08
CTA L 0.01
CTG L 0.77
ATT I 0.34
ATC I 0.66
ATA I 0.01
ATG M 1.00
GTT V 0.40
GTC V 0.14
GTA V 0.20
GTG V 0.27
TCT S 0.32
TCC S 0.27
TCA S 0.05
TCG S 0.07
CCT P 0.11
CCC P 0.02
CCA P 0.15
CCG P 0.72
ACT T 0.29
ACC T 0.54
ACA T 0.05
ACG T 0.13
GCT A 0.28
GCC A 0.16
GCA A 0.24
GCG A 0.32
TAT Y 0.35
TAC Y 0.65
TAA X 0.63
TAG X 0.08
CAT H 0.30
CAC H 0.70
CAA Q 0.19
CAG Q 0.81
AAT N 0.17
AAC N 0.83
AAA K 0.79
AAG K 0.22
GAT D 0.46
GAC D 0.54
GAA E 0.75
GAG E 0.25
TGT C 0.39
TGC C 0.61
TGA X 0.35
TGG W 1.00
CGT R 0.64
CGC R 0.33
CGA R 0.01
CGG R 0.01
AGT S 0.05
AGC S 0.24
AGA R 0.01
AGG R 0.00
GGT G 0.51
GGC G 0.43
GGA G 0.02
GGG G 0.04
Frequency Range Number of Codons
0% - 4%
5% - 9%
10%
15%
20%
25%
30%
35%
40%
- 14%
- 19%
- 24%
- 29%
- 34%
- 39%
- 44%
45% - 49%
>= 50%
7
148
Total Codons Used = 239
Tm Range # of Overlaps
<58
59
60
61
62
63
64
65
>=66
Tm Range = 1.9
Ovrlap Len Range # of Oligos
<17
17
162
18 3
19 3
20 5
21 6
22 1
23 1
24 2
25 1
26 1
>=27 1
Lowest Overlap = 16
Length Range # of Oligos
<49 2
49-50 0
51-52 0
53-54 0
55-56 0
57-58 0
59-60 28
61-62 0
63-64 0
65-66 0
67-68 0
>=69 0
Longest = 60
There are 3 repeats greater than 8 nt:
PR Posl = 65 Pos2 = 65 Size = 18 Seql = GGATCGAGATCTCGATCC
Seq2 = GGATCGAGATCTCGATCC
PR Posl = 167 Pos2 = 167 Size = 8 Seql = ACCATGGT
Seq2 = ACCATGGT
DR Pos1 = 898 Pos2 = 901 Size = 16 Seql = TCATCATCATCATCAT
Seq2 = TCATCATCATCATCAT
Sequence Patterns Screened (As Supplied By User)
None found
30 oligonucleotides need to be synthesized
1 CGGTCACGCTTGGGACTGCC 20
2 CTACGCCGGACGCATCGTGGCCGGCATCACCGGGCCAGCCTATGGCAGTCCCAAGCGTGA 60
3 CGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTAT 60
4 AAATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCG 60
5 AACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGTTAG 60
6 GAACAACGCCGGTGAACAGTTCTTCACCCTTGCTAACCATGGTATATCTCCTTCTTAAAG 60
7 CTGTTCACCGGCGTTGTTCCGATCCTGGTTGAACTCGACGGCGATGTTAACGGTCATAAA 60
8 TAGGTCGCGTCACCCTCACCTTCACCAGAAACAGAGAATTTATGACCGTTAACATCGCCG 60
163
9 TGAGGGTGACGCGACCTACGGCAAACTGACCCTGAAATTCATCTGTACCACCGGTAAGCT 60
10 CAGGTCAGGGTGGTAACCAGGGTTGGCCACGGAACCGGCAGCTTACCGGTGGTACAGATG 60
11 CTGGTTACCACCCTGACCTGGGGTGTTCAGTGCTTCGCGCGTTACCCGGATCACATGAAA 60
12 GTAACCTTCAGGCATCGCAGATTTGAAAAAATCGTGTTGTTTCATGTGATCCGGGTAACG 60
13 CTGCGATGCCTGAAGGTTACGTTCAGGAACGTACCATTTTCTTCAAAGATGATGGCAATT 60
14 TCGCCTTCGAATTTGACTTCCGCACGGGTTTTGTAATTGCCATCATCTTTGAAGAAAATG 60
15 GGAAGTCAAATTCGAAGGCGATACGCTCGTTAACCGTATCGAGCTCAAGGGTATTGATTT 60
16 TCCAGTTTGTGGCCCAGGATATTGCCGTCTTCCTTAAAATCAATACCCTTGAGCTCGATA 60
17 CCTGGGCCACAAACTGGAATACAACGCGATCTCTGACAACGTTTATATCACGGCGGACAA 60
18 TGACGGATTTTGAAGTTCGCTTTGATACCGTTTTTCTGTTTGTCCGCCGTGATATAAACG 60
19 AGCGAACTTCAAAATCCGTCACAACATCGAGGACGGCTCTGTTCAGCTGGCAGACCACTA 60
20 GAGGAGAACCGGACCGTCACCGATAGGAGTATTCTGCTGATAGTGGTCTGCCAGCTGAAC 60
21 GACGGTCCGGTTCTCCTCCCTGACAATCACTACCTGTCTACTCAATCTGCCCTGTCCAAG 60
22 ACTCCAGCAGCACCATGTGGTCACGTTTCTCGTTTGGGTCCTTGGACAGGGCAGATTGAG 60
23 CACATGGTGCTGCTGGAGTTTGTTACCGCGGCAGGTATCACCCTGGGTATGGACGAACTG 60
24 ATTAATGATGATGATGATGATGAGAACCCCCCCCTTTGTACAGTTCGTCCATACCCAGGG 60
25 GTTCTCATCATCATCATCATCATTAATAAAAGGGCGAATTCCAGCACACTGGCGGCCGTT 60
26 ACTCAGCTTCCTTTCGGGCTTTGTTAGCAGCCGGATCCACTAGTAACGGCCGCCAGTGTG 60
27 GCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT 60
28 TCAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCAAGGGGTTATGCTAGTTATTGCT 60
29 TCTTGAGGGGTTTTTTGCTGAA AACTATATCCGGAGCGACTCCCACGGCACGTT 60
30 TCGAGCTTGCCAACGTGCCGTGGGAGTC 28
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